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Abstract 
Pichia pastoris has become one of the most popular recombinant protein expression platforms, 
despite the lack of understanding into the fundamentals of protein expression. Whilst P. pastoris 
exhibits high volumetric productivity, it has a low specific productivity, which can be further 
reduced by protein-specific problems. This thesis employs several strategies commonly used to 
increase specific productivity, and assesses their impact on the productivity and cell biology of P. 
pastoris.  
Gene dosage has been reported to increase titre; therefore multiple copies of human serum 
albumin were integrated into P. pastoris to assess the correlation between recombinant protein 
productivity and copy number. Post-transformational vector amplification was used to generate 
clones containing up to five copies of HSA. However it was not possible to correlate copy number 
and yield as 15 L bioreactor cultures showed significant genetic instability. The mean final copy 
number was 2.6 ± 1.0. Further work was undertaken to evaluate possible ways to prevent 
instability, such as different selection methods, mutation of RAD51 and RAD52 which are both 
possible RecA homologs and whether the locus of vector integration plays a part. Integration into 
the rDNA locus resulted in increased stability with a five copy clone averaging 3.8 ± 1.6. 
Furthermore, no clones showed complete loss of the integrated vector as observed with 
integration into the AOX1 locus. 
Additionally, the little understood phenomenon of clonal variation was investigated which has 
been reported to affect specific productivity. Nine clones, with a range of productivity, were 
chosen for transcriptomic analysis. Variation between different clones was not uniform, even 
within the high, mid and low secretor groups. However, the ER associated degradation pathway 
was consistently upregulated in the high secretors which could be exploited in the future for 
strain development and selection. 
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1 Introduction 
1.1 Recombinant Proteins for the Biopharmaceutical Industry 
 It is predicted that by 2013 the protein therapeutic industry will be worth US$160 billion 
worldwide, with therapeutics making up 70% of the predicted biologics market [1]. Recombinant 
therapeutic proteins offer an alternative to extracting proteins from the natural hosts and the 
associated disadvantages of limited sources, possibility of toxins, antigenic rejection and the risk 
of transmissible spongiform encephalopathies from the host animal [2]. A main drawback to 
current recombinant therapeutic proteins is cost. A single dose of Herceptin®, a monoclonal 
antibody used to treat breast cancer on initial diagnosis, costs €39,608 [3-4]. Although 
monoclonal antibodies are more expensive to manufacture than recombinant proteins, the 
wholesale cost per cycle of treatment is only US$3672 indicating the huge mark-up in price that 
pharmaceutical companies rely on [5]. Efforts to develop a cheaper efficient platform process are 
under way which will deliver results in efficient, humanized and more economical alternatives. 
The first recombinant protein manufactured was human insulin made using Escherichia coli in 
1978 [6]. By 1982 Genetech Inc. and their licensing partner Eli Lilly were the first to gain approval 
from the Food and Drug Association (FDA) for a recombinant protein, which they aptly named, 
Humulin™ [7]. By 2006 over 200 recombinant proteins had been approved by the FDA [8]. In 
2009, 151 proteins had been approved for use in the USA and EU, of which 50% were produced 
using only E. coli and Saccharomyces cerevisiae [9]. The remaining 50% were produced by higher 
eukaryotic cells such as insect cells (1%), hybridomas (10%), mammalian cells (39%) and 
transgenic animals (1%) [10]. Evidently E. coli is the most popular choice of expression system 
accounting for 29.8% of all FDA drugs in 2009 [10]. However, increasingly more complex systems 
are required to produce larger and more complex proteins.  
1.2 Bacteria as Recombinant Expression Platforms 
The first recombinant protein was made in a bacterial system mainly due to the ease of genetic 
manipulation and since then it has become one of the most widely used hosts [11]. There are 
many advantages to using a bacterial host system such as speed of growth, rapid expression and 
high product yields [8]. Nonetheless as requirements for protein production become more 
complex it is apparent that perhaps bacterial systems are not sufficient. 
1.2.1 Escherichia coli  
The most prominent example of a bacterial expression platform is, as discussed, E. coli. There are 
many advantages of using E. coli including the ease of genetic manipulation, high growth rates 
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and the in-depth knowledge that comes from the published genome sequence. In fact, it is in the 
detailed investigation into the fundamentals of E. coli that makes it the most popular microbial 
host for recombinant proteins. Due to fast growth rates, evaluating the process of producing 
recombinant protein in E. coli can take as little as one week. Development in yeast can take over a 
month, while in mammalian cells after development of a stable cell line (which in itself can take 
several years) a minimum of three months is expected [12]. 
However, E. coli, by nature, is a pathogenic strain and is not on the FDA’s list of generally 
regarded as safe (GRAS) organisms, although lab strains have been genetically modified and 
deemed non-pathogenic [13]. While most of the strains used for genetic modification have been 
adapted to reduce pathogenicity there are obvious drawbacks for extensive use. One of the most 
fundamental disadvantages of using E. coli is the lack of post-transformational modification, such 
as glycosylation [14]. 
1.2.2 Bacillus subtilis 
Bacillus subtilis is a Gram positive rod-shaped bacteria and a GRAS organism [15]. One of the key 
advantages to using B. subtilis over E. coli is that the outer membrane has no lipopolysaccharides 
(LPS), which are known endotoxins and are pyrogenic in humans and other mammals [11]. B. 
subtilis has naturally high expression capability and yields can reach up to 3 g L-1 for the 
production of α-amylase from Bacillus amyloliquefaciens [16]. A further advantage of B. subtilis is 
direct secretion into the extracellular medium; however bottlenecks in the secretory pathway 
make expressing secretory proteins difficult. Difficulties include degradation of the secretory 
protein, incorrect folding and poor targeting to the translocase [2, 15]. Furthermore the lack of 
suitable expression vectors, plasmid instability and the presence of proteases limit the feasibility 
of B. subtilis as a heterologous expression system host. 
1.3 Mammalian Cells as Recombinant Expression Platforms 
The choice of mammalian cells as a recombinant expression platform decreases the risk of 
immune rejection when producing therapeutic proteins. Without any genetic manipulation 
mammalian cells are able to efficiently and accurately perform post-translational modifications 
[8]. The development of Chinese hamster ovary (CHO) cells led to the flourish of proteins 
produced as biopharmaceuticals; 70% of all therapeutic proteins developed in mammalian 
systems are produced using CHO cells [17]. Between 2006 and 2010 among the 58 
biopharmaceuticals produced were produced from mammalian cells [18]. In 2011 the CHO 
genomic sequence was published extending the scope of functionality of this recombinant 
expression platform [19].  
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Irrespective of all of the advantages that using mammalian cell lines bring, in particular reducing 
the need for post-translation modifications, the main disadvantage is cost. It has been calculated 
that in CHO systems for GMP-production media alone costs about €1 per litre [20]. Additionally 
production time for mammalian cells can last for up to 21 days (compared to bacteria which can 
express in a single day) [21]. Furthermore, secretion rates are low and cellular stress responses 
(such as the unfolded protein response) can result in protein degradation leading to reduced 
yields. Yield from mammalian cells is on average between 1 – 5 g L-1, which is only achieved 
through extensive optimisation, whereas through the use of E. coli yields can reach 5 g L-1 [21-22]. 
1.4 Insect Cells, Plant Cells and Other Organisms 
1.4.1 Insect Cells 
Like mammalian cells insect cells are capable of complex post-translational modifications [8]. The 
creation of baculovirus vectors made insect cells a good candidate for heterologous protein 
production. Key advantages lie in the ease of genetic manipulation, stress-resistance, ease of 
protein folding and, most importantly, higher yields [2, 23]. Transformation of insect cells with 
baculoviruses have yielded up to 11 g L-1 [24]. Therapeutic vaccines are produced particularly well 
in insect cells through the use of virus-like particles (VLP), which contain the native virus 
expressing surface protein of the virus but do not contain the genetic material [2, 25-26]. In 2000 
the first therapeutic protein produced from insect cells released onto the market was a veterinary 
vaccine against swine flu, since then many other veterinary vaccines have been produced using 
this expression platform [27]. 
The main disadvantage of insect cells as a recombinant protein expression host is that, despite 
post-translational modifications, an immune response may occur as the glycosylation may induce 
antibodies against the recombinant protein. 
1.4.2 Green Algae 
As a unicellular eukaryotic organism Chlamydomonas reinhardtii has advantages over other 
expression systems due to its ability to translate and fold proteins effectively and maintain similar 
growth rates to microbial cells [28-29]. Other advantages include the ease of transformation into 
the nucleus or chloroplast and the development time between initial transformation to scale up is 
much shorter than in mammalian cells or in plants [30]. C. reinhardtii like B. subtilis is considered 
a GRAS organism and as is not susceptible for viral infections or toxic contaminations [31]. There 
are a number of promoters available for recombinant protein production coupled to the ability to 
grow phototrophically. The cost of media for this is expression system is similar to that of plants, 
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roughly US $0.08 L-1, and soluble protein can account for up to 25% of the dry weight [32]. Both 
recombinant proteins and monoclonal antibodies have been produced in C. reinhardtii [30-31, 
33]. However the amount of development into production of recombinant proteins using this 
system is still relatively limited. 
1.4.3 Transgenic Crops 
Plants have been used to produce recombinant pharmaceutical products since the late 1980s, 
with the production of interferon (1986) and serum albumin (1990) [8, 34]. The first therapeutic 
vaccine was raised against the Hepatitis B surface antigen in 1992 using tobacco plants [35-36]. 
Tobacco plants are common hosts as expression vectors are easily introduced into the genome 
using either Agrobacterium tumefaciens or tobacco mosaic virus, [8]. Indeed there are many 
advantages to using a plant system over other systems such as the reduced risk of contamination 
with viruses or other pathogens and the low cost of cultivating plants, which only require water, 
minerals and sunlight. It has even been suggested that the cost of large scale production is 
cheaper in plants than it is in microbes [37]. Furthermore, plants are able to carry out 
glycosylation and folding of complex proteins. Titre levels have been reported up to 0.2% of the 
dry cell weight of the plant or crop. In 2011 human serum albumin (HSA) was produced in Oryza 
sativa up to 2.75 g Kg-1 of rice [38-39]. Disadvantages of transgenic crops include the potential 
exposure to pesticides, herbicides and toxic plant metabolites [40]. Moreover from initial 
transformation to the production of reasonable titre (mg to g) development can take up to three 
years [30].  
1.4.4 Filamentous fungi 
Filamentous fungi have been a popular choice for producing recombinant proteins due to their 
ability to secrete high titres of proteins that are bioactive and have the correct post-translational 
modifications [8]. One of the most favoured of these fungi is Aspergillus niger which has been 
reported to secrete up to 25 g L-1 of glucoamylase [41]. Other proteins produced with Aspergilli 
include amylases, pectinases, lipases, cellulases, proteases, phytases and xylanases [42]. With the 
whole genome sequencing being published for both A. niger and A. oryzae the scope for further 
development has increased [43-44]. A. niger can secrete over ten times as much native protein as 
yeast [45]. Despite the potential for protein production recombinant protein titres are not always 
comparable with low yields produced. Typical methods for increasing titre including increasing 
gene dosage, strong promoters and gene fusions have not consistently improved yield. 
Transcription has been identified as the main bottleneck in protein production. Nonetheless the 
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extensive work on vectors that allow for integration of recombinant genes highlights filamentous 
fungi as a strong tool as a recombinant expression platform [45].  
Like all the production systems described, filamentous fungi have disadvantages as a recombinant 
expression platform as whilst high levels of expression have been obtained with fungal proteins, 
non-fungal proteins are a much greater challenge [46]. Although the creation of strains containing 
multiple copies of the gene of interest will result in an increase in gene expression, there is no 
direct correlation between copy number and titre [45]. Furthermore like mammalian and yeast 
cells filamentous fungi are known to have an unfolded protein response [47]. The UPR can result 
in the targeting of misfolded proteins down the degradation pathways thus reducing yield. 
Additionally production of recombinant protein can be severely inhibited by fungal proteases. 
Aspergillus nidulans contains 80 protease genes; however investigations to generate new 
protease deficient strains (but that do not result in lethal mutations) are being undertaken [48]. 
Perhaps it is fair to say that the strengths of filamentous fungi lie in the production of fungal 
metabolites and further work is needed to produce non-fungal heterologous proteins with the 
same efficiency. 
1.4.5 Other Recombinant Protein Expression Platforms 
A variety of other platforms are currently being developed for production of recombinant 
proteins. Plant cells, other than green algae and transgenic crops, have been developed for the 
past 20 years and in the past decade progress has been made using whole plants as well as in 
vitro plant cells for the development of plant-made pharmaceuticals (PMP) as well as plant-made 
industrial products (PMIP) [49-51]. Transgenic animals are also an important source for 
biologically active proteins and development is currently being undertaken to create an effective 
and cost-efficient method [52-53]  
1.5 Yeast as Recombinant Expression Platforms 
Similarly to bacterial expression systems one of the key advantages of yeast as a heterologous 
expression platform is the ability to grow to high cell densities, up to 130 g L-1 (dry cell weight) 
[54]. Additionally most yeasts are not pathogenic, although Candida albicans is, and they have the 
capability to secrete efficiently as well as carrying out posttranslational modifications [2]. Several 
species have been established as industrial expression platform systems including Saccharomyces 
cerevisiae, Kluyveromyces lactis and Pichia pastoris.  
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1.5.1 Saccharomyces cerevisiae 
Saccharomyces cerevisiae was originally the preferred choice as a recombinant protein 
production platform due to the vast wealth of information garnered over decades including a 
published genome sequence [55-56]. The functionality for S. cerevisiae has expanded through the 
development of the Saccharomyces Genome Database, which lists common genes, proteins and is 
integrated with bioinformatic tools including genome browsers and engine searches [57]. 
Up until January 2009 18.5% of all approved recombinant pharmaceuticals were generated using 
S. cerevisiae [58]. These proteins include hormones, vaccines and virus-like particles [10]. One of 
the key advantages of using S. cerevisiae is that it has been awarded GRAS status by the FDA [59] 
and like other eukaryotes, S. cerevisiae performs post-translational modifications. Up to 70% of all 
mammalian proteins that were unable to be expressed in E. coli were successfully produced 
intracellularly using S. cerevisiae [60]. Titre has been recorded up to 9 g L-1 for the expression of 
glucose oxidase from A. niger [61].  
Unfortunately there are disadvantages with S. cerevisiae, predominantly S. cerevisiae 
hyperglycosylates proteins resulting in reduced secretion rates [62]. The N-linked glycans in yeast 
differ from those of mammalian cells and affects the half life of the proteins once administered 
[63]. The hyper-mannose N-linked glycans result in binding to mannose receptors in humans and 
therefore reduces the available protein [64]. Therefore, although S. cerevisiae holds potential for 
the production of intracellularly recombinant proteins or for the production of those that do not 
require glycosylation, the ability of this yeast to compete with CHO cells is limited. 
1.5.2 Pichia pastoris 
In the last 15 years P. pastoris has surpassed S. cerevisiae as the preferred yeast recombinant 
expression system due to the reported high titres produced. P. pastoris, unlike other yeast, does 
not ferment sugar; thus eliminating the toxic fermentative product ethanol. The lack of toxic 
products results in very high cell densities; dry cell weights (DCW) can reach up to 130 g L-1, 
similar to S. cerevisiae which will reach up to 140 g L-1, though E. coli is limited to 50 g L-1 [65-67]. 
Furthermore P. pastoris is a methylotrophic yeast, i.e. capable of using methanol as its sole 
carbon source. Growth on methanol is inducible by a variety of genes including alcohol oxidase I 
&II (AOX1). AOX1 is a particularly strong promoter and proteins expressed from this promoter can 
comprise up to 30% of the biomass [12]. Huge investment has been undertaken to develop this 
recombinant protein production system. A clear advantage of using P. pastoris over S. cerevisiae 
is that it does not glycosylate as extensively; thus reducing the risk of immune activation [68]. 
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P. pastoris has flaws that need to be addressed in order to stamp its authority in the 
pharmaceutical industry. Fundamentally despite high volumetric productivity, which results in the 
large protein production, cell specific productivity is relatively low. It is hypothesised that this 
predominantly stems from bottlenecks in the secretory pathway, which, if they can be resolved 
could lead to P. pastoris becoming a key platform for expression of recombinant proteins [69-72]. 
1.6 The History of P. pastoris 
In 1969 a Japanese group first described a yeast that was capable of using methanol as its sole 
carbon source [73]. At the time yeast that could grow on such a low cost carbon source was 
beneficial and in the 1970s Phillips Petroleum invested millions of dollars into the development of 
P. pastoris as a single cell protein for use in animal food source. However, in the 1970s with the 
oil crisis the cost of methanol rose extortionately making this an unviable option and other 
foodstuffs such as soybeans were developed preferentially. In the 1980s the decision was made 
by Phillips Petroleum and Salk Institute Biotechnology/Industrial Associate Inc (SIBA; California, 
USA) to invest in using P. pastoris for the production of recombinant protein [74-75]. In 1993 the 
technology was sold to Research Corporation Technology (RCT; Tucson, USA) and simultaneously 
the license to Invitrogen Corporation (California, USA) to produce an expression kit for easy 
distribution [75]. It was this decision to create a quick and effective expression kit that 
guaranteed the success of P. pastoris as a heterologous protein expression platform. 
1.7 P. pastoris as a Methylotrophic Yeast 
P. pastoris, a methylotrophic yeast, is such a popular choice for heterologous protein expression 
due to its ability to utilise methanol as the sole carbon source [65, 76].  Using methanol has two 
main advantages; firstly as a carbon source it is inexpensive and secondly the alcohol oxidase 
gene (AOX) promoter allows for the tightly regulated expression of the recombinant proteins [77] 
(Fig 1.1).  
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Figure 1.1 Methanol Utilisation in P. pastoris 
1
AOX, alcohol oxidase, 
2
FLD, formaldehyde dehydrogenase, 
3
FGH, S-formylglutathione 
hydrolase, 
4
FDH, formate dehydrogenase, 
5
CAT, catalase, 
6
DAS, dihydroxyacetone 
synthase, 
7
DAK, dihydroxacetone kinase, 
8
TPI, triosephosphate iosmerase, 
9
FBA, fructose-
1,6-bisphosphate aldolase, 
10
FBP, fructose1,6-bisphosphatase, DHA, dihydroxyacetone, 
GAP, glyceraldehydes-3-phosphate, DHAP, dihydroxyacetone phosphate, F1,6BP, fructose-
1,6-bisphosphate, F6P, fructose-6-phosphate, Pi, phosphate, Xu5P, xlyulose-5-phosphate, 
GSH, glutathione. 
 
This complex metabolic pathway contains many genes that have been developed for use of their 
promoters due to their strength but none more so than the alcohol oxidase genes (AOX). The 
effect of using methanol as the sole carbon source is visible when looking at the cells under an 
electron microscope as the number of peroxisomes, where the methanol is brought into the cell, 
accumulates [78]. Peroxsiomes are vacuole-like organelles found in nearly all eukaryotes and are 
required for methanol assimilation in methylotrophic yeast [79]. Upon the switch from methanol 
to another carbon source peroxisomes are degraded by an autophagy-like process referred to as 
pexophagy [80]. 
1.7.1 The Alcohol Oxidase (AOX) genes 
Growth on methanol is conferred by a specific set of metabolic enzymes, which are regulated 
according to induction by methanol. The alcohol oxidase genes (AOX1 and AOX2) are switched off 
when cells are grown in the presence of glucose or other carbon sources but upon exposure to 
methanol expression increases to the extent that it contributes up to 30% of the total cellular 
protein [65, 76, 81]. AOX is the first enzyme in the methanol activation utilisation pathway, but it 
is encoded by both the AOX1 and AOX2 [82]. The AOX1 and AOX2 genes share 92 and 97% 
nucleotide and amino acid sequence identity, respectively, with the main differences located in 
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the 5’ end of the protein-coding proportion of the genes and very different promoters [65, 82-
83]. 
The main advantage relates to the strength of the promoter and the fact that it is an inducible 
and tightly regulated [74]. Cultures can be grown in the presence of a non-methanol carbon 
source to high cell densities; once this has been achieved induction via methanol activates 
transcription. In the absence of methanol AOX1 mRNA is not detectable although can reach ~5% 
of the total mRNA once induced [84]. Furthermore, the strength of the promoter results in high 
protein titre, even if they are toxic to the cell [65, 74, 76, 84].  The disadvantages to using the 
AOX1 promoter include that methanol is a toxic and highly flammable substance and as a result 
new promoters are being investigated that do not rely on this potentially hazardous feed [85]. 
1.7.2 Methanol Utilisation Phenotypes 
Depending on the expression the AOX genes, three methanol utilisation (Mut) phenotypes exist 
with varying ability to grow in the presence of methanol[86]. Interruption of the AOX1 and/or 
AOX2 genes will impact the ability to grow on methanol resulting in different Mut phenotypes. 
The most common phenotype employed by researches is Mut+, in which the AOX1 and AOX2 
promoter and gene remain intact [87]. In contrast, MutS (slow) uses the secondary and less-well 
expressed AOX2 gene and promoter, with the AOX1 gene being either disrupted in the parent 
strain or during recombinant strain production. While this strain has the ability to grow in the 
presence of methanol growth is substantially reduced. The final phenotype is Mut- which is 
unable to grow in the presence of methanol due to a disruption in both the AOX1 and AOX2 
genes. The choice of Mut phenotype is often dependent on the protein being produced, for 
instance hepatitis B surface antigen expresses most efficiently using the MutS strain [74]. 
1.8 Strains of P. pastoris 
As with most industrially relevant species P. pastoris has been genetically modified to create 
different strains that can be used for recombinant engineering  [76] such as  knockouts in 
metabolic pathways for auxotrophic selection, i.e. histidine (HIS4) or arginine (ARG4) [65]. The 
selection of the expression strain is critical for the successful production of heterologous protein 
in P. pastoris. All expression strains are derived from the parental NRRL-Y 11430 (Northern 
Regional Research Laboratories, Peoria, IL; Table 1) [75]. 
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Table 1.1 P. pastoris host strains 
 
Strain Genotype 
Media 
Supplementation 
Reference 
Y-11430 Wild type None NRRL 
X33 Wild type None Invitrogen 
GS115 his4 Histidine [84] 
GS190 arg4 Arginine [88] 
JC220 ade Adenosine [88] 
JC254 ura3 Uridine/Uracil [88] 
GS200 arg4   his4 Arginine/Histidine [84] 
KM71 Δaox1 : : SARG4   his4   arg4 Histidine [89] 
SMD1168 Δpep4 : : URA3   his4   ura3 Histidine [90] 
SMD1163 pep4   prb1   his4 Histidine [90] 
 
1.8.1 Y-11430 
The parental strain Y-11430 has been deposited in the Northern Regional Research Laboratories 
(NNRL; Peoria, IL). It is from this strain that two of the most popular strains, GS115 and X33, were 
derived. In 2011 this strain was sequenced in order to determine key aspects of secretion that 
had yet to be established, such as identifying an alternative to the S. cerevisiae alpha pre-pro 
signal [91].  
1.8.2 X33 
Similarly to Y-11430, X-33 is a also a wild-type strain, although it was created by using GS115 
(his4) and re-complementing with the wild-type HIS4 gene [65]. This prototrophic strain is the 
wild-type strain that is supplied by Invitrogen Corporation. As a wild-type strain there is no media 
supplementation required for growth. 
1.8.3 GS115 
GS115 is one of the most common strains used for expression studies in P. pastoris; it is a 
histidinol dehydrogenase (his4) mutant and thus requires histidine supplementation when grown 
on minimal media. This strain is also supplied by Invitrogen Corporation, when purchasing the 
Pichia Expression Kit. One of the reasons GS115 is now such a popular strain is because in 2009 
the genome sequence was released [92]. The presence of a genome sequence has enabled faster 
development of strategies for heterologous protein expression. The mutation in the HIS4 gene 
allows for complementation during recombination to allow for selection of vectors containing the 
HIS4 gene. Complementation selection is minimal media grown in the absence of histidine. 
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1.8.4 Protease Deficient Strains 
An increasingly popular choice for expression strains are the protease deficient strains. These 
strains reduce the amount of degradation of secreted protein due to knockouts of either the 
proteinase A (PEP4) or proteinase B (PRB1) [90, 93]. In the absence of proteinase A Prb1p is not 
fully active and as a result SMD1168 is also expected to have a lower proteinase B activity. Like Y-
11430 and GS115, SMD1168 was recently sequenced, making it a more popular choice for the 
protease deficient strains [93]. However, it has been reported that all proteinase deficient strains 
are less robust and have low storage viability [94]. SMD1168 can, like the other strains 
sequenced, be expressed with a Mut+ phenotype, whereas KM71 is a Δaox1 knockout (where the 
AOX1 gene is replaced with ARG4 from S. cerevisiae), and thus always results in a MutS or Mut- 
phenotype. 
1.8.5 The truth about Komagataella phaffi and Komagataella pastoris 
In 1995 Yamada et al. noted that 18S and 26S sequences from P. pastoris strains were 
significantly different from other methanol assimilating yeast [95]. From this a new genus was 
proposed, Komagataella, to which P. pastoris should be added. However, in 1998 Kurtzman 
rejected a new genus due to the lack of species that would be distinctly varied when looking at 
phylogenetic trees [96]. Nevertheless, in 2003 Dlauchy et al. described Pichia pseudopastoris, a 
species that is closely related to P. pastoris and with this it was possible to establish Komagataella 
as a distinct genus [97]. To date gene sequences have confirmed the presence of two species 
within the Komagataella genus; K. pastoris and K. phaffi [98-99]. 
Kurtzman undertook the investigation to establish which P. pastoris strains belonged to the newly 
classified species; characterised by phylogenetic trees using sequences from domains 1 and 2 of 
the nuclear large subunit ribosomal RNA, mitochondrial small unit rRNA, translation elongation 
factor 1-α (ER-1α) and RNA polymerase I. It was determined that NRRL Y-11431 (a variant wild-
type strain) belonged to K. pastoris, whereas NRRL Y-11430 (the parental wild type strain of 
GS115 and X33) belonged to K. phaffi [99]. The sequencing data collected by Mattanovich et al. 
(2009) was done so on SMD1168, which is a K. pastoris strain [93]. The Invitrogen expression kit 
uses K. phaffi as opposed to K. pastoris, purely by coincidence as the development for 
biotechnological expression was chosen at random. 
However, although it has been acknowledged that P. pastoris now exists as two separate species 
under K. pastoris and K. phaffi, this nomenclature has yet to be adopted into the literature. As a 
result to keep in line with current publications for the remainder of the thesis, P. pastoris will 
continue to be used. 
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1.8.6 Humanized P. Pastoris strains 
In 2006 a major breakthrough was achieved for the use of P. pastoris as an expression host for 
production of glycoproteins for pharmaceutical uses; the advent of a humanized strain, yAS309 
[100]. This glycoengineered strain was modified to perform human-like N-glycosylation. The initial 
step was to remove the α-1,7 mannose extension, which is responsible for the hyper-
mannosylation in yeast. The α-1,2 mannosidase from Trichoderma reesei was fused to an HDEL-
retention signal [101]. Jacobs et al. described a method for creating complex-type N-glycosylation 
using GlycoSwitch technology, using five GlycoSwitch Vectors [102]. This humanized P. pastoris 
strain was used to successfully produce sialylated human-type recombinant erythropoietin [100]. 
In 2009 Potgieter et al. reported the production of 1 g L-1 of functional monoclonal antibody with 
uniform N-linked glycans [103]. Furthermore Ye et al. (2011) designed an optimal feeding strategy 
that resulted in up to 1.6 g L-1 of monoclonal antibody in a scaled-up process to a 1200 L scale 
[104]. The development of a humanized strain allows for the cultivation of commercially available 
monoclonal antibodies and raises the profile of P. pastoris as a true competitor to CHO cells.  
1.9 Expression Vectors for P. pastoris 
When Phillips Petroleum passed over the rights to Invitrogen Corporation in 1993 an aggressive 
attitude was taken to the creation and distribution of cheap expression kits [105]. One of the key 
aspects of this was designing a library of expression vectors that could be used under varying 
conditions. Almost all of the vectors are E. coli/P. pastoris shuttle vectors, containing an origin of 
replication in E. coli and a functional selection marker in both organisms. 
1.9.1 Promoters 
One of the key aspects in vector selection is the choice of promoter. There are several promoters 
that are frequently used in P. pastoris, most commonly AOX1 promoter as previously described 
[65]. The strength of the promoter is one of its main advantages; however particularly for 
intracellular proteins the strength of the AOX1 promoter can be detrimental; thus other weaker 
promoters are sometimes preferred. The AOX2 promoter, which is also inducible by methanol, 
has been reported to have lower activity than the AOX1 promoter [106]. Strains with a disrupted 
AOX1 gene contained approximately one third of the AOX activity compared to wild-type strains 
[82]. Another inducible promoter is the formaldehyde dehydrogenase (FLD1) gene promoter, 
which is strongly induced using methanol as a carbon source or methylamine as a nitrogen source 
[107]. 
While these examples are strong inducible promoters the induction via methanol can be 
construed as detrimental as some industries (such as the food industry) are unable to use 
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methanol due to fire and health hazards. Additionally switching from a glycerol feed to a 
methanol feed during fermentation can be inconvenient; thus other non-utilising methanol 
promoters have been developed. Of these, the most common one is the glyceraldehydes-3-
phosphate dehydrogenase (GAP) gene promoter [85],  a constitutive promoter. Unlike the AOX1 
promoter driven vectors, which are grown on a glucose carbon source initially to achieve high cell 
densities before they are induced with methanol, the GAP promoter will start producing proteins 
at the same time as growing.  On methanol the GAP promoter will secrete approximately 50-65% 
less protein than using the AOX1 promoter [108]. 
1.9.2 Selectable Markers 
In order for the shuttle vectors to work in both E. coli and P. pastoris selection markers must exist 
that work in both species. One of the most popular antibiotic selection markers is Zeocin, using 
the Sh ble gene from Streptoalloteichus hindustanus [109-110]. The reason for its popular nature 
is the fact that it works in both E. coli and P. pastoris. 
Another popular method of selection is to use biosynthetic markers; however such selection will 
only occur in P. pastoris. As a result the vector will contain an E. coli selection marker, most 
commonly the Bleomycin (bla) gene, which confers resistance to ampicillin [110-111]. Five 
biosynthetic markers are currently available commercially these include; HIS4 , ADE1 (PR-
amidoimidazolesuccinocarboxamide synthase), ARG4 (arginosuccinate lyase), URA3 (orotidine-5’-
phosphate decarboxylase) and URA5 (orotate phosphoribosyltransferase) [65]. 
Other selection methods currently being used include the use of a modified Tn903kanr gene that 
allows for direct selection on both P. pastoris using G418 (Geneticin) and kanamycin on E. coli 
[112-113]. 
1.9.3 Secretion Signal 
P. pastoris secretes very few native proteins therefore purification can be made easier by 
signalling recombinant proteins to the supernatant. The most commonly used secretion signal is 
the α-mating factor (α-MF) pre-pro peptide from S. cerevisiae [75].  Following the sequencing of 
NRRL-Y11430 the P. pastoris α-MF prepro peptide equivalent has been identified but has yet to 
be evaluated [91, 114]. The secretion signal from the native acid phosphatise (PHO1) isolated 
from P. pastoris is also frequently used with successful secretion [75]. More recently PHA-E from 
the plant lectin Phaseolus vulgaris agglutinin has been used for the expression of green 
fluorescent protein (GFP) as well as two plant lectins [115]. This has been reported to work in 
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situations where the Kex2 site is not properly cleaved resulting in N-terminus ends of the α-MF 
signal peptide attached to the recombinant protein [65].  
Additionally if the existing secretion signals have not worked it is possible to develop synthetic 
leader sequences [116-117]. In 2011 Kottmeier et al. undertook an investigation into using three 
novel secretion signals from hydrophobins of Trichoderma reesei [118]. Due to the length of the 
existing secretion signals research was undertaken to reduce the amino acid length to less than 
25. The group claimed that they were successfully able to include a secretion signal through the 
use of PCR primers and successfully secrete enhanced green fluorescent protein (EGFP). 
1.10 Homologous recombination 
One of the advantages of P. pastoris is the highly recombinogenic nature and as such vectors 
created with regions of homology can often be used to target integration at a specific gene of 
interest [119]. Depending on the design of a vector, homologous recombination can either result 
in gene insertion, through a single crossover event, or gene replacement through a double 
crossover event. A single crossover event can occur in the AOX1 region by linearising the plasmid 
so that integration only occurs in the 5’ AOX1 region (Fig 1.2). 
 
Figure 1.2 Single Crossover Homologous Recombination 
Integration occurs through linearising the vector in the 5’ AOX1 region to create two 
copies of the AOX1, each made up partially from the genome AOX1 and partly from the 
plasmid counterpart. 
 
Single crossovers will create a Mut+ phenotype when used for integration into the AOX1 locus. In 
order to create gene replacements a double crossover event must be used. In the example of 
integration into the AOX1, the vector can be cut with BglII to linearise the plasmid at the very 
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start of the 5 AOX1 fragment, the second crossover will occur downstream at the 3’ AOX1 region; 
thus completely replacing the genome fragment (Fig 1.3). 
 
Figure 1.3 Double Crossover Homologous Recombination 
Integration occurs through linearising the plasmid at the very beginning of the 5’ AOX1 
region of homology; thus forcing the second recombination event to occur at the 3’ AOX1 
region. This double crossover will create a gene replacement. 
 
For auxotrophic strains regions of homology, such as to the HIS4 gene, this will result in 
complementation with an additional advantage of being used as a selection method [84, 112]. 
However, in the example of auxotrophic strains that contain either the GAP promoter or AOX1 
promoter integration can occur into these regions. If integration has not occurred at the designed 
site (based on the location of the linearisation of the vector) then it is important to check other 
regions where homology exists in the vector [120]. However, non-homologous recombination can 
occur in P. pastoris, and it has been noted that certain loci result in better protein secretion [121]. 
The homologous recombination pathway is well studied in S. cerevisiae and it is this in-depth 
knowledge that enables parallels to be drawn to P. pastoris (Fig 1.4). 
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Figure 1.4 Homologous Recombination Pathways in S. cerevisiae 
An induced double stranded break may illicit one of three repair pathways in S. 
cerevisiae; double-strand break repair (DSBR), synthesis-dependent strand annealing 
(SDSA) and break-induced replication (BIR).   
 
Once the linear piece of DNA containing the gene of interest has integrated successfully into the 
genome; either through a single or double crossover event then the P. pastoris cells are capable 
of turning into microbial factories in order to produce the recombinant protein.  
1.11 pPICz and pPICzα 
Examples of vectors sold by Invitrogen Corporation are pPICz and pPICzα. These vectors use the 
AOX1 promoter and rely on the Sh ble gene for resistance to the antibiotic Zeocin. The vectors 
come in three frames; A, B and C, so the end user can clone the gene of interest into the correct 
reading frame. The distinguishing difference between the two vectors is the fact that the pPICzα 
vector contains the S. cerevisiae α-MF signal peptide for secretion. 
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To ensure production of the protein of interest a Kozak consensus sequence is required before 
the ATG of the protein. However in the case of pPICzα, the Kozak consensus sequence is already 
integrated into the vector in front of the alpha factor signal peptide [122-124]. Both pPICz and 
pPICzα are designed for integration into the AOX1 region, although the precise location varies 
depending on the restriction digest. If the vectors are digested with BglII which is located at the 5’ 
end of the promoter region, AOX1 gene replacement is possible and a MutS phenotype can be 
achieved. With all other restriction digest locations a Mut+ phenotype occurs, unless the selecting 
strain already contains an AOX1 knockout (Fig 1.5). 
  
Figure 1.5 pPICz and pPICzα Plasmid Maps 
A) pPICz. B) pPICzα. Both vectors contain the AOX1 promoter, the Sh ble gene for 
Zeocin resistance (ZeoR), as well as the pUC origin of replication for growth in E. coli. 
pPICzα contains the additional α-MF signal peptide for secretion. Both the BglII and 
PmeI restriction sites are represented as these are popular sites for linearisation for 
homologous recombination.  
 
1.12 Production of Recombinant Proteins in P. pastoris 
LacZ was the first gene to be expressed in P. pastoris, which encodes β-galactosidase [89]. As of 
2000 over 200 proteins have been produced in P. pastoris, all from a wide range of hosts 
including bacteria, fungi, protists, plants, animals viruses and humans [125]. In addition to 
proteins, P. pastoris is being used to produce enzymes and antibodies. Proteins may be produced 
intracellularly, a trait important for the production of membrane proteins, or they can be 
secreted with the addition of a signal peptide. The flexibility of the P. pastoris system has opened 
the doors for scientists to take advantage of this high secreting strain in order to produce large 
quantities of protein. 
In 2004 human insulin was first manufactured globally by Biocon, who aptly named it INSUGEN® 
[126]. Since then other proteins produced by P. pastoris been added to the global market such as 
recombinant human serum albumin (HSA), alternatively known as Medway, which is used as a 
blood expander [127]. However; it was not until 2009 that FDA approved the first protein 
A B 
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produced from P. pastoris for therapeutic purposes. Dyax Corporation (Burlington, MA, USA), 
received approval for their drug KALBITOR® (ecallantide), which is used in the treatment of acute 
attacks of hereditary angioedema [128].  
A brief summary of proteins produced in Table 1.2 highlights the powerful tool that this organism 
has become.  
Table 1.2 Overview of Protein Production in P. pastoris 
 
Protein 
Expressed 
Function 
Expression 
Level 
Available on 
the market? 
Product Name 
Reference 
Escherichia coli 
phytase 
Used in animal feed 
industry to improve 
phosphorous 
utilisation 
6.4 g L
-1 Phytex LLC 
(India) 
Recombinant 
Phytase 
[129] 
Thermus 
aquaticus YT-I 
aqualysin I 
Heat-stable subtilisin-
type serine protease 
1 g L
-1 
No N/A [130] 
Trametes 
veriscolor  laccase 
(lcc I) 
Phenoloxidase 23.9 U mL
-1 
No N/A [131] 
Anti –IL6 
Receptor 
Single domain antibody 
fragment for 
rheumatoid arthritis 
treatment 
30 mg L
-1 Albynx 
(Belgium) 
Nanobody® 
ALX-0061 
[132] 
Mouse endostatin 
Tumour growth 
suppressor 
133 mg L
-1 
No N/A [133] 
Anti-HBs Fab 
fragment 
Prevention and 
treatment of Hepatitis 
B virus 
800 mg L
-1 
Shantha/ 
Sanofi 
(India) 
Shanvac™ [134] 
Trypsin Digestion of proteins 14.4 U mL
-1 
Roche 
Applied 
Science 
(Germany) 
Recombinant 
Trypsin 
[135] 
Interferon-alpha 
2b 
Hepatitis C and cancer 
treatment 
200 mg L
-1 
Shantha/ 
Sanofi 
(India) 
Shanferon™ [136] 
Interleukin-22 
Novel human cytokine 
important for 
promoting 
antimicrobial defence 
and preventing 
epithelial damage 
100 mg L
-1 
No N/A [137] 
Insulin 
Treatment of diabetes 
mellitus 
250 mg L
-1 Biocon 
(India) 
Insugen® [138] 
Serum albumin 
Binding and transport, 
colloid osmotic 
pressure 
10 g L
-1 
Mitsubishi 
Tanabe 
Pharma 
(Japan) 
Medway [139-140] 
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1.13 Increasing the yield of P. pastoris 
A key limiting factor of protein expression in P. pastoris is the low cell specific productivity. This 
aspect is countered via the high volumetric productivity, which is bolstered by the high cell 
densities that P. pastoris is able to grow to. Nevertheless many different techniques have been 
used to try to increase the cell specific productivity and increase the overall yield of protein. 
Tactics include genetic manipulation of the secretion pathways in order to reduce stress levels 
that can result from secreting proteins, expressing the target protein with a folding chaperone 
such as protein disulfide isomerase, and perhaps most commonly and for certain one of the 
earliest methods increasing gene dosage [72, 74, 141]. To date there is no systematic procedure 
that effectively increases yield, yet each of the techniques outlined have been reported to be 
successful in increasing yield in specific cases. It is becoming more apparent that individual 
systems require specific optimisation based on the protein being produced. 
1.13.1 Creating Multiple Copy Clones 
Multi-(gene)copy clones were originally evaluated by Clare et al. in 1991 [142], who determined 
that an increase to 14 copies from a single copy of the tetanus toxin fragment C results in a 10% 
increase of heterologous protein to total cell protein [76]. Whilst this method was successful for 
proteins such as tetanus toxin fragment C the production of other proteins via this method were 
not as successful, such as with the expression of hepatitis B surface antigen [143]. To date there 
are several methods used to create multi-copy clones. Traditional selection of multi-copy clones 
was performed by screening large number of colonies for spontaneously occurring colonies with 
high gene dosage [142, 144-145]. Initially only two resistant markers were capable of generating 
multi-copy strains by selection on a higher concentration, these were Sh ble (ZeocinR) and BSD 
(blastidineR) ( [144]. 
Two other selectable markers that can result in the production of multi-copy clones are more 
laborious and thus are often not chosen as efficient methods. The FLD1 gene (resulting in 
resistance to formaldehyde) requires an initial selection on minimal plates containing 
methylamine chloride as the carbon source [146]. It is then possible to plate on formaldehyde 
containing plates in order to select multi-copy clones. Of most concern is that this selection 
marker is only capable of being used with an fld1 mutant [147]. 
The second alternative resistance marker is the Tn903kanr marker which confers resistance to 
G418; originally like FLD1 selection, a pre-selection was required, this time on minimal plates 
lacking in HIS4. The vector originally used containing the Tn930kanr included a HIS4 gene for 
complementation on a HIS4- strain, before selection could occur on G418 plates. However in 2008 
38 
 
Lin-Cereghino established that the bacterial promoter and transcription terminator region was 
preventing direct selection on G418 and replacing them resulted in a new generation of G418 
vectors capable of direct selection in both E. coli and P. pastoris, removing the need for a 
preliminary HIS4 complementation selection [112]. 
Other methods to create multi-copy clones are being expanded at present including an in-vitro 
multimerisation method suggested by Invitrogen Corporation and a method referred to as post-
transformational vector amplification (PTVA). 
1.14 In-vitro Multimerisation 
The presence of a commercial kit that specifically aims to increase copy number only highlights 
the importance placed on the production of multi-copy clones in P. pastoris. The premise behind 
this multi-copy kit sold by Invitrogen Corporation is that multi-copy clones can be made with 
specific vectors either in-vivo or in-vitro [148]. Briefly, the in-vivo method uses one of two vectors; 
pPIC3.K or pPIC9K. Both vectors contain the HIS4 gene for complementation, a kanamycin gene 
for in-vivo selection and the AOX1 promoter. pPIC3.K produces proteins intracellularly whilst 
pPIC9K secretes proteins into the supernatant. The in-vivo screening method is carried out by 
selection of His+ transformants (generated from complementation with the active HIS4 gene) and 
then plated onto varying concentration of G418. This method is the same as what was originally 
described for the Tn903Kanr gene before Lin-Cereghino et al.(2008) made modifications to allow 
for direct selection [112]. 
Unlike the in-vivo method which can still require the screening of thousands of colonies the in-
vitro method should create clones with a more directed copy number and a less intensive 
screening step. Invitrogen Corporation provides the vector pAO815, which contains the HIS4 
gene, the AOX1 promoter and the 3’ AOX1 fragment (to allow for double crossovers for gene 
replacement). The downside to the in-vitro method is that the amount of work to create the 
correct number of copies can be very intense and furthermore the size of the vector may become 
very large, which can be detrimental to transformation into P. pastoris.  
The premise behind the in-vitro mechanism is that multimers can be created based on creating 
expression cassettes through digesting a complete vector (with the required gene of interest) 
with the restriction enzymes BglII and BamHI. The vector is either digested with BamHI, or with 
both BglII and BamHI. As BglII (AGATCT) and BamHI (GGATCC) restriction sites differ in the first 
and sixth base only, the restricted DNA has compatible ends. If ligated together in a head-to-tail 
direction neither restriction site is recreated (GGATCT). However if multimers form in a head-to-
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head or tail-to-tail orientation either the BglII or BamHI site is recreated and the fragment will be 
cut; thus reducing them to the individual vector and expression cassette fragment (Fig 1.6). 
 
Figure 1.6 Schematic diagram of the method suggested by Invitrogen Corporation for 
in vitro multimerisation 
Initially an expression cassette is isolated by digestion with BglII and BamHI. These 
expression cassettes are then ligated together with a linearised BamHI vector to create 
multimers. This can be repeated multiple times, depending on the success rate and the 
size of the gene of interest. 
 
This in-vitro multimerisation method can be repeated several times to obtain a larger number of 
gene copies. It should be noted however that the pAO815 vector alone is 7.7 Kb so any additional 
insertions of the expression cassette will mean that this increases significantly. Nonetheless this 
method offers an invaluable tool in ascertaining the precise number of copies of the gene of 
interest (considering recombination does not occur elsewhere within the genome either through 
homologous recombination at the HIS4 or non-homologous recombination). 
1.14.1 Post-Transformational Vector Amplification 
In 2008 Sunga et al. published a new protocol for the production of multi-copy clones entitled 
post-transformation vector amplification (PTVA) [149]. This method works on the premise 
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described by Schimke in mammalian systems whereby a stepwise increase in the concentration of 
antibiotic the methotrexate results in directed selection of cell lines that contain more copies of 
the antibiotic resistance marker. The theory follows that amplification in the antibiotic resistance 
gene is mirrored by amplification of the whole vector and produces more copies of the gene of 
interest [150]. This method has been applied to strains containing vectors expressing both the Sh 
ble resistance marker (Zeocin) and the Tn309kanr gene for selection on G418.  
For Zeocin the initial transformation was selected on 100 μg mL-1 and the selected colonies 
streaked to single colonies three times to ensure a pure culture. Clones were then spotted onto 
YDP plates containing increasing concentrations of antibiotic in a step-wise manner from 100 μg 
mL-1 to 2000 μg mL-1, and left to recover for 3-5 days at 30°C.  The main advantage of the method 
is the proportion of cells that contain high copy numbers. Traditional methods, such as selecting 
directly onto high concentrations of antibiotic, produce less than 1% of colonies containing 
greater than 10 gene copies (known as “jackpot” colonies) through PTVA this percentage was 
reported to have risen to 5-6% of all of enriched strains tested. 
Since the method was first suggested other groups have used this method to obtain multi-copy 
strains, for instance porcine insulin precursor (PIP) was reported to have been enriched to 52 
copies of the gene in a Mut+ strain [151]. Furthermore, the method of gene amplification has 
been used to increase copy number of clones that are directed into the rDNA locus [152]. 
1.15 Unfolded Protein Response (UPR) 
Secretory stress can be monitored by assessing the upregulation of  unfolded protein response 
(UPR); a conserved cellular stress response observed in most eukaryotes [153]. This adaptive 
cellular response aims to restore homeostasis to the balance between unfolded protein and the 
capacity of the ER and aims to prevent an accumulation of unfolded protein which can be 
detrimental to the cell [154].  
In higher eukaryotes there are three pathways capable of inducing UPR all activated via 
transmembrane ER stress sensors; inositol requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK) 
and activating transcription factor 6 (ATF6) [155-158]. While all three mechanisms show 
similarities acting through the oligmerisation of the respective transmembrane domains resulting 
in the recruitment of mRNA to the ER,  the precise mechanism of sensing stress is not well 
understood [154, 159]. While the PERK and ATF6 pathways are found in mammalian systems 
these systems are not present in yeast; thus indicating the redundancies of the systems [159].  As 
only the IRE1 pathway is present in yeast it serves that this pathway will be described in detail. 
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UPR has been studied intensively in S. cerevisiae and three gene products have been identified as 
requirements for activation; Ire1p, Kar2p and Hac1p [71]. Kar2p binds to unfolded protein; 
therefore upon an increase in unfolded protein, Kar2p will dissociate from Ire1p. As mentioned, 
Ire1p is a transmembrane domain that will oligomerise upon the dissociation of Kar2p. When 
Ire1p oligomerises the endoribonuclease activity at the cytoplasmic side splices an intron from 
HAC1 mRNA. Once activated Hac1pi is produced and acts as a transcription factor to upregulate 
further UPR genes, such as Kar2p and protein disulfide isomerase (PDI; Fig 1.7) [70].  
 
Figure 1.7 A schematic visualisation of the upregulation of the unfolded protein 
response (UPR) in yeast 
Modified from Schroder et al. and Guerfal et al. [156, 160] 
 
Recently it has been identified that in addition to activating UPR through accumulation of 
misfolded protein, unfolded protein can directly induce the UPR by binding to the core ER-luminal 
domain (cLD) of Ire1p [161]. 
As UPR has been extensively investigated in S. cerevisiae it is of interest to note that subtle 
differences exist when compared to P. pastoris. The most controversial of these is the presence or 
absence of an intron in HAC1 and whether this protein is constitutively expressed or induced as is 
seen in S. cerevisiae. In 2010 and 2011 two papers were published on this subject with conflicting 
views; the first paper by Guerfal et al. suggests that while the splice sites are present in HAC1 
mRNA in P. pastoris no evidence exists of an unspliced form in an unstressed condition [160]. 
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Early in 2011 Whyteside et al. published that in addition to the intron site being identified (and 
was in fact the same site that had been identified by Guerfal et al.) there was clear evidence that 
an unspliced variant of the HAC1 mRNA was identified [162]. To date it has yet to be clarified as 
to whether the intron must be spliced for activation or whether the activated Hac1pi is always 
present. Irrespective of these discrepancies in the functionality of HAC1 there is no doubt as to 
the importance of attempting to curb the effects of the UPR in order to achieve the highest cell 
specific productivity. 
1.16 Endoplasmic Reticulum Associated Degradation (ERAD) Pathway  
While initial upregulation of the UPR can be viewed as an important step for the regulation of 
protein folding, and potentially be advantageous, prolonged induction will result in the 
upregulation of the endoplasmic reticulum degradation pathway (ERAD) [163-164]. Induction of 
ERAD results in retrotranslocation of misfolded proteins to the cytosol for degradation by the 
proteasome [71, 156, 165-166]. ERAD is dependent upon UPR for activation and UPR results in an 
increase of the ERAD capacity [163]. 
The fate of misfolded protein assigned to the ERAD is dependent on where the proteins are 
misfolded. In yeast there are three membrane machineries that define the different types of 
ERAD pathways; ERAD-L, ERAD-M and ERAD-C [69, 167-169]. Proteins that misfold in the lumen 
are degraded by ERAD-L, in the membrane ERAD-M and in the cystol ERAD-C [170]. For proteins 
that misfold in the lumen the E3 ubiquitin ligase Hrd1p initiates the degradation of the protein 
through association with Hrd3p. The additional requirements of the ERAD-M compared to the 
ERAD-C are not currently known, though the Der1p and Usa1p are suspected to be excluded (Fig 
1.8) [167, 169]. 
 
Figure 1.8 Membrane Protein Complexes that Define the ERAD pathways 
ERAD pathways involved in the degradation of proteins. A) ERAD-L pathway through the 
use of the Hrd1p complex. B) ERAD-C pathway utilising the Doa10p complex. This figure is 
adapted from Carvalho et al. and Denic et al. [167-168] 
 
A B 
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The induction of ERAD will have detrimental effects on protein production. Therefore increasing 
gene dosage may be counterproductive if upregulation of UPR and ERAD is evident.  
1.17 Human Serum Albumin – The Model Protein 
Many different proteins have been expressed extensively in P. pastoris including human serum 
albumin, human trypsinogen, human lysozyme and porcine insulin precursor [74, 87, 151, 162, 
171-173]. To investigate secretion saturation an ideal model protein would not put a strain on the 
secretory pathway and ideally be one that folds well (to prevent the induction of UPR). The more 
stable a protein the better it folds and the less stress it puts on the secretory pathway; thus 
reducing induction of UPR [173]. Human serum albumin (HSA) was selected as the model protein 
for evaluation throughout this thesis. Production up to 10 g L-1 has been reported using P. pastoris 
[140]. The high titres achieved have led to many fusion proteins being produced with HSA in 
order to increase the secretion of complex proteins [174-176].  
HSA is the most abundant protein in the body, is soluble, globular and unglycosylated [63, 177]. It 
is important therapeutically for stabilizing blood volume in burns and shock patients and is a 
carrier protein for steroids, fatty acids and thyroid hormones [177-179]. Furthermore HSA is used 
as an excipient for vaccines or therapeutic proteins and as a result demand for this protein is 
incredibly high [179-181]. It has been reported that due to the expanding use of HSA the 
worldwide market stands at approximately 500 tonnes a year; in doses of up to 10 g per dose it 
can be used to treat severe hyperalbuminemia or traumatic shock [39, 172]. The main source of 
HSA is plasma HSA (pHSA), which is extracted from blood donations; however there are several 
problems including the shortage of supply and the risk of the spread of pathogenic viruses [140]. 
HSA has been produced in a range of expression systems including  B. subtilis but incorrect 
processing of the protein resulted in immune rejection [182]. More recently successful large scale 
production of HSA has been produced using Oryza sativa yet no testing has been done on its 
immunological compatibility [39]. Recombinant HSA was first produced in P. pastoris by 
Kobayashi et al. in 1998 and since then developed has continued extensively [172, 182-184]. 
In 2005 Bipha Corporation (Hokkaido, Japan) became the first company worldwide to produce 
rHSA from P. pastoris on an industrial level, calling this Medway [127, 185]. In 2008 the first 
clinical study was conducted as a comparison between pHSA and rHSA from P. pastoris with 
favourable results towards the use of the recombinant protein [186]. In terms of use as a model 
protein HSA is an atypical protein, not due to its ease of expression (which is beneficial) but in the 
fact it is such a highly charged protein, which may have different effects than a less charged and 
globular protein [187]. 
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1.18 Aims and Objectives 
This thesis aims to explore various factors that can affect the specific productivity of 
recombinant protein expression using the heterologous expression platform P. pastoris. 
Through examining in detail various aspects that have been reported to show increased titre 
a better system is hoped to be achieved for streamlined production. Aspects to be 
investigated will include the use of multi-copy clones, an optimised protein and the effects 
of clonal variation. In order to achieve these aims the following objectives must be met:  
 To determine the effects of multi-copy clones on production levels using the model 
protein HSA. 
 To investigate negative effects of using multi-copy clones such as secretion 
saturation, induction of the unfolded protein response and genetic instability.  
 To establish possible solutions to issues of genetic instability.  
 To determine whether clonal variation is caused solely by integration of the vector. 
 To observe the effects of clonal variation strains on transcript levels through the use 
of transcriptomic analysis. 
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2 Materials and Methods 
2.1 Strains and Plasmids 
Table 2.1 E. coli strains used in this study 
 
Strain Description Source Reference 
E. coli DH5α 
F, φ80dlacZΔM15 Δ(lacZYA-argF)U169 
deoR recA1 endA1 hsdR17(rK-.mK+) 
phoA supE44 λ- thi-1 gyrA96 relA1. 
Invitrogen 
Invitrogen 
Catalogue 
E. coli JM109 
endA1, recA1, gyrA96, thi, hsdR17 (rk., 
mk+), relA1,supE44, Δ(lac-proAB), [F′, 
traD36, proAB, laqIqZΔM15]. 
Promega Promega Catalogue 
E. coli BioBlue 
recA1 ,em>endA1 gyrA96 thi-1 
hsdR17(rk-, mk+) supE44 relA1 lac [F’ 
proAB lacI
q
ZΔM15 Tn10(Tet
r
)] 
Bioline Bioline Catalogue 
E. coli pPICzA 
JM109 (pPICzA:: AOX1 Zeo) 
Invitrogen 
Invitrogen 
Catalogue 
E. coli pPICzαA 
JM109 (pPICzαA:: AOX α-MF Zeo) 
Invitrogen 
Invitrogen 
Catalogue 
E. coli pPICz-HSA JM109 (pPICzA:: HSA) This Study Unpublished 
E. coli pα-HSA JM109 (pPICzα:: HSA-SP) This Study Unpublished 
E. coli pαTX3 JM109 (pPICzα:: Try1 x3) 
Imperial 
College 
Dr. Bryn Edwards-
Jones, unpublished 
E. coli pαTX3R51 JM109 (pPICzα: Try1 x3 RAD51) This Study Unpublished. 
E. coli pαTX3R52 JM109 (pPICzα:: Try1 x3 RAD52) This Study Unpublished. 
E. coli pIB2 MC1061 (pIB2:: HIS4 GAP) Addgene [188-189] 
E. coli pIBTX3 JM109 (pIB2:: AOX1 Try1 x3 ) This Study Unpublished. 
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Table 2.2 P. pastoris strains used in this study 
 
Strain Description Source Reference 
X-33 Wild type, biotin auxotroph Invitrogen 
Invitrogen 
Catalogue 
GS115 his4 Invitrogen 
Invitrogen 
Catalogue 
SMD1163 pep4 prb1 his4 Invitrogen 
Invitrogen 
Catalogue 
GpPICz-HSA GS115 (pPICz A; HSA) This Study Unpublished 
GpαH GS115 (pPICzα A; HSA-SP) This Study Unpublished 
GpαHopt GS115 (pPICzα A; HSAopt) This Study Unpublished 
GpαTx3 GS115 (pPICzα A; TRY1 (3 copies)) 
Imperial 
College 
Dr. Bryn Edwards-
Jones, unpublished 
GpαTx3R51 
GS115 (pPICzα A; TRY1 (3 copies); 
RAD51) 
This Study Unpublished 
GpαTx3R52 
GS115 (pPICzα A; TRY1 (3 copies); 
RAD52) 
This Study Unpublished 
GpIBAOXTx3 GS115 (pIB2; TRY1 (3 copies); HIS4) This Study Unpublished 
GpIBTx3R51 GS115 (pIB2; TRY1 (3 copies); RAD51) This Study Unpublished 
GpIBTx3R52 GS115 (pIB2; TRY1 (3 copies); RAD52) This Study Unpublished 
GS115 HIS4-R52 GS115 (HIS4-RAD51) This Study Unpublished 
GS115-HIS4-R52 GS115 (HIS4-RAD52) This Study Unpublished 
GpGRzαHSA GS115 (pGRzα; HSA-SP; rDNA locus) This Study Unpublished 
GpGRzαHSAopt GS115 (pGRzα; HSAopt; rDNA locus) This Study Unpublished 
GpARzαHSA GS115 (pARzα; HSA-SP; rDNA locus) This Study Unpublished 
GpARzαHSAopt GS115 (pARzα; HSAopt; rDNA locus) This Study Unpublished 
GpARzαHSAopt BglII 
GS115 (pARzα; HSAopt; rDNA locus, 
integrated using BglII 
This Study Unpublished 
Promega, Southampton, UK 
Invitrogen, Paisley, UK 
Bioline, London, UK 
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Table 2.3 Plasmids used in this study 
 
Plasmid Description Source Reference 
pPICz A 
Expression vector based on AOX1 promoter  
MCS; Sh ble; pUC ori; 5’AOX1-MCS-AOX1 TT 
Invitrogen 
Invitrogen 
Catalogue 
pPICzα A 
Expression vector based on AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
Sh ble; pUC ori; 5’AOX1-MCS-AOX1 TT 
Invitrogen 
Invitrogen 
Catalogue 
pPICz-HSA 
Expression vector based on AOX1 promoter 
MCS; Sh ble; pUC ori; 5’AOX-MCS-AOX1 TT 
HSA containing native secretion signal 
This Study Unpublished 
pα-HSA 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
Sh ble; pUC ori; 5’AOX1-MCS-AOX1 TT 
HSA with native secretion signal removed 
This Study Unpublished 
pα-HSAopt 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
Sh ble; pUC ori; 5’AOX1-MCS-AOX1 TT 
Optimised HSA gene with native secretion 
signal removed. 
This Study Unpublished 
pα-TX3 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
Sh ble; pUC ori; 5’AOX1-MCS-AOX1 TT  
TRY1 gene (3 copies) 
Imperial 
College 
Dr. Bryn Edwards-
Jones, 
unpublished 
pIB2 
Expression vector based on the GAP promoter 
AOX1 TT; pMB1 ori; AmpR; HIS4 
Addgene [188-189] 
pIBAOXTx3 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
pUC ori; 5’AOX1-MCS-AOX1 TT; AmpR; HIS4 
TRY1 gene (3 copies); 
This Study Unpublished 
pIBTx3R51 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
HIS4; pUC ori; 5’AOX1-MCS-AOX1 TT TRY1 gene 
(3 copies); 500 bp sequence identity  to RAD51 
This Study Unpublished 
pIBTx3R52 
Expression vector based on the AOX1 promoter 
α-mating factor prepro signal sequence; MCS; 
HIS4; pUC ori; 5’AOX1-MCS-AOX1 TT  
TRY1 gene (3 copies); 500 bp sequence identify 
to RAD52 
This Study Unpublished 
pGRzαHSA 
Expression vector on the GAP promoter, α-
mating factor prepro signal sequence; MCS;HSA 
removing minus the native secretion signal; Sh 
This Study Unpublished 
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ble; pUC ori; rDNA locus for integration 
pGRzαHSAopt 
Expression based on the GAP promoter; α-
mating factor prepro signal sequence; MCS; 
HSA optimized gene; Sh ble; pUC ori; rDNA 
locus for integration 
This Study Unpublished 
pARzαHSA 
Expression based on the AOX1 promoter; α-
mating factor prepro secretion signal; MCS; 
HSA removing native secretion signal; Sh ble; 
pUC ori; rDNA locus for integration 
This Study Unpublished 
pARzαHSAopt 
Expression based on the AOX1 promoter; α-
mating factor prepro secretion signal; MCS; 
HSA optimized gene; Sh ble; pUC ori; rDNA 
locus for integration 
This Study Unpublished 
pARzαHSAopt BglII 
Expression based on the AOX1 promoter; α-
mating factor prepro secretion signal; MCS; 
HSA removing native secretion signal; Sh ble; 
pUC ori; rDNA locus (integrated at the BglII site) 
for integration 
This Study Unpublished 
Invitrogen, Paisley, UK 
2.2 Media 
2.2.1 Miller Lysogeny Broth (LB) Media 
1% (w/v) Peptone au casein (Merck, Nottingham, UK), 0.5% (w/v) Yeast Extract (Merck, 
Nottingham, UK), 1% (w/v) NaCl. For agar plates 1.5% (w/v) agar included. 
2.2.2 Lennox Lysogeny Broth (LB) Media 
For pPICz vectors propagated in E. coli low salt LB must be used; 1% (w/v) Peptone au casein 
(Merck, Nottingham, UK), 0.5% (w/v) Yeast Extract (Merck, Nottingham, UK), 0.5% (w/v) NaCl. For 
agar plates 1.5% (w/v) agar included. 
2.2.3 Yeast Extract Peptone Medium (YPD) 
1% (w/v) Yeast Extract (Merck, Nottingham, UK), 2% (w/v) Peptone au casein (Merck, 
Nottingham, UK), 2% (w/v) Dextrose (glucose). For agar plates 2% (w/v) agar included. 
2.2.4 Buffered Glycerol-complex Medium (BMGY) or Buffered-Methanol-complex 
Medium (BMMY) 
1% (w/v) Yeast Extract (Merck, Nottingham, UK), 2% (w/v) Peptone au casein (Merck, 
Nottingham, UK), 100mM potassium phosphate, pH6.0, 1.34% (w/v) Yeast Nitrogen Base (YNB),  4 
x 10-5% (w/v) d-Biotin, 1% (v/v) glycerol or 0.5% (v/v) methanol. 
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2.2.5 Minimal Dextrose Medium (MD) or Minimal Methanol Medium (MM) 
1.34% (w/v) Yeast Nitrogen Base (YNB), 4 x 10-5% (w/v) d-Biotin, 2% (w/v) Dextrose (glucose) or 
0.5% (v/v) methanol. Plus or minus 4 x 10-3% (w/v) Histdine when using a his4 mutant strain.  
2.2.6 Buffered Minimal Glycerol Medium (BMG) or Buffered Minimal Methanol 
Medium (BMM) 
1.34% (w/v) Yeast Nitrogen Base (YNB), 4 x 10-5% (w/v) d-Biotin, 1% (v/v) glycerol or 0.5% (v/v) 
methanol. Plus or minus 4 x 10-3% (w/v) Histdine when using a his4 mutant strain. 
2.2.7 Tryptone Soy Agar (TSA) 
1.7% (w/v) Peptone au casein (Merck, Nottingham, UK), 0.3% (w/v) Select Soytone (Merck, 
Nottingham, UK), 0.3% (w/v) Dextrose (glucose), 0.5% (w/v) Sodium Chloride, 0.25% (w/v) 
Dipotassium Phosphate, 1.5% (w/v) agar.  
2.2.8 Pichia Cell Bank Medium (PCMB) 
3% (w/v) Yeast Extract (Merck, Nottingham, UK), 1.8% Dextrose (glucose), 1.74% (w/v) 
Dipotassium phosphate, 0.01% (w/v) d-Biotin. Adjusted to pH 6.0 ± 0.2 with 85% (v/v) Phosphoric 
Acid 
2.2.9 Pichia Freezer Mix (PFM) – Cryopreservation Medium 
8.5% (v/v) Glycerol, 1.5% (w/v) Yeast Extract (Merck, Nottingham, UK), 2.18% (w/v) Dipotassium 
Phosphate (adjust pH to 6.0 ± 0.2 using 85% (v/v) Phosphoric Acid), 1.8% (w/v) Dextrose 
(glucose), 2 x  10-4% (w/v) d-Biotin.  
2.2.10 Fermentation Inoculation Media 
2.2.10.1 Yeast Extract/Peptone Media 
0.495% (w/v) Yeast Extract (Merck, Nottingham, UK), 0.99% (w/v) Select Soytone (Merck, 
Nottingham, UK), 4.5 x 10-3% (v/v) Polypropylene Glycol 2000. pH adjusted to 6.0 ±0.2 at 20-25°C 
using 85% (v/v) Phosphoric acid. 
2.2.10.2 Glucose Solution 
2.2% (w/v) Glucose monohydrate, filter sterilised.   
2.2.11 Fermentation Media 
A complex fermentation medium was used which is the proprietary intellectual property of 
Fujilfilm Disoynth Biotechnologies. 
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2.3 Molecular Biology Methods 
2.3.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was employed to separate DNA and RNA fragments based on size. 
Typically 1% (w/v) agarose gels were used, with the exception of small fragments, such as RAPD-
PCR products  where a 2.5% (w/v) agarose gel was used instead. Agarose was dissolved in 1x TAE 
buffer (50X TAE Buffer; 242 g L-1 Tris base, 57.1 mL L-1 glacial acetic acid, 100mL   L-1 0.5 M EDTA, 
pH 8.0) and heated until all the agarose had melted before being left to cool to approximately 
50°C. SYBR® Safe (Invitrogen, Paisley, UK) was diluted 1 in 20,000 in the agarose and poured into a 
mould and left to solidify. 
DNA samples were diluted into 5X Loading Buffer (30% [v/v] glycerol, 0.25% [w/v] bromophenol 
blue) and loaded onto the gel. 5 μL of molecular weight marker was added to one of the lanes, 
typically GeneRuler™ 1kb DNA Ladder (Fermentas, York, UK; Fig 2.1) was used. 
 
Figure 2.1 DNA Molecular Marker Size 
5 μL of GeneRuler™ 1 kb DNA ladder run on a 1% (w/v) agarose gel. Size of bands is 
indicated by annotations (bp) and relative quantity (ng) per each 5 μL. 
 
Agarose gels were typically run in Bio-Rad Wide Mini-Sub Cell GT Tanks at 100V using power 
supplied from a Bio-Rad Power Pac Basic (Bio-Rad, Hemel Hempstead, UK). DNA was visualised 
using a short wave-length UV transilluminator and photographed using a Syngene G:Box ChemiHR 
system (Syngene, Cambridge, UK). The G:Box relies on GeneSnap for the acquisition of pictures 
and GeneTools for all analytical purposes. Once collected images were printed on a Mitsubishi 
P93D thermal printer (Syngene, Cambridge, UK). 
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2.3.2 Plasmid DNA Isolation  
Plasmid DNA was isolated from E. coli using either a Qiagen Spin Mini-prep Kit or hi-speed Midi-
prep kit (Qiagen, Crawley, UK), depending on the amount of DNA required, following the 
manufacturer’s protocol. Both protocols use alkaline lysis and SDS-precipitation. 
2.3.3 Isolation of Yeast Genomic DNA 
Genomic DNA was prepared using one of three methods. For qPCR the DNeasy Plant Mini Kit 
(Qiagen, Crawley, UK) was used according to the manufacturer’s protocol. For RAPD-PCR and 
other basic PCR, genomic DNA was extracted using MasterPure Yeast DNA purification Kit 
according to the manufacturer’s protocol (Cambio, Cambridge, UK). 
For Southern blots, genomic DNA was isolated based on the method of Philippsen [190]. All 
centrifugation steps were performed at 4°C at 4000 rpm. A 10 ml culture of P. pastoris was grown 
in YPD overnight at 30°C at 250rpm in 50 mL centrifuge tubes. Cells were centrifuged for 10 
minutes, resuspended in 10 ml water and centrifuged for a further 10 minutes. Cells were 
resuspended in 3 mL of 0.9 M sorbtiol, 0.1 M EDTA and 14 mM β-mercaptoethanol. Two hundred 
units of lyticase (Sigma-Aldrich, Dorset, UK) were added and cells left to form spheroplasts at 37°C 
for 2 hours. Spheroplasts were centrifuged for 5 minutes and the supernatant discarded. The 
pellet was resuspended in 3 mL of 50 mM Tris-HCL, 50 mM EDTA, pH 8.0, mixed with 0.3% SDS 
and incubated at 65°C for 30 minutes. 1 mL 5 M KOAc was added and left on ice for 60 minutes. 
Samples were centrifuged for 30 minutes, the supernatant transferred to a 15 mL centrifuge tube 
to which 4 mL ice-cold absolute ethanol was added and the tube centrifuged for 10 minutes. 
Supernatant was discarded, the pellet washed with 70% (v/v) ethanol and centrifuged for a 
further 10 minutes. The pellet was resuspended in 300 µL TE, pH 7.5 then 15 µL of 10 mg mL-1 
DNase-free RNase was added and the mixture incubated for 30 minutes at 37 °C. 300 µL phenol-
chloroform (1:1) was added and mixed by inverting the tube, which was then centrifuged for 10 
minutes. Supernatant was removed and transferred to a 1.5 mL eppendorf tube; 15 µL of 3 M 
NaOH and 700 µL isopropanol was then added. The sample was centrifuged for 10 minutes and 
the pellet washed in 80% (v/v) ethanol and air dried before resuspending in a final volume of 100 
µL TE, pH 7.5. 
2.3.4 DNA quantification 
DNA and RNA was quantified by absorbance measurements at 260/280 nm. A sample of 5 μL of 
DNA was added to 45 μL of water and loaded onto a Grenier Bio-One 384 well plate (Scientific 
Laboratory Supplies, Nottingham, UK). The absorbance was measured at 260 nm and 280 nm 
using a Synergy HT multi-detection microplate reader (Bio-Tek, Potton, UK). Concentration of 
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DNA was calculated from the absorbance at 260 nm, while protein contamination was 
determined by the ratio of absorbance at 260/280 nm. 
Quantities were also estimated based on comparison of the fluorescence of bands (of known 
amount) of the DNA molecular size ladder and the sample of interest, on agarose gels. 
2.3.5 DNA Purification and Concentration 
DNA was concentrated using the Zymo Clean and Concentrate kit (Cambridge BioScience, 
Cambridge, UK) following the spin column instructions from the manufacturer’s manual. PCR 
products were purified using the microcentrifuge protocol in the Zymo Gel Extraction and 
Purification Kit (Cambridge BioScience, Cambridge, UK). 
2.3.6 Restriction Enzymes 
Restriction enzymes were purchased from New England Biolabs (Hertfordshire, UK), Promega 
(Southampton, UK) or Fermentas (York, UK) and digestions were performed according to the 
manufacturer’s instruction manual, typically at 37°C for 3 hours. Double digests were carried out, 
where appropriate, using multi-core buffer Tango as provided by Fermentas. Digested products 
were purified on agarose gels or using spin columns. 
2.3.7 HSA Codon Optimised Gene 
The HSA gene was codon optimised and synthesised by GenScript (Piscataway, NJ, USA) using the 
algorithm OptimumGene™ [191].  
The complete gene sequence can be seen in Appendix 9.1. 
2.3.8 Ligation  
Ligation was carried out using T4 DNA Ligase (Fermentas, York, UK) according to the 
manufacturer’s instructions. The molar ratio of plasmid to insert was typically 3:1, respectively, 
for cohesive end ligation. The ligation mixture was incubated for 1 hour at room temperature or 
overnight at 4°C. 
2.3.9 Easy Cloning Vectors 
pGEM®-T Easy Vector System (Promega, Southampton, UK) was used for T/A cloning according to 
the manufacturer’s protocols. The reaction was set up as 5 μL 2X rapid ligation buffer, 1 μL 
pGEM®-T Easy Vector, 3 μL PCR product and 1 μL T4 DNA Ligase, and incubated for 1 hour at 
room temperature. The ligation mixture was then transformed into JM109 chemically competent 
cells. The pGEM®-T Easy Vector contains the lacZ gene, which allows for blue white colony 
screening when spread onto plates containing X-Gal. 
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For blunt end cloning CloneJET™ PCR Cloning Kit (Fermentas, York, UK) was used. The reaction 
was set up as per the manufacturer’s protocol; 10 μL 2X Reaction Buffer, 2 μL PCR product, 1μL 
pJET 1.2/blunt Cloning Vector (50 ng μL-1), 1 μL T4 DNA Ligase and made up to a total of 20 μL 
with nuclease free water. The mixture was incubated for 5-30 minutes at room temperature. 10 
μL of the reaction was used to transform JM109 chemically competent cells. The pJET1.2/blunt 
vector contains a gene that encodes a lethal product that becomes disrupted upon the successful 
insertion of blunt ended DNA such as a PCR product; thus only recombinant vectors containing a 
DNA insert are able to form colonies. 
2.3.10 Transformation and preparation of competent cells of E. coli 
Chemically competent JM109 cells were prepared according to the method described by Chung et 
al. [192] using TSS (5 g PEG8000, 1.5 mL 1M MgCl2, 2.5 mL DMSO, LB to 50 mL). An overnight 
culture in  5 mL of LB was grown at 37°C and diluted the next morning into 50 mL LB in a 250 ml 
conical flask. OD600 was monitored and the cells harvested at an OD600 0.2-0.5. The cells were put 
into 50 mL centrifuge tubes, incubated for 10 minutes on ice then centrifuged at 4000 rpm at 4°C 
for 10 minutes before being resuspended in 5 mL chilled TSS. Aliquots of 100 µL were added to 
ice-cold eppendorf tubes and either used immediately or frozen at -80°C [192-193]. 
An aliquot of 100 µL cells was thawed on ice for 5 minutes before 1-50 ng (in a volume no greater 
than 10 µL) of ligated DNA was added and the mixture incubated on ice for 10 minutes. Cells were 
heat shocked at 42°C for 45 seconds, before returning to ice for a further 2 minutes. 1 mL of LB 
was added to the microcentrifuge tube and cells were recovered at 37°C with shaking at 250 rpm 
for 1 hour. Cells were centrifuged and resuspended in 100 µL LB, to be spread on appropriate 
antibiotic plates and incubated overnight at 37°C. 
Chemically competent BioBlue cells (Bioline, London, UK) were transformed according to the 
manufacturer’s protocol. 
2.3.11 Collection of cells for RNA Extraction 
In order to store cells for RNA extraction at a later date 3 x 108 cells were aliquoted into 5 mL of 
RNAlater® (Applied Biosystems, Warrington, UK), this was equivalent to 1 mL of an OD600 10 of P. 
pastoris culture. Cells were then centrifuged for 5 minutes in an Eppendorf  5810-R centrifuge 
fitted with a A-4-62 rotor (Eppendorf UK Limited, Histon, UK) at 4°C and 9000 x g. The 
supernatant was removed and cells resuspended in 0.5 – 1 mL RNAlater®. 
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2.3.12 Isolation of RNA 
RNA was isolated using RiboPure – Yeast Kit (Applied Biosystems, Warrington, UK) according to 
the manufacturers’ instruction manual. RNase-free pipette tips and microcentrifuge tubes were 
used throughout the protocol along with RNase-free water. Typically 3 x 108 yeast cells were 
collected, equivalent to 1 mL culture of OD600 10 of P. pastoris. DNase I treatment was done 
according to manufacturer’s protocol except incubation was extended to 1 hour before DNase 
Inactivation reagent was added to the mixture. 
2.3.13 Quantification and Quality Checks of RNA  
RNA was quality checked using an Experion Automated Electrophoresis System and the RNA 
StdSense chip and reagents (Bio-Rad, Hemel Hempstead, UK). RNA was prepared and the chip 
primed according to the manufacturer’s protocol. Quantification and quality was recorded as 
generated by Experion software (Bio-Rad, Hemel Hempstead, UK).  
2.3.14 cDNA 
cDNA was prepared using the High-Capacity cDNA Archive Kit (Applied Biosystems, Warrington, 
UK) according to the manufacturer’s instruction manual. 1 µg RNA was used in a total reaction 
volume of 20 µL. 
2.3.15 Polymerase Chain Reaction (PCR) 
Oligonucleotides were purchased from Invitrogen, Paisley, UK, a full list of primers used can be 
seen in Appendix 9.2. PCR reactions were carried out in sterile 0.2 ml PCR tubes (Thermo Fisher 
Scientific, Loughborough, UK) in either an Eppendorf Mastercycle Gradient or Bioer Gene Pro 
thermal cycler (Eppendorf UK, Histon, UK; Alpha Laboratories, Eastleigh, UK). Reactions using 
Phusion Hot Start II (New England Biolabs, Herefordshire, UK) were set up with 10 µL Buffer, 4 µL 
2.5 mM dNTPs, 2.5 µL Primer 1, 2.5 µL Primer 2, 1 µL of template DNA made up to 50 µL with 
water. An annealing temperature of 60°C was used for all reactions and elongation at 72°C for 15-
30 seconds per expected Kb of fragment for 35 cycles. For analytical PCR Biomix Red solution 
(Bioline, London, UK) or REDTaq Ready Mix (Sigma-Aldrich, Dorset, UK) mix comprised of 10 µL 
Biomix Red/REDTaq, 1.5 µL Primer 1, 1.5 µL Primer 2, 1 µL template DNA and made up to a total 
of 20 µL with water. Annealing temperature was adjusted depending on the melting temperature 
of the primers used and elongation was at 72°C for 1 minute per Kb of expected PCR fragment for 
35 cycles. 
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2.3.16 Gibson Assembly Protocol 
Construction of vectors using the Gibson assembly protocol was adapted from Gibson et al. [194-
195]. Up to four PCR products were annealed together using the one-step isothermal DNA 
assembly protocol. Briefly, 5x isothermal reaction buffer was prepared containing 25% PEG-8000, 
500 mM Tris-HCL pH7.5, 50 mM MgCl2, 50 mM DTT, 1mM of each dNTPs and 5 mM NAD. 320 μL 
of the 5x isothermal reaction buffer was used to create the assembly master mix, with the 
addition of 0.64 μL 10U μL-1 T5 exonuclease (Epicentre Biotechnologies, Madision, US), 20 μL of 
2U μL-1 Phusion DNA polymerase (New England Biolabs, Herefordshire, UK), 160 μL of 40U μL-1 
Taq DNA Ligase (New England Biolabs, Herefordshire, UK) with dH2O to a final volume of 1.2 mL.  
Primers were designed with a 30-50 bp region of sequence identical to that flanking the DNA 
fragment to which it was to be joined. Once all the relevant fragments had been amplified with 
the added linker regions, equimolar concentrations of up to 100 ng of DNA from each fragment 
were added to 15 μL master mix and incubated for one hour at 50°C before being transformed 
into chemically competent E. coli. 
2.3.17 Random-Amplification of Polymorphic DNA (RAPD)-PCR 
Random decamer primers were selected and purchased from Invitrogen, Paisley, UK. PCR primers 
were designed to amplify random segments of genomic DNA using a single primer. Reactions 
were set-up comprised of 12.5 μL Biomix Red (Bioline, London, UK), 1 μL decamer primer, 1 μL 
genomic DNA made up to 25 μL with water. Cycling conditions used were an initial denaturation 
at 95°C for 5 minutes, 94°C for 1 minute, 35°C for 1 minute, 72°C for 2 minutes for 45 cycles 
followed by a final extension step at 72°C for 5 minutes. PCR reaction products were separated on 
2.5% (w/v) agarose gels.  
2.3.18 Quantitative Polymerase Chain Reaction (qPCR) 
Genomic DNA prepared using Qiagen DNeasy Plant Mini Kit (Qiagen, Crawley, UK), was 
normalised to 10 ng µL-1. qPCR primers were designed for the amplification of a region of the 
gene of interest no bigger than 200 bp (Appendix 9.2). 
Reactions were set up using 2X SYBR® Green JumpStart Taq Ready Mix (Sigma-Aldrich, Dorset, 
UK), 1 µL of forward and reverse primers and 3 µL of normalised genomic DNA were made up to 
20 µL with water. A Chromo4™ Real-Time Detector using the thermal cycler software Opticon 3 
(Bio-Rad, Hemel Hempstead, UK) was used. qPCR settings were: 96°C for 5 minutes and 40 cycles 
of 96°C for 30  seconds, 55°C for 30 seconds then 72°C for 30 seconds with the plate read at the 
end of each cycle, and finally 72°C for 10 minutes. A melting curve was recorded from 55°C - 95°C 
and the plate read at every 0.2°C and held for 2 seconds. 
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2.3.18.1 qPCR calculations 
Data was analysed using the comparative Delta-delta-Ct (ΔΔCt) method and all samples 
normalised to ACT1 (housekeeping gene). The equations required to calculate fold change are 
shown below. 
 
 
 
ΔΔCt works on the assumption of 100% accuracy for the primer sets. The Pfaffl method, which 
was implement for this thesis takes into account the specific primer efficiencies [196-197]. To 
calculate primer efficiencies four 10-fold serial dilutions of genomic DNA were used as a template 
in qPCR. A standard curve exhibiting Ct values was plotted against log concentration and the 
slope of the line used to calculate efficiencies. Table 6 outlines primer efficiencies for qPCR 
primers used. 
Table 2.4 qPCR Primer Efficiencies 
 
Gene of Interest Primer 1 Primer 2 Primer Efficiencies (%) 
ACT1 020-ACT1q1 021-ACT1q2 91.05 
HAC1 067-HAC1q3 066-HAC1-q4 90.24 
KAR2 010-kar2q1 011-kar2q2 87.23 
PDI 012-PDIq1 013-PDIq2 86.96 
HSA 070-HSAq1 071-HSAq2 90.77 
HSAopt 188-HSAoptq3 189-HSAoptq4 97.82 
Zeo (R) 040-Zeoq3 041-Zeoq4 88.23 
TRY1 383-Try1q7 384-TRY1q8 100.67 
 
2.3.19 Quantitative Reverse Transcription (RT)-qPCR 
RT-qPCR was carried out using the same protocol as qPCR, using cDNA as opposed to genomic 
DNA.  Of the initial reverse transcription reaction (diluted 1:10), 5 μL of cDNA was used in a 20 μL 
reaction volume. Prior to conversion to cDNA an RT-qPCR control plate was used to confirm the 
absence of genomic DNA, using 5 μL of 1 μg RNA diluted in 200 μL water. 
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2.4 Transformation of P. pastoris by Electroporation 
2.4.1 Preparation of DNA for Transformation 
To achieve site directed homologous recombination in P. pastoris the vector was linearised within 
the region of homology. After confirmation that the plasmid had been digested, by analysis on 
agarose gel, P. pastoris was transformed with 5-10 µg of the linearised DNA. 
2.4.2 Electroporation Protocol 
The electroporation protocol was modified from the Pichia manual (Invitrogen, Paisley, UK). A 5 
mL culture of P. pastoris in YPD was grown overnight at 250 rpm at 30°C. The overnight culture 
was used to inoculate 200 mL YPD to an OD600 0.5. The culture was incubated until OD600 1.3-1.5, 
which took approximately 4 hours. Cells were centrifuged at 4000 rpm for 5 minutes, washed 
with 200 mL ice-cold autoclaved deionised water, and centrifuged again. Cells were washed with 
100 mL water and finally with 10 mL of ice-cold 1 M sorbitol, before being resuspended in 1 mL 1 
M sorbitol. Aliquots of 80 μL of cells were incubated on ice for 5 minutes before 5-10 μL of 
linearised DNA was added and incubated for a further 5 minutes. The cells were pulsed at 2000V, 
25 µF, 200 Ω, for approximately 5 milliseconds, using the GenePulser electroporator in 2 mm 
cuvettes (Bio-Rad, Hemel Hempstead, UK). Immediately 1 mL of ice-cold 1M sorbitol was added 
to the cuvette and the contents transferred to a sterile eppendorf tube. The transformation was 
incubated at 30°C without shaking for 1-2 hours. After suitable incubation the transformation was 
plated onto appropriate selection. The plates were incubated for 3-5 days at 30°C. 
2.5 Post-transformational Vector Amplification 
Post-transformational vector amplification (PTVA) utilised a gradual step-wise increase in Zeocin 
concentration to generate multi-copy inserts of heterologous genes and selectable markers in P. 
pastoris [149]. Transformants were initially isolated on 100 µg mL-1 Zeocin YPD plates as 
described. Single colonies were streaked to single colonies on a fresh 100 µg mL-1 Zeocin YPD 
plate and grown for 3-5 days at 30°C. Individual colonies were selected and spotted onto 100 µg 
mL-1 and left to grow under the same conditions. Tolerant strains were then selected by spotting 
progressively on YPD plates containing 200 µg mL-1, 300 µg mL-1, 500 µg mL-1, 1000 µg mL-1 and 
finally 2000 µg mL-1 Zeocin.  
The liquid variant of PTVA was adapted to ensure isolation of microbiologically pure samples. 
Individual colonies isolates from 100 μg mL-1 Zeocin plate were inoculated into 5 mL YPD and left 
to grow for 24 hours. After 24 hours cultures were centrifuged removing the spent media, before 
resuspending in YPD containing 200 μg mL-1 Zeocin. This was continued with every 24 hours 
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growth medium being replaced containing increasing concentration of Zeocin as described above. 
After 24 hours growth on 2000 μg mL-1 Zeocin cultures were plated onto a YPD plate containing 
2000 μg mL-1 and left to incubate for 3-5 days at 30°C. 
2.6 Preparation of Cell Banks for Fermentation 
Two research cell bank (RCB) flasks were prepared containing 250 mL Pichia Cell Bank Medium 
(PCBM) and 100 μg mL-1 Zeocin were inoculated with a single colony from a 100 μg mL-1 Zeocin 
YPD plate and incubated at 30°C and 250 rpm in an orbital shaker. Cultures were grown for 20 
hours until OD600 of between 6 and 20 was reached. Samples were transferred to 50 mL sterile 
centrifuge tubes and spun for 20 minutes at 5000 rpm, at 4°C. The supernatant was discarded and 
the pellet was resuspended to approximately OD600 10 in Pichia Freezer Mix (PFM) using the 
following equation; 
 
 
The resuspended culture was separated into 1 mL aliquots in cyrovials and stored at -80°C.  
2.6.1 Microbiological Purity Test 
From a single vial of prepared cell bank 10 μL was streaked out onto a TSA and YPD plates in 
duplicate and incubated at 30°C and 37°C for 72 hours. Fresh samples of culture were analysed by 
microscopic examination of Gram stained slides. Liquid culture was mixed with ¼ Strength Ringers 
(Sigma-Aldrich, Dorset, UK) onto a glass side and left to dry at 105°C for 5 minutes. The slide was 
treated using Gram Stain Reagents according to the manufacturer’s protocol (Sigma-Aldrich, 
Dorset, UK.). The slide was viewed under oil immersion at 1000x TM. Only vials that indicated 
pure cultures were used for fermentation. 
2.7 Small Scale Heterologous Protein Expression from Recombinant P. pastoris 
Strains 
2.7.1 Expression in 24-well microtitre plates 
The protocol was adapted from the Pichia manual (Invitrogen, Paisley, UK) for growth in 24 deep-
well microtitre plates (Whatman, Maidstone, UK) with adhesive gas permeable seals (Thermo 
Fisher Scientific, Loughborough, UK). Single colonies were used to inoculate 3 mL of BMGY and 
grown at 30°C, 250 rpm for 24 hours. The OD600 was measured and cultures normalised to OD600 
10. Cells were centrifuged for 5 minutes at 4000 rpm at room temperature and the supernatant 
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removed. The cultures were then resuspended with methanol containing BMMY and left to grow 
for a further 24 hours. Cells were grown for up to 3 days at 250 rpm, 30°C, with 100% methanol 
added to a final concentration of 0.5% (v/v) every 24 hours. 
2.7.2 Expression in 50 mL centrifuge tubes 
Expression was carried out as described previously, with the exception that 5 mL of culture was 
grown in 50 mL centrifuge tubes with the lid loosely attached for gas exchange. 
2.7.3 Expression in 250 mL baffled flasks 
Expression was carried out as described previously, with the exception that 20 mL of culture was 
grown in 250 mL baffled flasks (SciLabware Ltd, Staffordshire, UK).  
2.8 Fermentation in 15 L Bioreactors 
2.8.1 Inoculation Preparation 15 L Bioreactors for Fermentation 
Two 1 L flasks per each strain were prepared with a total of 450 mL Yeast Extract/Peptone Media 
and autoclaved at 121°C for 30 minutes. 50 mL of Glucose Solution was added to the flasks 
aseptically and placed in a shaking incubator for 1 hour at 30°C and 275 rpm. One RCB vial was 
removed from the -80°C freezer and left to thaw for 15 minutes. After an hour the flasks were 
inoculated aseptically with 220 μL of RCB suspension. The flasks were incubated for 20 hours at 
30°C and 275 rpm. 10 mL of sample was removed and aseptically aliquoted into two equal 
volumes. One of the aliquots was used to determine OD600 and the other was used to assess 
microbiological purity by Gram staining. Only cultures that appeared pure were used for 
fermentations. 
2.8.2 15 L Fermentation 
Fermentation 15 L vessels (Braun Biostat ED, Sartorius, Epsom, UK) were prepared prior to 
inoculation. Separate stab ports were prepared for ammonia, phosphoric acid, glycerol/yeast 
extract feed, antifoam, methanol feed and inoculum and sealed before autoclaving. Vessels were 
pre- sterilised before addition of 12.5 L fermentation media and re-sterilised at 121°C for 30 
minutes. Media volume was drained to 6 L before the addition of 60 mL trace elements solution 
and 12 mL d-Biotin solution (FDBK-Pichia medium).  
Pre-prepared stab ports were sterilely inserted into the 15 L vessel via one of the head plate 
septum for glycerol feed, antifoam, acid, base and inoculum. Additionally a stab port was inserted 
sub-surface level for the methanol port. Feed reservoirs were prepared for both the glycerol and 
methanol feeds (100% methanol; Merck, Germany). Fermentation parameters were established 
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on the digital control unit (DCU) to 28°C, stirrer at 700 rpm, airflow at 6 slpm and pH 5.0, while 
the pO2 controller was set to a minimum point of 30% via cascade 1 to stirrer and cascade 2 to 
gasmix. 
The fermenter was inoculated by transferring 240 mL of shake flask culture. Samples were 
removed asceptically at intervals to measure wet and dry cell weights, OD600 and to test for 
microbiological purity. Exhaustion of glycerol in the growth medium was characterised by a 
sudden fall in carbon dioxide evolution rate (CER) and agitator speed and a rise in pO2. Glycerol 
was then fed at 160 g h-1. Once 3900 g glycerol had been fed and OD600 reached 500-600 a 50 mL 
shot of methanol was added during over 10 minutes, simultaneously the glycerol feed was 
switched off. Methanol consumption was monitored by the agitator speed, before continuous 
methanol feed was established at 20 mL h-1. Fermentation was run for 48 hours post-induction. 
Samples were taken at 0, 2, 4, 6, 24 and 48 hours post-induction for analysis.  
2.9 SDS-PAGE Protein Gel 
2.9.1 12% (v/v) Resolving gel 
A 5 mL 12% (v/v) consisted of 2 mL Acrylamide mix (30% v/v acrylamide, 0.8% v/v bis-acrylamide), 
1.3 mL Tris-Cl (1.5 M, pH8.8), 50 μL 10% (w/v) SDS, 50 μL 10% (w/v) Ammonium persulphate, 2 μL 
Tetramethylethylenediamine (TEMED) and 1.5 mL distilled water.  
2.9.2 Stacking gel  
A 1 mL stacking gel consisted of 170 μL Acrlyamide mix (30% v/v acrylamide, 0.8% v/v bis-
acrylamide), 130 μL Tris-Cl (1 M, pH 6.8), 10 μL 10% (w/v) SDS, 10 μL 10% (w/v) Ammonium 
persulphate, 1 μL TEMED and 680 μL distilled water.  
2.9.3 SDS-PAGE Running Buffer (1x)  
3 g Tris-base, 14.4 g Glycine, 1g SDS 
2.9.4 1x SDS-PAGE Loading Buffer 
1x SDS-PAGE loading buffer contained 2.5% (w/v) 2M Tris-HCl pH 6.8, 0.2% (w/v) SDS, 0.6% (v/v) 
Glycerol, 0.05% (v/v) β-mercaptoethanol and 0.416% (w/v) bromophenol blue in a total volume of 
100 ml. 
2.9.5 Coomassie Blue Stain (1 Litre) 
0.2% (w/v) Coomassie Blue, 7.5% (v/v) acetic acid and 50% (v/v) ethanol made up to 1 L with 
water. 
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2.9.6 Coomassie Blue Destain (1 Litre) 
10% (v/v) acetic acid, 30% (v/v) ethanol made up to 1 L with water. 
2.9.7 Protein gel electrophoresis 
Culture supernatant samples were boiled with 5x SDS-PAGE loading buffer for 5 minutes. Cells 
were centrifuged and supernatant was loaded onto the gel along with 5 μL of unstained protein 
molecular marker or 10 μL PageRuler™ Prestained Protein ladder (Fermentas, York, UK). 
Electrophoresis was run in a Mini-PROTEAN® Tetra Cell (Bio-Rad, Hemel Hempstead, UK) at 25 mA 
for the stacking gel and 35 mA for the resolving gel for approximately one hour in 1X SDS-PAGE 
Running buffer.  
Gels were stained with either Coomassie Blue or SimplyBlue SafeStain (Invitrogen Corporation 
Paisley, UK). For gels stained with Coomassie Blue, gels were washed briefly in water and then left 
to stain on a shaker one hour. The gels were then transferred to Coomassie Blue stain for one 
hour while shaking. For SimplyBlue SafeStain, gels were washed 3 times in deionised water with 
shaking for 5 minutes. SimplyBlue SafeStain was added and left to stain for one hour. The gel was 
then washed with deionised water and left to destain for one hour. After an hour the water was 
changed and left to destain for another hour in deionised water. 
Gels with both types of staining were photographed using a G:Box SynGene gel doc (Syngene, 
Cambridge, UK). 
2.10 Albumin Blue Florescence Assay 
Albumin concentration was determined using the Albumin Blue Fluorescence assay according to 
the manufacturer’s instructions (Active Motif, La Hulpe, Belgium). Samples were equilibrated to 
room temperature prior to use. A HSA standard curve in duplicate was set up using the 
concentrations 200, 100, 50 25, 12.5, 6.3, 3.2 and 0.0 µg mL-1 in a black microtitre 96-well plate. 
The fluorescence was measured at excitation 560nm, emission 620nm using Synergy HT multi-
detection microplate reader (Bio-Tek, Potton, UK). 
2.11 Southern Blots 
2.11.1 0.2 M HCl 
2.4% (v/v) concentrated HCl made up to 400 mL with water. 
2.11.2 Denaturation Solution  
2% (w/v) NaOH, 8.7% (w/v) NaCl, made up to 800 mL with water. 
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2.11.3 Neutralisation Solution 
8.76% (w/v) NaCl, 6% (w/v) Tris-Base, 0.2% (v/v) 0.5 M EDTA, pH adjusted to 7.2-7.5 with HCl, 
made up to 800 mL with water. 
2.11.4 1 X Maleic Acid  
1.16% (w/v) Maleic Acid, 0.87% (w/v) NaCl, 0.85% (w/v) NaOH pellets, pH adjusted to 7.5 with 
NaOH, made up with 1 L with water and autoclaved. 
2.11.5 20 X SSC    
17.5% (w/v) NaCl, 8.8% (w/v) Na-Citrate, pH adjusted to 7.0 with HCl and made up with 1 L with 
water and autoclaved. 
2.11.6  Washing Buffer 
0.3% (w/v) Tween-20 in 500 mL maleic acid. 
2.11.7 Detection Buffer 
1.2% (w/v) Tris base, 0.58% (w/v) NaCl, pH adjusted to 9.5 with HCl made up to 1 L with water.  
2.11.8 Preparing the DIG-labelled DNA probe 
Template DNA was labelled according to the DIG-High Prime DNA Labelling instruction manual 
(Roche, West Sussex, UK). Briefly, template DNA (1 µg) was added to 16 µL filtered autoclaved 
dH2O and denatured by heating in boiling water for 10 minutes and chilled on ice; 4 µL DIG-High 
prime (Roche, West Sussex, UK) was added and centrifuged briefly followed by incubation for one 
hour at 37°C. The reaction was stopped by adding 0.2 M EDTA and/or by heating to 65°C for 10 
minutes. 
2.11.9 Blotting protocol 
The DIG-High Prime DNA Labelling and Detection Starter Kit were used for hybridization of DIG-
labelled probes for nucleic acid detection according to the manufacturer’s instructions (Roche, 
West Sussex, UK). All hybridisation steps were carried out in the Techne Hybridisation oven (Bibby 
Scientific Ltd, Staffordshire, UK).  
Briefly, genomic DNA (5-10 mg) was digested overnight with the respective restriction enzymes 
and visualised on a 1% (w/v) agarose gels. Gels were then washed in 0.25 M HCl for 10 minutes, 
rinsed in dH2O, soaked in 2-3 gel volumes of denaturing solution for 2 x 15 minutes, rinsed again in 
dH2O and soaked in 2-3 gel volumes of neutralisation solution for 2 x15 minutes. Gels were 
blotted onto Amersham Hybond-N+ membrane (GE Healthcare, Little Chalfont, UK) using 20 X 
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SSC. Post-transfer the membrane was soaked in 0.4 M NaOH for 2-60 minute and washed in 5 X 
SSC. 
Hybridization, stringency washes and detection were carried out according to the manufacturer’s 
protocol. The membrane was incubated with 1 mL CSPD ready to use (Roche, West Sussex, UK) at 
room temperature for 5 minutes. Membranes were visualised using the G:Box SynGene gel doc 
(Syngene, Cambridge, UK). 
2.12 Flow Cytometry Analysis 
Strains were expressed for 24 hours in BMMY in 250 mL baffled shake flasks as previously 
described. After 24 hours expression 1 mL of culture was collected through centrifugation and 
washed in 1x TBS (0.605% Tris, 0.876% NaCl, pH adjusted with 1 M HCl). Samples were washed for 
a second time before being resuspended in a final volume of 10 mL of buffer to create a 1 in 10 
dilution. Samples were stained according to the LIVE/DEAD® FungalLight™ yeast viability kit 
protocol (Invitrogen Corporation, Paisley, UK). Cells were measured using a FACscan flow 
cytometer (Becton Dickinson, Oxford, UK). Data was acquired using CellQuest software (Becton 
Dickinson, Oxford, UK) with samples measured on a high flow rate for 30 seconds. Data was 
analysed using Cylogic software (CyFlo Ltd, Turku, Finland).  
2.13 Statistical Analysis 
Statistical analysis was calculated with unpaired T-test or one-way or two-way ANOVA using Prism 
software (GraphPad, California, USA). Experiments were repeated in biological triplicates unless 
otherwise stated. All p values of 0.05 or less were considered significant. 
2.14 Microarray Analysis 
Strains used for microarray analysis were expressed for 24 hours in BMMY in 250 mL baffled 
shake flasks as previously described. RNA was extracted using the RiboPure Yeast Kit (Applied 
Biosystems, Warrington, UK) and quantification and quality checks were carried out using the 
Experion Automated Electrophoresis System and the RNA StdSense chip and reagents (Bio-Rad, 
Hemel Hempstead, UK). Requirements of samples were 10 μg of RNA, with a RQI rating over 7. 
Custom probes were designed in accordance with previous experiments (data not shown) on 
8x60K slides. Probe coverage was a minimum of nine per gene.  
RNA was delivered to the Bacterial Microarray Group at St George’s Hospital for analysis. Cy3-
labelled cRNA was prepared from 1 µg total RNA using the Agilent One-Colour Quick Amp 
Labelling kit according to the manufacturer’s instructions (Agilent Technologies UK Ltd, 
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Wokingham, UK). One Color Spike-In controls were labelled together with the RNA samples. 
Purified samples were hybridised to an Agilent 8x60k format Sureprint G3 gene expression 
custom array and incubated overnight in a rotating oven (Agilent Technologies UK Ltd, 
Wokingham, UK) at 65°C, 20 rpm. After hybridization, slides were washed for 1 minute at room 
temperature in GE Wash Buffer 1 and 1 minute at 37°C in GE Wash buffer 2 (Agilent Technologies 
UK Ltd, Wokingham, UK), placed beneath an Ozone Barrier Slide cover (Agilent Technologies UK 
Ltd, Wokingham, UK) and scanned immediately, using an Agilent High Resolution Microarray 
Scanner, at 2 µm resolution.  Scanned images were quantified using Feature Extraction software v 
10.7.3.1. 
2.14.1 Gene Expression Analysis 
Analysis was carried out by Bioinformatics Support Service, Imperial College London, using the 
Bioconductor package in the R programming language to identify differentially expressed genes 
[198]. Each of the clonal variation (CV) strains was contrasted to wild-type X33 in order to 
determine statistically significant differences. The Empirical Bayes method was applied to identify 
statistical significance in contrast between gene expression profiles [199]. The false discovery rate 
(fdr) based on Benjamini and Hochberg’s method, which assumes that all genes are statistically 
different from one another was set to be less than 5% [200]. Gene functionality was assigned with 
reference to a created Pichia pastoris genome (www.blugen.org/gbrowse-bin/gbrownse/Pichia/). 
2.14.2 Pathway Analysis 
Pathway analysis was used to identify pathways were significantly up- or downregulated in 
accordance with the gene expression data. Initially significantly up- or downregulated genes were 
run through KOBAS (KEGG Orthology Based Annotation System), which assigns genes to pathways 
based on the KEGG maps specifically for P. pastoris [201-203]. Once pathways were identified the 
KEGG Search & Colour pathway was used to visually map the differentially expressed genes [204-
205].
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3 Determining the Effects of using Multi-Copy Clones in Pichia pastoris 
3.1 Introduction 
3.1.1 Advantages of Multi-Copy Clones 
Low specific productivity is highlighted as a key detriment to using P. pastoris as a heterologous 
expression system. This is somewhat compensated by high cell densities thereby achieving high 
volumetric productivity [74]. Should specific productivity be increased then the potential of using P. 
pastoris as the preferred heterologous protein expression platform expands enormously. One of the 
best established methods to achieve this is to increase the number of cognate genes. The approach 
of using multi-(gene) copy strains to increase the production of heterologous protein has been used 
since the early 1990s [146, 206], particularly for intracellular expression where expression in high 
quantities is particularly difficult [87, 171, 207-208].  
3.1.2 Traditional Methods for Making Multi-Copy Clones 
Traditionally multi-copy strains have been generated by three main methods; sequential 
transformations, transformation directly on high concentrations of antibiotic and in vitro 
multimerisation [65]. Sequential transformation, which can integrate up to 10 copies of the gene of 
interest, is achieved through repeatedly transforming a linearised vector into the same locus or into 
different loci. However the screening process is laborious and this method is only feasible with a 
number of selection markers being applied [206]. Transformation directly onto high concentrations 
of antibiotics such as Zeocin and G418 results in low transformation efficiencies with ≤5% resistant 
clones containing multiple copies of the gene of interest. Furthermore this is not applicable with 
auxotrophic markers and requires extensive screening with only 1-2% of clones containing “jackpot” 
colonies of 10 or more gene copies [149]. The final method using in-vitro multimerisation creates 
multi-copies of the gene of interest in an E. coli shuttle vector prior to being transformed into P. 
pastoris [148]. Nonetheless due to the size of the pAO815 vector limited number of copies may be 
integrated and extensive screening is required in E. coli. Additionally increased copy number will 
decrease transformation efficiencies into P. pastoris [112]. 
3.1.3 Post-Transformational Vector Amplification 
In 2008 Sunga et al. proposed an alternative to the typical methods of creating multimers; post-
transformational vector amplification (PTVA) [149]. This method relies on a step-wise increase in 
Zeocin concentration in order to progressively select colonies that are able to resist higher 
concentrations. The Sh ble gene produces proteins that sequester Zeocin; thus theoretically 
increasing the number of copies of Sh ble gene should result in increased resistance to Zeocin. Sunga 
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et al. (2008) suggested that PTVA results in the complete amplification in a head-to-tail orientation 
of the entire vector, which is important in order to obtain a uniform recombinant product.  
Advantages of PTVA include an increase in the frequency of “jackpot” colonies to 5-6%, compared to 
<1% by traditional methods [149]. Most importantly an increase in the amount of recombinant 
protein was observed. PTVA is becoming increasingly popular for generating multi-copy clones, with 
up to 15 copies of human Cu/Zn superoxide dismutase (hSOD) and 52 copies of porcine insulin 
precursor (PIP) reported in P. pastoris [151-152]. Due to the apparent ease and simplicity of this 
method and the reported successful results, PTVA was adopted in this project in order to create 
multiple copies of human serum albumin (HSA). 
3.1.4 Negative Effects of Multi-Copy Clones 
Multi-copy clones when coupled with proteins expressed intracellularly have been reported to 
increase titres. However, proteins targeted to the secretory pathway and expressed extracellularly 
show evidence of secretion saturation whereby increased gene copy number does not equate to 
higher titre [87]. Although secretion saturation does not occur at the same copy number for 
different proteins the trend of plateauing secretion is the same. Marx et al. (2009) observed that 
when expressing HSA, integrated into the rDNA locus, expression capped at approximately five 
copies [152].  
In addition to secretion saturation investigations have reported  that high copy-number clones 
induce the unfolded protein response (UPR) [87]. This is of particular interest as induction of UPR 
can lead to activation of the ER associated degradation pathway (ERAD) [209]. Due to the inclusion 
of multi-copy clones excess transcript will pass through the secretory pathway; thus increasing the 
likelihood of ERAD upregulation. Proteins that are poor folders are more likely to induce the UPR and 
these are the proteins that are liable to activate the ERAD;  thus result in lower expression especially 
in multi-copy strains [173]. HSA is known to express and secrete well from P pastoris; thus, at low 
copy number, expression is unlikely to induce UPR. Therefore it is of interest to determine whether 
UPR upregulation will occur through the inclusion of multiple copies of the HSA gene. The use of 
multi-copy strains to produce high titre levels using a protein that clearly folds well allows us to 
investigate secretion saturation as a separate issue from folding stress in order to gain a better 
understanding of the pressures on the secretory pathway. 
3.1.5  Aims for the Investigation of Multi-Copy Clones 
 To evaluate the method of Post-Transformational Vector Amplification (PTVA) in making 
multi-copy strains 
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 To create clones containing multiple copies of the HSA gene and examine the effect of 
multiple copy clones on: 
o Titre 
o Secretion saturation 
o UPR signals 
o Genetic Instability 
3.2 Creating Multi-Copy Clones 
3.2.1 Vector Creation 
3.2.1.1 pα-HSA 
The HSA gene was amplified by PCR using the proof-reading enzyme Phusion Hot Start II and primers 
047-HSA2 and 053-HSA4-SP (Appendix 9.2) excluding the region encoding the native signal peptide 
(SP). The vector pPICzαA (Invitrogen Corporation) contains the sequence encoding the 
Saccharomyces cerevisiae α-mating factor (MF) signal peptide which, when expressed in frame, can 
target the HSA protein to the secretion pathway. pPICzαA and the amplified HSA-SP were digested 
using restriction enzymes EcoRI and NotI. The resulting  fragments were ligated together using T4 
DNA ligase before being transformed into TSS competent E. coli JM109 cells (Table 2.1) by heat 
shock and plated onto Lennox LB plates containing 100 μg ml-1 Zeocin. The pPICzαA vector contains a 
Sh ble gene, expression of which provides resistance to Zeocin in both E. coli and P. pastoris. The 
pPICzαA vector is 3.6 kb, while the modified HSA gene is 1.8 kb, giving a total size of 5.4 kb (Fig 3.1). 
 
Figure 3.1 pα-HSA Plasmid Map 
pα-HSA is based on the pPICzα vector (Invitrogen, Paisley, UK) containing a truncated HSA 
gene to remove the SP. pPICzα contains the Sh ble gene, which encodes the Zeocin 
resistance protein allowing for selection in both E. coli and P. pastoris and the α-MF signal 
peptide for secretion.  
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Once the recombinant vector had been successfully transformed into JM109 the plasmid was 
reisolated using a Qiagen mini-prep kit and a double digest using EcoRI and NotI used to confirm the 
presence of the HSA-SP gene (Fig 3.2). 
 
Figure 3.2 Agarose gel confirms the successful construction of the pα-HSA vector 
1% agarose gel electrophoresis of restriction fragments to confirm the construction of pα-
HSA. 1: 1 Kb DNA Ladder (Fermentas); 2:pPICzα A; 3: HSA PCR product; 4: HSA PCR 
product; 5: pα-HSA 1 digested with EcoRI and NotI; 6: pα-HSA 2 digested with EcoRI and 
NotI. pPICzα A is 3.6 kb and HSA is 1.8 kb. 
 
3.2.1.2 pPICz-HSA 
Many heterologous proteins that are secreted using P. pastoris are not naturally secreted; thus the 
importance of using the α-MF secretion signal from S. cerevisiae. As HSA is a natively secreted 
protein, it was of interest to compare the effect of secretion using the native signal peptide and the 
α-MF signal peptide. Therefore pPICz-HSA was designed to include the intact HSA gene, retaining its 
native signal sequence, which should still result in the secretion of the HSA protein. The full HSA 
gene was amplified by PCR using primers 047-HSA2 and 050-HSA3 (Appendix 9.2). The fragment was 
digested using EcoRI and NotI and ligated to the pPICz vector which had also been digested with 
EcoRI and NotI (Fig 3.3). The pPICz vector differs from the pPICzα vector in the absence of the α-MF 
signal peptide, but in all other factors the vectors are the same. The absence of the α-MF signal 
peptide ensures that any secreted product is a result of the native signal peptide encoded by the 
HSA gene.  
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Figure 3.3 pPICz-HSA Plasmid Map  
pPICz-HSA contains the full HSA gene ligated together with the pPICz vector, which 
contains the Sh ble gene encoding a Zeocin resistance protein.  
 
The ligated vector was transformed into E. coli JM109 as described for pα-HSA, reisolated and 
digested with EcoRI and NotI to confirm the presence of the HSA gene. The pPICz vector is 3.3 kb, 
while the HSA gene containing the native secretion signal sequence is 1.8 kb (Fig. 3.4).  
 
Figure 3.4 Agarose gel confirms the successful construction of the pPICz-HSA vector 
1% agarose gel electrophoresis of restriction fragments to confirm the construction of 
pPICz-HSA. 1: 1 Kb DNA Ladder (Fermentas); 2: pPICz A; 3: HSA PCR product; 4: HSA PCR 
product; 5: pPICz-HSA 1 digested with EcoRI and NotI; 6: pPICz-HSA 2 digested with EcoRI 
and NotI. pPICz A is 3.3 kb and HSA is 1.8 kb. 
 
3.2.2 HSA Production in P. pastoris  
After successful construction of pPICz-HSA and pα-HSA 5-10 ng was linearised using the restriction 
enzyme PmeI, which cuts within the 5’ AOX1 promoter in the vector and allows for homologous 
recombination into the P. pastoris genome (Fig 3.1 and 3.3). Homologous recombination occurs 
through the free DNA termini and results in a single crossover type integration [65]. Linearising the 
plasmid using PmeI facilitates integration at a pre-determined locus, in this instance AOX1. 
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Integration of this type results in the Mut+ phenotype as two copies of the AOX1 promoter will result 
from recombination, one driving expression of AOX. 
A 200 mL culture of GS115 (his4) was prepared for electroporation as described in the Pichia 
Expression Kit manual and transformed with linearised pα-HSA or pPICz-HSA [120]. The transformed 
cells were left to recover at 30˚C for 1 hour, without shaking, before being plated on YPD containing 
100 µg mL-1 Zeocin. The plates were left to incubate at 30°C for 3-5 days. Individual colonies were 
selected and streaked onto YPD plates before being re-plated onto YPD 100 μg mL-1 Zeocin plates to 
ensure that the original colonies were not transiently resistant to Zeocin but were true 
transformants containing the Sh ble gene. Once colonies had been re-streaked onto YPD plates 
containing 100 μg mL-1 Zeocin individual colonies were selected for further study.  
Individual colonies were used to inoculate a glycerol based medium (BMGY) and left to grow for 24 
hours before being induced with methanol (BMMY) in order to evaluate expression of HSA. Due to 
both constructs containing secreting signal peptides targeting the HSA protein for secretion an 
evaluation of the supernatant would determine the functionality of the vectors. After 24 hours 
expression in the methanol containing media cultures, the supernatant was recovered by 
centrifugation for analysis. A 40 μL sample mixed with 5X Loading buffer was then analysed on a 12% 
SDS-PAGE gel. One advantage of using P. pastoris as an expression host is that it does not secrete 
many native proteins; thus the presence of a secretion signal peptide on both constructs makes the 
target protein easy to identify (Figure 3.5) [65, 74]. 
 
 
 
71 
 
 
Figure 3.5 Production of HSA after 24 hour production in methanol containing media 
SDS-PAGE analysis of spent culture broth after 24h expression in liquid culture of clones 
isolated on 100 μg mL
-1
 Zeocin and expressed in BMMY for 24 hours indicates HSA 
production. 1: BMMY media only; 2: GS115 untransformed; 3: GS115 HSA control strain 
(Invitrogen Corporation); 4: GpPICzH1_100; 5: GpPICzH1_100; 6: GpαH1_100; 7: 
GpαH2_100; M: Unstained molecular marker (Fermentas). 
 
Once it had been established that both pPICz-HSA and the pα-HSA had integrated into the genome 
and the resulting transformants were secreting HSA (a 66.5 KDa protein) it was then possible to 
proceed with the creation of multi-copy strains. 
3.2.3 Making and Selecting Multi-Copy Clones using PTVA 
Individual colonies of both GpPICz-HSA and Gpα-HSA were selected from plates containing 100 μg 
mL-1 Zeocin and streaked onto a fresh plate containing 100 µg mL-1 Zeocin, in order to ensure 
uniformity and left to incubate to for 3-5 days. As described by Sunga et al. each clone was then 
sequentially spotted onto increasing concentrations of Zeocin, (200, 300, 500, 1000, 2000 µg mL-1) 
[149].  Any clones that do not have an increase in copy number should be unable to grow in the 
presence of higher concentrations of Zeocin as they would produce insufficient resistance protein to 
titrate out the Zeocin (Fig. 3.6). 
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Figure 3.6 Plates of parental clones isolated on 100 μg mL
-1
 Zeocin plates and progeny 
clones post PTVA isolated on 2000 μg mL
-1
 Zeocin. 
The top half of the plates contains single spots of GS115 transformed with pα-HSA, while 
the bottom half of the plates contain spots of GS115 transformed with pPICz-HSA. A: 100 
µg/ml Zeocin plate; B: 2000 µg/ml Zeocin plate.  
 
There was a visible difference in clones spotted onto the YPD 100 µg mL-1 plates and those spotted 
onto the 2000 µg ml-1 plates in terms of both size and morphology, with growth on the high 
concentrations considerably reduced (Fig 3.6). Additionally there was a noticeable difference 
between clones containing either the pα-HSA or pPICz-HSA vector. It would appear that clones 
containing the pPICz-HSA vector grown in the presence of 2000 μg mL-1 show reduced resistance. 
Potentially the growth rate may be reduced in clones containing pPICz-HSA as growth on 100 μg mL-1 
Zeocin also differs between strains integrated with the different vectors.  
As a result of the differences seen between clones containing pα-HSA or pPICz-HSA it was 
determined that only strains containing the pα-HSA vector were used. As many proteins produced 
by industry are not natively secreted and the α-MF signal peptide is the preferred choice, the pα-
HSA vector may be considered more industrially relevant [75]. For ease of identification clones were 
named GpαH#_100 (for clones selected on 100 μg mL-1 Zeocin), or GpαH#_2000 for those selected 
post-PTVA. All twenty-six clones that were selected for enrichment through PTVA were selected for 
further study.  
3.3 Testing Multi-Copy Clones 
In order to determine the effects of PTVA on amplification from single clones, titre and HSA copy 
number were determined for both parental and progeny clones. HSA protein concentrations were 
measured using the Albumin Blue Fluorescence assay (Active Motif). HSA protein titre was recorded 
for all clones that had been isolated in the presence of 100 μg mL-1 of Zeocin and 2000 μg mL-1 
A B 
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Zeocin (post PTVA). In order to clearly display whether clones post-PTVA showed an increase or 
decrease in protein expression, relative expression of HSA was calculated, a percentage above 100% 
indicates  that post-PTVA secretion increased, while a decrease in expression is represented by a 
percentage of less than 100 (Fig 3.7). 
 
Figure 3.7 Post-PTVA Expression of HSA compared to levels pre-PTVA both Increases and 
Decreases in Progeny Clones 
Comparison of the relative expression, measured by Albumin Blue Assay (Active Motif) 
between original transformants isolated on 100 µg/ml Zeocin plate (set at 100%) and 
clones isolated after PTVA on 2000 µg/ml Zeocin. Values over 100% indicate a higher level 
of secretion of progeny clones post-PTVA, while values under 100% indicate a lower level 
of HSA secretion. 
 
In equal proportions clones post-PTVA showed both increased and decreased HSA titre according to 
their corresponding parental clones (Fig 3.7). Furthermore there were strains, for instance 
GpαH15_2000, which showed no change in HSA titre compared to GpαH15_100. In order to 
determine the relevance of HSA expression levels copy number was calculated for parental and 
progeny clones. Potentially GpαH15_2000 does not contain increased HSA copy number compared 
to GpαH15_100; thus explaining the unchanged expression. 
Copy number was analysed by qPCR of genomic DNA isolated using the DNeasy Plant mini-prep Kit 
(Qiagen). DNA was quantified using the Synergy HT multi-detection microplate reader (Bio-Tek) and 
normalised to 10 ng μL-1 of which 3 μL was added to each reaction. HSA was amplified using primers 
070-HSAq1 and 071-HSAq 2 and primers 020-ACT1q1 and 021-ACT1q2 (Appendix 9.2) were used to 
amplify the housekeeping gene ACT1. Fold change was calculated using the amended delta-delta-CT 
according to Pfaffl (Fig. 3.8) [196]. 
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PTVA successfully generated multi-copy clones; however this was not consistent for all clones 
analysed (Fig 3.8). In addition to clones showing increased copy number, there is evidence that 
clones retain a single copy of HSA post-PTVA. qPCR data suggests that some clones post-PTVA show 
a decrease in copy number in comparison to the parental counterparts. As hypothesised there was 
no evident increase in copy number within the GpαH15_2000 strain compared to its parental 
counterpart, which may, in part, explain the equivalent secreted protein titre (Fig 3.7). Clone 
GpαH16_100 appears to be a multi-copy clone, but there is evidence of a decrease in copy number 
in the progeny clone post PTVA. Instability observed post-PTVA has been reported for high copy 
clones (over 10 copies); however stability has not been seen for clones with less than six copies 
[210]. A decrease in copy number could potentially result in a decrease in protein production, 
although this does not seem to have been the case with GpαH16_2000 (Fig 3.7). 
Sunga et al. highlighted the importance of clones integrating as complete vectors within the AOX1 
region [149]. If only the Zeocin resistance marker had inserted into the vector then the clone would 
not benefit from an increase in copy number of the HSA. Southern blot was used to analyse whether 
an increase in copy number was as a result of complete amplification of the vector in a head to tail 
manner [149]. A digest with EcoRV was used to linearise the genomic DNA in the CYC1 transcription 
termination region. A single copy should produce a band at 8 Kb, while multiple copy clones will 
show an additional band at approximately 5.4 Kb (Fig. 3.9). 
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Figure 3.9 Southern blot of genomic DNA digested with EcoRV from a selection of 
parental and progeny clones of PTVA determines a head-to-tail insert orientation. 
A) Schematic diagram to depict the sites of digestion using EcoRV in multi-copy colonies in 
a head-to-tail orientation.  B) Samples were digested with EcoRV and probed with DIG-
labelled HSA.  1: GpαH1_100; 2: GpαH1_2000; 3: GpαH3_100; 4: GpαH3_2000; 5: 
GpαH6_100; 6: GpαH16_2000; 7: GpαH21_100; 8: GpαH21_2000; 9: GpαH23_100; 10: 
GpαH23_2000. 
 
From the five clone pairs selected it is evident that there are multiple copies of the HSA gene in all of 
the progeny strains, including GpαH16_2000. Interestingly both GpαH16_100 and GpαH21_100 are 
multi-copy strains, with the progeny strains retaining multiple copies. Should the vectors have 
integrated in a head-to-head orientation bands of approximately 2.5 Kb and 4.4 Kb would be 
present. Additionally if bands integrated in a tail-to-tail orientation a 7.8 Kb band and 1.9 Kb band 
would have been visible. Head-to-tail integration (as suggested by Sunga et al.) would result in an 
additional 5.4 Kb band. The presence of the band at approximately 6 Kb indicates that multimers 
have indeed integrated in a head-to-tail manner as suggested by Sunga et al. [149]. 
The method of spotting cultures raises questions about the purity of each culture. Zeocin resistance 
occurs through sequestering the antibiotic, but if cultures are growing in spots there is potential that 
A 
B 
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a form of “protection” may occur. Theoretically, if one colony is producing an excessive amount of 
Zeocin resistant protein then colonies within the same spot may be able to survive without 
increased numbers of Zeo(R) genes, and hence lower numbers of HSA genes. Theoretically spots may 
be mixed cultures; thus colonies existing containing different copy numbers, which may ultimately 
affect titre. To determine microbiological purity, seven clones were selected from the 2000 μg mL-1 
plate and streaked to single colonies on fresh YPD plates containing 2000 μg mL-1 Zeocin. Four to five 
colonies were then selected from each plate and genomic DNA extracted before copy number was 
established by qPCR using primers 070-HSAq1 and 071-HSAq2(Fig. 3.10). 
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qPCR results show that spots contain mixed cultures with individual colonies displaying different 
copy numbers (Fig 3.10). Interestingly, through both qPCR and Southern blot GpαH16_100 appears 
to be a multi-copy clone, but there is clear evidence through qPCR that post-PTVA not only does 
copy number decline (Fig 3.8), but some clones revert to containing a single copy of the HSA gene 
(Fig 3.10). This would imply that multi-copy clones generated through PTVA may not be stable; an 
issue that requires further investigation. 
3.4 Clones that grow in the presence of 2000 μg mL-1 Zeocin but do not show an 
increase in copy number 
Through the stepwise exposure to higher concentrations of Zeocin some clones showed an increase 
in copy number of the HSA gene, which according to the Southern blot resulted from an increase in 
copy number of the whole vector. However, some clones exhibited the ability to grow in the 
presence of 2000 μg mL-1 Zeocin but did not show any increase in HSA copy number. It is possible 
that mutations have arisen within either the Zeocin resistance gene or the promoter regions that 
allow for an increase in protein activity or transcription of the Zeocin resistance gene resulting in 
resistance to higher antibiotic concentrations. In order to evaluate the effect of selecting on high 
concentrations of Zeocin the TEF1 and EM7 promoter regions, Sh ble gene and the CYC1 
transcription terminator were amplified using primers 280-ZeoSeqF and 281-ZeoSeqR (Appendix 9.2) 
and the PCR product sequenced. Clones GpαH6_100, GpαH6_2000, GpαH14_100, GpαH14_2000, 
GpαH17_100, GpαH17_2000, GpαH22_100, GpαH22_2000, GpαH25_100 and GpαH25_2000 were 
selected based on the evidence from qPCR that copy number had not increased post-PTVA. HSA titre 
levels for the strains varied including some showing no increase in secretion (GpαH17_2000), some 
showing a decrease in protein secretion (GpαH6_2000, GpαH14_2000) and some that showed an 
increase in protein secretion (GpαH22_2000, GpαH25_2000) in the progeny clones compared to the 
parental clones. 
pPICzα was included for sequencing, as well as four strains (GpαH1_100, GpαH1_2000A, 
GpαH11_100 and GpαH11_2000B), which showed an increase in copy number and expression post-
PTVA.  From the sequencing results it was evident none of the strains selected had a mutation in the 
Sh ble gene; however there were small variations in the TEF1 promoter region (Fig 3.11; Appendix 
9.3). 
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Figure 3.11 Alignment of DNA sequences within the TEF1 promoter region from strains 
selected on 100 μg mL-1 Zeocin or 2000 μg mL
-1
 suggest variation within the promoter 
regions 
 
Surprisingly strains GpαH1_2000A and GpαH11_2000B showed variation in the sequence within the 
promoter region. It is possible that this variation affected expression levels, adding to the ability to 
grow at high Zeocin concentrations. To investigate this issue further, mRNA levels of Zeo(R) gene 
were established from parental and progeny clones using RT-qPCR. The six parental and progeny 
strains analysed by DNA sequencing were expressed for 24 hours in rich methanol containing media 
in a 24-well microtitre plate. Parental and progeny strains were grown in the presence of 100 μg mL-1 
Zeocin and 2000 μg mL-1 Zeocin respectively. After 24 hours growth 1 mL of culture was stored in 
RNA Later® (Applied Biosystems) before the RNA was extracted using the RiboPure Yeast RNA 
Extraction Kit (Applied Biosystems). Transcript levels of the mRNA from the Zeocin resistant (ZeoR) 
gene were calculated as relative expression between the parental and progeny clones using primers 
022-Zeoq1 and 023-Zeoq2 (Fig. 3.12). 
                 10        20        30        40        50        60        70        80        90                  
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pPICzαA  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
1_100    GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
1_2000A  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTT-CTTTT-CTTGAAAATTTTTTTTTTT-GATTTTT  
11_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
11_2000B GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTT--GATTTT  
6_100    GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTTTGATTTTT  
6_2000   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCT-GAAAATTTTTTTTTTT-GATTTTT  
14_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
14_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
17_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAAATTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTG--ATTTTT  
17_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
22_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTG--ATTTTT  
22_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
25_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTT-GATTTTT  
25_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
 
                100       110       120       130       140       150       160       170       180         
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pPICzaA  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
1_100    TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
1_2000A  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
11_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
11_2000B TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
6_100    TTCTCTTTCGATGACCTCCCCATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
6_2000   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
14_100   TTCTCTTTCGATGACCTCC--ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
14_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
17_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
17_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
22_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
22_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
25_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
25_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
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Figure 3.12 Zeo(R) mRNA Levels from Single Copy Clones Post-PTVA Show an Increase 
and Decrease in Transcript levels 
Zeo(R) transcript levels were calculated by the ΔΔCt method using primers 022-Zeoq1 and 
023-Zeoq3 using ACT1 as the housekeeping gene compared to Gpαh11_100. Six parental 
(100 μg    mL
-1
) and progeny (2000 μg mL
-1
) clones monitoring the Zeo(R) mRNA levels 
after 24 hours growth in the presence of the respective Zeocin concentrations were 
analysed. GpαH11_100 and GpαH11_2000B (5 copy) were included for comparison with 
clones known to have an increase in copy number post-PTVA. Statistically significant 
values of p<0.05 (progeny clones compared to parental clones) are indicated by a *. 
 
There was a significant difference in Zeo(R) mRNA produced in GpαH11_2000B, a five copy clone 
post-PTVA, compared with GpαH11_100 (two-tailed t(4) p=0.0062). This was to be expected as 
Southern blot analysis (Fig 3.9) indicated an amplification of the entire vector, including the Zeocin 
resistance marker. Predominantly where clones did not show an increase in HSA copy number there 
was still an increase in Zeo(R) transcript, although with the exception of GPαH22_2000 (two-tailed 
t(4) p=0.0284) this was not significant (Fig 3.12). GpαH17_100 showed reduced Zeo(R) mRNA 
compared to the other parental clones; furthermore GpαH17_2000 showed a decrease in Zeo(R) 
transcript level (two-tailed t(4) p<0.0001). Potentially there is a variation within GpαH17_100 and 
GpαH17_2000 that affects the ability to grow on high concentration of Zeocin. As there are no 
apparent differences within the promoter regions or Sh ble gene differences in resistance to Zeocin 
may be as a result of naturally occurring mutations which affect the permeability of Zeocin. 
3.5 Analysis of Secretion Saturation in Multi-Copy Clones 
Producing multi-copy clones is labour-intensive and potentially expensive (if PTVA is used); therefore 
if secretion plateaus at increased copy number pharmaceutical companies may decide that it is not 
worth the investment. To assess evidence for secretion saturation two families were selected for 
further study; GpαH1 and GpαH11. Clones were selected for further analysis based on copy number; 
* 
* 
* 
* 
82 
 
GpαH1_100 (1 copy), GpαH1_2000A (2 copy), GpαH11_100 (1 copy), GpαH11_2000A (3 copy) and 
GpαH11_2000B (5 copy). Due to issues of clonal variation [211-212], it was deemed important to 
analyse clones from family groups to ensure any differences in expression were the consequence of 
an increase in the HSA gene and not clonal variation. 
Each clone was cultured in a 15L bioreactor (Braun Biostat ED) initially with a glycerol fed batch for 
approximately 18 hours, before induction with methanol once OD600 500-600 had been reached and 
wet cell weight (WCW) was 400-500 g L-1 (Appendix 9.4). Methanol was fed for 48 hours at 20 mL h-1 
with samples taken at 24 hours and 48 hours. HSA titre was analysed from culture supernatants 
(after removal of cells) using the Albumin Blue fluorescence assay kit (Active Motif). Titre was 
calculated as mg L-1 g DCW-1 (Fig. 3.13). 
 
Figure 3.13 Titre levels of HSA (mg L
-1
 DCW
-1
) during 48 hour fed batch methanol 
induction  
Samples were taken from 5 L bioreactors pre-induction (0 hours) and 24 hours and 48 
hours post-induction with methanol. Error bars indicate represent the Albumin Assay run 
in triplicate. 
 
All strains showed an increase in the titre of secreted HSA over 48 hours with the exception of 
GpαH11_2000B (5 copy), which exhibited a lower protein titre at 48 hours compared to that at 24 
hours (Fig 3.13). A possible reason for this decrease in expression could be the cells reaching 
secretion saturation coupled with the induction of the UPR, which then leads to the induction of the 
ERAD and protease production [213].  Furthermore, GpαH11_2000A (3 copy) appears to have a 
higher titre of HSA after 48 hours than GpαH11_2000B (5 copy). As these clones were from the same 
family this suggests that inserting five copies exerts additional stress, thereby inducing the UPR, 
ultimately leading to protein degradation through the activation of ERAD. Although the initial rate of 
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expression at 24 hours is higher, expression for 48 hours results in less protein that the equivalent 
three copy strain. If the ERAD is activated within GpαH11_2000B (5 copy) this can lead to increased 
cell death, which would result in increased proteases released into the supernatant. This suggests 
that high copy numbers may actually be detrimental to protein expression after 48 hours expression. 
Additionally, when comparing the different families, GpαH1 and GpαH11, there is significant 
variation in HSA titre secretion between GpαH1_100 and GpαH11_100 after 48 hours (two-tailed 
t(4) p=0.0007). Furthermore GpαH1_100 has comparable titre to that of GpαH11_2000A (3 copy 
clone) after 24 hours. However, GpαH1_2000A (2 copy) clone secreted HSA titre equivalent to the 
parent clone GpαH1_100. We can hypothesise that either an increase in HSA copy to two does not 
result in increased expression, or the parental strain of GpαH1_100 produces enough protein to 
reach secretion saturation. This would suggest that secretion saturation in GpαH1 is lower than in 
GpαH11. This highlights the issue of clonal variation and underlines the importance of screening a 
variety of clones to select the best secretor. 
3.6 Effects of Gene Copy-Number on induction of UPR 
Increased copy number has been noted to result in upregulation of UPR, which could impact 
expression titre [87]. In order to investigate whether UPR was upregulated, RT-qPCR was used to 
analyse the expression of UPR associated genes, such as HAC1, KAR2 and PDI. Samples taken at 0 
hours (pre-induction) as well as 24 hours and 48 hours post-induction were analysed by RT-qPCR 
(Fig. 3.14). 
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GpαH11_100 shows increased upregulation of UPR compared to GpαH1_100 (Fig 3.14). As 
GpαH1_100 shows increased titre compared to GpαH11_100, it is possible to hypothesise that there 
is an additional secretory stress on GpαH11_100 (Fig 3.14), which may result in the induction of 
ERAD; thus resulting in reduced titre. UPR induction levels in multi-copy clones at 48 hours were 
higher that the corresponding parental clones (Fig 3.14). The decrease in HAC1 upregulation of 
GpαH11_2000B (5 copy) after 48 hours suggests that due to decreased protein production (as 
suggested by titre levels, and potentially due to the induction of ERAD) stress on the secretory 
pathway will be reduced; thus reducing HAC1 upregulation. The continued upregulation of HAC1 
seen after 48 hours for GpαH11_2000A (3 copy) suggests that the high production maintains 
secretory stress. Potentially if yield was observed until 72 hours GpαH11_2000A (3 copy) may show 
similar trends as GpαH11_2000B (5 copy) in terms of protein production and UPR stress.  
3.7 Genetic Instability in Multi-Copy Clones 
To investigate whether a counter-selection against high copy clones existed (which would reduce the 
stress on the secretory pathway) a population study was carried out on individual colonies selected 
during the fermentation run to determine copy number post-expression. Samples were taken from 0 
hours (pre-induction), 24 and 48 hours post-induction and were serially diluted and plated onto 100 
μg mL-1 Zeocin YPD plates as well as YPD plates with no antibiotic. Colony counts were used to 
compare the ability to grow in the presence of Zeocin (Fig. 3.15). 
 
Figure 3.15 Colony count (x10
7
) of serial dilutions plated onto either YPD plates (no 
selective pressure) or 100 μg mL
-1
 Zeocin YPD plates shows a loss of resistance to Zeocin. 
Samples were taken from the appropriate 15L bioreactor at 0 hrs (pre-induction), 24 hours 
or 48 hours post-methanol induction. Error bars represent standard error. 
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From the comparison of colonies grown in the presence or absence of Zeocin it appears that, 
particularly after 48 hours, not all colonies have the ability to grow in the presence of Zeocin, 
implying they have lost either the Sh ble gene or the entire construct has been lost. This is 
particularly noticeable in GpαH1_2000A (2 copy) after 48 hours. Interestingly GpαH11_2000B 
appears to have a reduced ability to grow in the presence of Zeocin even after 0 hours (pre-
induction) which is typically 18 hours into the fermentation run. Due to the number of repeats of the 
AOX1 promoter through integration of five pα-HSA vectors the regions of homology for 
recombination is significantly increased. This suggests in the absence of secretory stress clones show 
evidence of instability. 
In order to determine the extent of genetic instability individual colonies were analysed for HSA copy 
number by qPCR. Single colonies were selected from the YPD plates (no selection) from the colony 
count. It was important to select colonies from the YPD plates and not those containing Zeocin, as 
this removed any selective pressure against maintaining the integrated vector. Genomic DNA was 
extracted and qPCR was used to analyse copy number of the HSA gene using ACT1 as a 
housekeeping gene (Fig. 3.16). 
 
Figure 3.16 Genetic instability is prevalent in GpαH11_2000B (5 copy) during a 48 Hour 
Fermentation 
Copy number was calculated by ΔΔCt using primers 070-HSAq1 and 071-HSAq2 to amplify 
the HSA gene. ACT1 was used as the housekeeping gene with reference to GpαH1_100, a 
known one copy clone. Single colonies of GpαH11_2000B (5 copy) were analysed at 0 
hours (pre-induction), 24 hours and 48 hours post-induction. 
 
GpαH11_2000B (5 copy) shows varying HSA copy number during the fermentation run (Fig 3.16). 
Copy number both increased and decreased at both 0 hours and 24 hours. At 0 hours pre-induction 
HSA copy number was eight in one of the clones analysed. However; after 48 hours post-induction 
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copy number was retained at five in only one colony, with all other colonies showing a decrease in 
copy number. This may be due to secretory stress caused by additional traffic through the secretory 
pathway, which would result in increased counter-selection against high copy clones.   There is 
evidence that some clones lose the HSA gene completely at both 0 hours and 24 hours. This supports 
evidence from reduced colonies isolated on YPD plates containing 100 μg mL-1 Zeocin, as the loss of 
the HSA gene is likely to correspond to a loss of the entire vector therefore showing an inability to 
grow in the presence of Zeocin (Fig 3.15). Theoretically if selection of GpαH1_2000A (2 copy), 
GpαH11_2000A (3 copy) and GpαH11_2000B (5 copy) had been grown in the presence of 2000 μg 
mL-1 Zeocin the number of resistant colonies may have decreased. This raises concerns regarding the 
stability of the vectors, an issue initially raised with GpαH16_2000 (Fig 3.10).  
The presence of variable copy number raises questions on the applicability of multi-copy clones to 
improve protein production, especially given the variation in copy number prior to induction (Fig 
3.16). Pre-induction there should be no protein production stress on the secretory pathway (as the 
cells are growing in glycerol and the AOX1 promoter is inactive); therefore the loss of copy number 
may be due to a more fundamental issue. In order to investigate this further, copy numbers from 
cells banks were examined to determine whether the initial starting culture was a genetically pure 
culture. To do this a cell bank vial was thawed and spread onto YPD plates and single colonies 
selected for genomic extraction and copy number was analysed by qPCR (Fig. 3.17). 
 
Figure 3.17 Genetic Instability is present in the cell banks of GpαH11_2000B (5 copy) 
determined by qPCR of HSA genes 
Copy number was analysed via ΔΔCt using qPCR primers 070-HSAq1 and 071-HSAq2 to 
amplify the HSA gene with comparison to ACT1 as the housekeeping gene. Copy number 
for individual colonies from GpαH11_2000B (5 copy) were selected from YPD plates and 
calculated as a comparison to GpαH1_100.  
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Cell bank cultures showed mixed HSA copy number indicating that the inoculum was not genetically 
homogeneous (Fig 3.17). Due to the repeat homologous sequences to the AOX1 promoter it is 
evident that recombination is occurring resulting in both an increase and decrease in HSA copy 
number. Furthermore, as no significant selective pressure was applied against an increase in copy 
number (as no expression was occurring) then cells with higher copy numbers were not counter-
selected. When preparing the fermentation inoculums selection was maintained at 100 μg mL-1 
Zeocin. Potentially if cell banks were prepared maintaining 2000 μg mL-1 Zeocin selective pressure 
even higher copy number may have been observed.  
To confirm that genetic instability was not isolated to GpαH11_2000B (5 copy) copy number was 
analysed for GpαH1_100, GpαH11_100, GpαH1_2000A and GpαH11_2000A. Single colonies were 
selected, after serial dilution, from cultures in cell banks, at 0 hours (pre-induction), 24 hours and 48 
hours post-induction (Fig. 3.18). 
 
 
A 
B 
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Figure 3.18 Genetic Instability occurs in GpαH1_100 (1 copy), GpαH11_100 (1 copy), 
GpαH1_2000A (2 copy) and GpαH11_2000A (3 copy) during a 48 hour Fermentation 
HSA copy number was analysed via the ΔΔCt method using qPCR primers 070-HSAq1 and 
071-HSAq2, with comparison to ACT1 as the house keeping gene. Individual colonies were 
selected from each fermentation run at the following time points; cell bank, 0 hours (pre-
induction), 24 hours and 48 hours post-induction compared to GpαH1_100. A) 
GpαH1_100, a one copy clone. B) GpαH11_100, a one copy clone. C) GpαH1_2000A, a two 
copy clone, D) GpαH11_2000A, a three copy clone. 
 
All strains showed mixed HSA copy number from initial cultures in cell banks through to 48 hours 
post-induction indicating genetic instability (Fig 3.18). This implies that instability is not restricted to 
GpαH11_2000B (5 copy). Genetic instability will have negative effects on production, as potentially 
clones with lower copy numbers will produce less protein, which has critical implications to using 
multi-copy strains as an approach for augmenting protein yields, particularly in industrial settings. 
Due to instability any conclusions regarding titre levels and copy number may be irrelevant, 
including those made with reference to secretion saturation.  
C 
D 
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3.8 Discussion 
The use of PTVA to develop multi-copy clones has recently become a preferred method by the 
scientific community to generate multi-copy clones [149, 152, 210]. However, our investigation into 
this method has identified issues that have not previously been examined in detail; increase in copy 
number is not consistent for all clones and genetic instability results in mixed cultures. 
Our initial findings showed that clones that exhibited an increased resistance to Zeocin did not 
consistently result in an amplification of the HSA gene (Fig 3.8). As PTVA works through amplification 
of the entire vector (Fig 3.9), this implies that no increase of the Sh ble gene occurred. However, it 
was noted that clones showed an increase in Zeo(R) transcript levels determined by RT-qPCR (Fig 
3.12). We can conclude that resistance to high concentrations of Zeocin does not solely occur 
through amplification of the Sh ble gene. Potentially mutations within the Sh ble gene may increase 
resistance; however DNA sequencing did not show any differences to the original pPICzα A vector. 
Conversely, variations were observed within the TEF1 and EM7 promoter regions, similar to 
differences in GpαH11_2000B (5 copy). Potentially it is these differences that result in increased 
production of transcript, but further analysis would be required to determine the full effects of these 
variations. Site-directed mutation within the promoter regions would be able to identify whether 
specific changes impact Zeo(R) mRNA transcript levels.  
GpαH17_2000 was the only strain that showed a decrease in Zeo(R) transcript post-PTVA, yet this 
did not impact resistance to high concentrations of Zeocin. We hypothesised that a natural variation 
within the strain may affect the permeability of the cell to Zeocin. This highlights issues of clonal 
variation, with some strains showing increased natural resistance to the antibiotic. Regardless of the 
mechanism clones that showed an increased resistance to high concentration of Zeocin despite no 
increase in Sh ble copy number emphasise the need for a meticulous screening method to determine 
complete amplification of the entire vector.  
Further problems with PTVA arose from the method of spotting colonies, as mixed copy number 
colonies were observed within a spot. Zeocin resistant proteins bind stoichiometrically to Zeocin 
antibiotic to inhibit strand cleavage activity. Therefore, if a high copy clone is producing an 
abundance of resistance protein the antibiotic in the surrounding area may be inhibited; thus 
allowing for growth of lower copy clones on the high concentrations of Zeocin. For future 
implementation of PTVA it would be essential to reassess the feasibility of spotting clones onto 
plates, as mixed copy number spots may be detrimental to yields. Theoretically using a liquid version 
of PTVA, where cultures are grown in increasing concentrations of Zeocin before being plated onto 
the highest level of Zeocin YPD plates, would prevent mixed copy number cultures from occurring. 
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Multi-copy clones were initially created to establish at what copy number secretion saturation 
occurs using a well-folding protein. Unfortunately it became apparent from analysing 15 L bioreactor 
samples that genetic instability was prevalent on an individual cell basis. Previous investigations into 
genetic instability utilize RT-qPCR on a populational level and do not take into consideration the 
behaviour of individual colonies [214]. The presence of unstable clones means we have been unable 
to determine the relationship between secretion saturation and UPR through HSA production. A 
plateau in titre may be due to secretion saturation as suggested by Hohenblum et al. [87], or the 
counter-selection against high copy clones. 
The identification of genetic instability on an individual cell basis raises questions regarding the 
reliability of PTVA. Zhu et al. showed clones with less than six copies of the PIP gene were stable 
[210]; however we have observed genetic instability in all of the clones tested including single copy 
clones. This will have detrimental effects on titre; as if colonies within fermentation cultures contain 
no copies of the recombinant gene volumetric titre will be reduced. In addition to instability 
observed through expressing strains evidence of genetic instability was observed under non-
expressing conditions. GpαH16_100 was identified as a multi-copy clone but post PTVA 
GpαH16_2000 progeny clones showed evidence of reversion to single copy clones. Instability under 
non-inducing conditions was also observed when analysing copy number from cell bank cultures 
maintaining selection at 100 μg mL-1 Zeocin. This suggests that despite the absence of secretory 
stress genetic instability is inherent. Due to repeat homologous regions of the AOX1 promoter 
events of homologous recombination frequency may be increased. If clones are not secreting 
proteins (and therefore there is no secretory stress) counter-selection may be reduced explaining 
why clones show both an increase and decrease in copy number. To reduce genetic instability multi-
copy clones without multiple homologous repeat regions may be required. 
If multi-copy clones are to be used extensively by biopharmaceutical companies it is imperative that 
our understanding of genetic instability improves, with investigations into the possibility of creating 
stable clones. 
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4 Investigation of the Prevalence of Genetic Instability in Multi-Copy Clones 
of Pichia pastoris  
4.1 Introduction 
Multi-copy clones are prevalent in the production of therapeutic proteins using Pichia pastoris and 
are regarded as highly stable [76, 142, 146, 206]. Determination of copy number is by Southern blot 
or more recently average copy number by RT-qPCR [152, 210, 215]. However since 1998 evidence of 
genetic instability has appeared in publications; Ohi et al. reported that a two-copy clone of human 
serum albumin (HSA) integrated into the HIS4 locus grown for a total of 83 generations (equivalent 
to approximately 163 hours) lost the foreign gene in 0.01% of cells [216]. However the titre of 
recombinant protein was not investigated and the effect of genetic instability on protein production 
remains unknown. In addition in 2002 it was reported that an excess of methanol feed at 4 g L-1 
resulted in the loss of a single copy of human chymotrypsinogen-B [217], potentially due to the 
increased stress caused by the excess induction of the AOX1 promoter. 
Generation of multi-copy clones via post-transformational vector amplification (PTVA) has resulted 
in two papers that analyse the stability of this technique. Zhu et al. integrated up to 52 copies of the 
porcine insulin precursor (PIP) into GS115 through PTVA, but found only clones with six copies or less 
were stable [151, 210]. Conversely Marx et al. found  clones containing 11 copies of the HSA gene 
were stable when integrating into the ribosomal DNA (rDNA) locus [152]. In contrast to analysing 
whole populations by RT-qPCR, our data suggests that individual cell evaluations do not represent 
stable cultures during expression. 
4.1.1 Current Investigations into Improving Genetic Stability 
Methods for preventing genetic instability will be investigated in an attempt to produce a more 
stable multi-copy strain.  
4.1.1.1 Stability through Integration at the rDNA locus 
In GS115 there are 16 repeats of the rDNA locus [92] and as a result it would be possible that 16 
copies of the vector could be inserted into these regions. Furthermore, as rDNA is essential for 
growth a selective pressure is constantly maintained. This method of using the rDNA locus has also 
been used in the methyltrophic yeast H. polymorpha with similar effects of stable multi-copy clones 
being achieved [218]. 
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4.1.1.2 Stability through a KU70 Knockout Strain 
Naatsaari et al. generated a KU70 knockout strain, preventing  the non-homologous end joining 
(NHEJ) recombination pathway [215]. Non-homologous integration occurs in P. pastoris and is 
detrimental to protein expression due to different loci having an impact on titre, especially when 
using auxotrophic strains. Naatsaari et al. showed that a side effect of the KU70 knockout strain, 
containing seven copies of a GFP based plasmid with an AOX1 promoter, was maintained stability 
similar to levels discussed by Zhu et al. [210].  
4.1.2 RecA- Homologs in P. pastoris 
RecA- strains are used in E. coli to prevent instability of transformed plasmids [219-220]. In 
eukaryotes the homolog for RecA is RAD51, a protein involved in the recombination pathway 
in single strand invasion and found in many different eukaryotes [221-223]. Bioinformatic 
analysis (blastn) revealed that the sequence similarity of RecA and RAD51 was 26.5%. However 
protein homology (blastp) was 67% [224]. There are two highly homologous regions; the 
surrounding area of the putative nucleoside triphosphate-binding sequence and the carboxy 
terminus [222-223]. These regions correspond to domains responsible for recombination, UV 
resistance and formation of the active oligomers [223]. In mice a mutation in MmRAD51 
results in embryonic arrest during early development [225-226]. However in S. cerevisiae a 
RAD51 knockout is not lethal due to the multiple repair pathways that exist [227-229].  
 Due to known predicted between S. cerevisiae and P. pastoris it was hypothesised that 
creating a knockout of a gene involved in the homologous recombination (HR) pathway, post-
integration of the vector of interest, would result in a more stable strain. The RAD51 gene is 
involved in the HR pathway whereas RAD52 affects both the HR and NHEJ pathways (Fig 1.5). 
We hypothesise that a RAD51 knockout strain may not prevent genetic instability, as it will 
only affect the HR pathway. Whereas a RAD52 knockout, which affects both recombination 
pathways, may result in a more stable strain, but could induce lethal mutations. In order for 
multi-copy clones to reach high titres the issue of stability needs to be addressed. Therefore 
genetic instability and prevalence of this phenomenon was investigated to generate stable 
clones. 
4.1.3 Aims for Genetic Instability 
 To establish whether maintaining constant selection pressure, using Zeocin, affects the 
prevalence of instability. 
 To compare a HIS4 complementation selection method against antibiotic resistance. 
 To investigate the genetic stability in P. pastoris of RAD51 or RAD52 knockout strains. 
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 To evaluate the affects of directed integration into the rDNA locus on genetic instability. 
 
4.2 Maintaining Zeocin Selection through Expression Does Not Prevent Genetic 
Instability 
In the previous chapter genetic instability was shown in all strains grown in 15 L bioreactors, 
including single copy clones, which questions the stability of clones in general (Fig 3.18). We 
hypothesised that continued selective pressure would reduce the prevalence of instability of 
GpαH11_2000B, a five copy clone. Selective pressure was maintained in all media through the 
presence of 2000 μg mL-1 Zeocin. GpαH11_2000B was inoculated into 3 mL of BMGY in microtitre 
plates prior to induction of protein expression with methanol for a further 24 hours. Following which 
serial dilutions were carried out and single colonies isolated on YPD plates (no Zeocin selection). 
Genomic DNA was extracted from colonies using the Plant DNeasy mini-prep kit (Qiagen) and copy 
number determined by qPCR using HSA primers. ACT1 was used as the housekeeping gene to 
determine copy number by ΔΔCt (Fig 4.1). 
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Figure 4.1 Clones of GpαH11_2000B Grown in the Presence of Constant Zeocin show 
evidence of Genetic Instability  
HSA Copy number was determined by qPCR from individual colonies following 24 hours 
expression in microtitre plates. 2000 μg mL
-1
 Zeocin was used to maintain selective 
pressure. A) 0 hours, pre-induction. B) 24 hours, post induction. 
 
Growth in the presence of 2000 μg mL-1 Zeocin ensured that an overall higher copy number was 
maintained (Fig 4.1). In the initial glycerol growth phase HSA copy number ranged from two to nine, 
indicating an increase and decrease relative to the initial five copies present pre-expression. 
Following methanol induction copy number ranged between two and six. The decrease in the HSA 
higher copy number could be due to an increased level of secretory or expression-associated stress. 
Previously the 15 L bioreactor expression profile in the absence of selective pressure, showed copy 
number ranging from zero to seven copies (Fig 3.16). While it appears that maintaining selective 
pressure results in increased genetic stability, as no clones lost the integrated vector completely, this 
A 
B 
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method is financially unfeasible on an industrial scale due to the high cost of Zeocin (Fig 4.1). 
Therefore we examined maintaining selection through the use of an auxotrophic selection marker. 
4.3 Using HIS4 for selection instead of Zeocin does not result in Increased Stability 
The auxotrophic selective marker, HIS4, does not require antibiotics and may be a preferred choice 
for creating stable multi-copy clones. GS115 contains a disrupted HIS4 gene [65, 76], and through 
complementation the inclusion of an intact HIS4 will result in the strain being able to produce 
histidine. Therefore any colonies that do not have an intact HIS4 integrated will not be able to grow 
on minimal media in the absence of histidine. However, the use of minimal media will result in a 
lower cell density and reduced titre due to an increase in protease activity [230]. 
Unfortunately, production of multi-copy clones by PTVA requires an increase in Zeocin (or another 
titratable antibiotic); therefore it is not possible to create multi-copy clones using an auxotrophic 
marker. For the selective process to work only one copy of the HIS4 gene is required to be 
integrated. Analysis of multi-copy clones using an auxotrophic marker requires the use of a vector, 
which contains multiple copies of the gene of interest, to ensure HIS4 integration. The multi-copy 
vector pα-Tx3 was created using the in-vitro multimerisation method to insert a further two copies 
of the gene of interest, trypsinogen (Bryn Edwards-Jones, unpublished). Previous experimentations 
from our lab indicated that pα-Tx3 integration into GS115 resulted in genetic instability under 
continuous culture (Bryn Edwards-Jones, unpublished). This may be due to the repetition of the 
three copies of the AOX1 promoter (Fig 4.3) which could lead to recombination in a similar way 
observed with the PTVA multi-copy strains. 
 
Figure 4.2 pα-Tx3 Plasmid Map 
pα-Tx3 contains three copies of the expression cassette; AOX1 promoter, α-MF signal 
peptide, TRY1 and AOX1 transcription terminator region. These are repeated in tandem, 
and selection and origin of replication are represented by Zeocin resistance gene Sh ble, 
and the pUC origin. 
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pα-Tx3 contains three copies of the TRY1 gene as opposed to the HSA gene as previously used. This 
was due to the size of the HSA gene (1.8 Kb) which was too big to create multimers in-vitro.  For 
growth on selective minimal media the pα-Tx3 was modified by replacing Zeo(R) resistance gene 
with HIS4 from pIB2 to create the vector pIBTx3. A restriction digest of pα-Tx3 with BglII and BamHI 
was used to extract  the three expression cassettes which were then ligated together with the pMB1 
ori, ampicillin (R) and HIS4 gene of pIB2 (Fig 4.3). 
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Figure 4.3 Vector Creation of pIBTx3 
A) pIB2 Plasmid Map. The pIB2 vector contains the GAP promoter followed by the AOX1 
transcription terminator region, and includes both an ampicillin resistance gene for 
selection in E. coli as well as the P. pastoris HIS4 gene for complementation. B) 1% 
Agarose gel of the vector creation of pIBTx3. 1: 1 Kb Ladder (Fermentas); 2: αTx3 digested 
with BglII and BamHI for extraction of the 7kb Try1 Expression cassette; 3: pIB2 inverse 
PCR to remove the GAP promoter; 4: pIBTx3 vector; 5: pIBTx3 digested with NheI. C) 
pIBTx3 Plasmid Map. The vector pIBTx3 was constructed using a restriction digest of BglII 
and BamHI on α-Tx3 to release the expression cassette, and pIB2 which had the GAP 
promoter removed through inverse PCR and the BglII and BamHI restriction sites added to 
the ends. 
A 
B 
C 
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pIBTx3 was transformed into E. coli JM109 for amplification of the plasmid and reisolated using the 
Qiagen mini-prep kit. The vector was sequenced to confirm correct construction (data not shown) 
and 5-10 ng of pIBTx3 was linearised for integration into the HIS4 locus with NheI before being 
transformed into GS115. Colonies were selected on minimal dextrose (MD) plates with the absence 
of histidine for selection. Individual colonies were selected to determine stability by qPCR using the 
primers 383-Try1q7 and 384-Try1q8 (Fig 4.4; Appendix 9.2). 
 
Figure 4.4 Transformation of pIBTx3 into GS115 results in Varying Copy Numbers 
Copy number was calculated via the ΔΔCt method using qPCR primers (383-Try1q7 and 
383-Try1q8) to amplify the TRY1 gene with comparison to ACT1 as the housekeeping gene. 
GpαTx1 strain (darker column) was used as a single copy reference. 
 
qPCR data shows that following transformation the entire construct did not fully integrate into the 
HIS4 locus as there is evidence of clones containing a single TRY1 gene (Fig 4.4). A digest using BglII 
will cut at the 5’ end of the first AOX1 promoter region; however due to the size of the vector 
recombination may occur with the other AOX1 region of homology. This would result in only one 
copy of the AOX1-TRY1 expression cassette being integrated into the genome (Fig 4.4). In addition it 
would be possible to see two copies integrating of the second and third AOX1 regions of homology, 
although this was not the case for the colonies that were tested (Fig 4.4). This highlights the need for 
an extensive screen if the in vitro multimerisation method is to be used. 
While instability was evident in vector integration it is essential to know the number of AOX1-TRY1 
expression cassettes when expressed in minimal media. Two clones, GpIBTx3 3-3 and GpIBTx3 3-6, 
were confirmed to have integrated the entire pIBTx3 vector and therefore selected for further 
analysis (Fig 4.4). Expression of clones GpIBTx3 3-3 and GpIBTx3 3-6 was examined in 24-well 
microtitre plates grown for 24 hours in a glycerol based minimal medium (BMG) prior to induction 
with methanol for a further 24 hours. Post-expression GpIBTx3 3-3 and GpIBTx3 3-6 were serially 
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diluted and plated to single colonies on YPD plates (no selection) to determine copy number of the 
TRY1 gene. Individual colonies were selected and genomic DNA extracted using the Plant DNeasy 
mini-prep kit. TRY1 gene copy number was determined by qPCR using primers 383-Try1q7 and 384-
Try1q8 and compared to GpαTx1, a single copy clone (Fig 4.6; Appendix 9.2). 
 
Figure 4.5 GpIBTx3 Clones show Genetic Instability post-24 hour Expression 
Copy number was calculated via the ΔΔCt method using qPCR primers (383-Try1q7 and 
383-Try1q8) to amplify the TRY1 gene with comparison to ACT1 as the housekeeping gene. 
Light grey bars indicate colonies from GpIBTx3-3 dark grey bars represent colonies from 
GpIBTx3-6. 
 
Post-expression TRY1 copy number ranged from one to three (Fig 4.5). This implies that genetic 
instability is still prevalent in GpIBTx3 3-3 and GpIBTx3 3-6 despite the maintenance of selection 
through the absence of histidine. This agrees with the findings by Ohi et al., which showed instability 
using a HIS4 complemented vector [216]. The in-vitro multimerisation method requires only one 
copy of HIS4 to maintain selection. Counter-selection against increased TRY1 copy number could 
result in recombination between the homologous AOX1 promoter regions to reduce the pressure on 
the secretory pathway. Therefore maintaining auxotrophic strain selection does maintain a level of 
stability, as no clones lost the pIBTx3 vector completely; however it is not a viable option for the use 
of creating multi-copy strains unless multiple auxotrophic markers are used. 
4.4 RAD51- and RAD52- Knockout Strains are not viable  
We hypothesised that by creating knockouts of the HR or NHEJ pathways genetic instability 
could be prevented. We investigated this by knocking out either the RAD51 or RAD52 genes. 
RAD51 and RAD52 knockout strains were constructed using a modified pα-Tx3 vector (Fig 4.2) 
that includes homology to250 bp of 5’ and 3’ ends of the RAD51 or RAD52 genes to 
respectively create the pαTx3R51 and pIBTx3R52 vectors. The Gibson assembly method was 
used to anneal fragments together without the use of restriction sites (Fig 4.6).  
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Figure 4.6 Construction of the pαTx3R51 and pαTx3R52 Vectors 
pαTx3R51 and pαTx3R52 were constructed using the Gibson Assembly method in order to 
add 250 bp of both the 5’ and 3’ end of either the RAD51 or RAD52 gene to the pαTx3 
vector. Final linearisation using SpeI allowed for integration into P. pastoris at the RAD51 
or RAD52 loci. A) Schematic Representation of the creation of pα-T3R51 using the Gibson 
Assembly Protocol B) 1% Agarose gel confirming the insertion of genes of the vectors 1: 1 
Kb Ladder (Fermentas); 2: pαTx3 linearised with BglII; 3: 5’ 250 bp RAD51; 4: 3’ 250 bp 
RAD51; 5: 5’ 250 bp RAD52; 6: 3’ 250 bp RAD52; 7: pαTx3R51; 8: pαTx3R52. 
A 
 
B 
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RAD51 and RAD52 homologous regions were ligated into pα-Tx3 and transformed into E. coli for 
amplification of the plasmid. Reisolated vectors were sequenced to confirm integration of the 
RAD51 and RAD52 fragments (data not shown). Isolated vectors were linearised with SpeI and 
transformed into P. pastoris with selection on 100 μg mL-1 Zeocin. In previous transformations it was 
observed that 100 μL of transformed P. pastoris equated to 100 to 200 transformants. However the 
maximum number of colonies that resulted from a pαTx3R51 transformation was 10 colonies, while 
no colonies were isolated from the transformation of the pαTx3R52 vector. 
Colony PCR was used to determine successful RAD51 knockout strains in pαTx3R51 transformants. 
Primers, 264-RAD51 SeqF1 and 265-RAD51 SeqR1 amplified the RAD51 gene to show gene 
replacement (Fig 4.7; Appendix 9.2). 
 
Figure 4.7 Amplification of the RAD51 gene showed no gene knockout post-integration 
of the pα-Tx3R51 vector 
Colony PCR on a 1% agarose gel was used to confirm pαTx3R51 integration into RAD51 
using primers 264-RAD51 SeqF1 and 265-RAD51 SeqR1. Integration of the vectors will 
result in a fragment length of approximately 13 Kb, while incomplete gene knockout will 
result in a 1.1 K b fragment. 1: 1 Kb Ladder (Fermentas); 2-8: Individual colonies from 
transformation; 9: GS115 
 
Integration of the pαTx3R51 vector into the RAD51 locus would show a 13 Kb band; however a band 
of this size may not be successfully amplified. However if the pαTx3R51 had not integrated into the 
RAD51 locus then the primers would amplify the uninterrupted 1.1 Kb RAD51 gene. The presence of 
the smaller band indicates that the pαTx3R51 vector had not integrated at the RAD51 locus (Fig 4.7). 
However integration of pαTx3R51 may occur at the AOX1 promoter and transcription terminator 
homologous regions. During gene replacement 10-20% of all transformants may integrate into the 
homologous regions as opposed to the RAD51 gene[120]. 
As no transformants displayed RAD51 or RAD52 gene knockouts this raised questions around the 
method for selection. Zeocin works through creating double stranded DNA breaks and if the 
recombination pathway has been compromised by the knockout then it is possible that strains were 
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unable to recover. While RAD51 mutants are not known to be lethal in S. cerevisiae, they are 
reported to have severe consequences in other eukaryotic systems, such as mouse mMRAD51 which 
results in embryonic lethality [221, 223, 225-226]. 
To investigate whether using Zeocin has detrimental effects on the success of the RAD51 or 
RAD52mutants pIBTx3R51 and pIBTx3R52 vectors were created. Both vectors rely on the 
auxotrophic selection marker HIS4. Selection through HIS4 complementation removes the 
requirements of the strains to recover from Zeocin induced double stranded breaks. This vector was 
made using the Gibson assembly protocol, as described for pαTx3R51/52 but using the pIBTx3 vector 
that had been linearised with BglII for the backbone (Fig 4.8). 
 
Figure 4.8 pIBTx3R51 and pIBTx3R52 Plasmid Maps 
pIBTx3R51 and pIBTx3R52 were created using the Gibson Assembly method; whereby 250 
bp from the 5’ and 3’ ends of the RAD51 and RAD52 genes were respectively 
complemented to the pIBTx3 vector.  
 
The pIBTx3R51 and pIBTx3R52 vectors were transformed into E. coli JM109 for amplification and 
reisolated using the Qiagen mini-prep kit. The isolated vectors were sequenced to ensure integration 
of the RAD51 and RAD52 homologous fragments (data not shown). Isolated DNA was digested with 
EcoRV for transformation into P. pastoris. Colonies were selected on MD plates with the absence of 
histidine for selection. Transformation using the vectors pIBTx3R51 and pIBTx3R52 resulted in a 
maximum of 10 colonies successfully showing complementation of the HIS4 gene (thus exhibiting 
growth on minimal media). These figures were similar the pαTx3R51 vector transformation 
efficiencies. Individual colonies were analysed by colony PCR to determine whether pIBTx3R51 and 
pIBTx3R52 had integrated into the RAD51 or RAD52 loci to determine if gene knockouts had been 
successful (Fig 4.9). 
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Figure 4.9 Amplification of the RAD51 or RAD52 genes showed no gene knockout post-
transformation of the pIBTx3R51 and pIBTx3R52 vectors 
Colony PCR on a 1% agarose gel was used to confirm integration of pIBTx3R51 and 
pIBTx3R52 using primers 264-RAD51 SeqF1 and 265-RAD51 SeqR1 or 266-RAD52 SeqF1 
and 267-RAD52 SeqR1 respectively. Integration of the vectors would result in a fragment 
length of approximately 13 Kb, while incomplete gene knockout would result in a 1.1 or 
1.2 Kb fragment respectively. A) Amplification of the RAD51 gene; B) Amplification of the 
RAD52 gene. 1: 1 Kb Ladder (Fermentas); 2-8: Individual colonies from transformation; 9: 
GS115 
 
Amplification of the RAD51 and RAD52 genes shows no integration of the pIBTx3R51 or pIBTx3R52 
vectors. This implies that the use of Zeocin was not the sole cause of the failure to generate RAD51 
or RAD52 gene knockouts. Vector size has an impact in the rate of integration; therefore due to the 
size at 12.5 Kb it may be impacting successful transformation [112]. Furthermore pIBTx3R51 and 
pIBTx3R52 integration can occur at several places; AOX1 promoter, AOX1 transcription terminator 
region, HIS4 and the RAD51 or RAD52 loci. A linearised PCR fragment containing only the 
RAD51/RAD52 fragments and the HIS4 gene was designed to determine if a smaller fragment results 
in gene knockouts. By implementing this method, if integration does not occur at the RAD51 or 
RAD52 locus the only other region of homology for integration would be the HIS4 locus. To create 
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this linear PCR product the Gibson Assembly method was used to ligate 250 bp from the 5’ and 3’ of 
RAD51 or RAD52 to flank the HIS4 gene (Fig 4.10). 
 
  
            
Figure 4.10 Creation RAD51-HIS4 and RAD52-HIS4 Linear DNA fragments 
A) Schematic representation of the creation of RAD51-HIS4 and RAD52-HIS4 fragments. 
HIS4 was flanked by 250 bp of the 5’ and 3’ regions of homology to the RAD51 or RAD52 
genes. B) 1% agarose gel confirming the creation of the RAD51-HIS4 linear DNA fragment 
1: 1 Kb Ladder (Fermentas), 2: 250 bp RAD51 gene (5’), 3: HIS4 gene, 4: 250 bp RAD51 
gene (3’), 5: RAD51-HIS4 linearised fragment constructed.  C) 1% agarose gel confirming 
the creation of the RAD52-HIS4 linear DNA fragment 1: 1 Kb Ladder (Fermentas), 2: 250 bp 
RAD52 gene (5’), 3: HIS4 gene, 4: 250 bp RAD52 gene (3’), 5: RAD52-HIS4 linearised 
fragment constructed.   
 
A 
B C 
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RAD51-HIS4 and RAD52-HIS4 linear DNA fragments were transformed into GS115 and transformants 
were selected on MD plates minus histidine for selection. Integration of the RAD51-HIS4 and RAD52-
HIS4 linear DNA resulted in a low number of transformants, similar to integration of the pαTx3R51, 
pIBTx3R51 and pIBTx3R52 vectors. Colonies were analysed by colony PCR using primers 264-RAD51 
SeqF1 and 265-RAD51 SeqR1 or 266-RAD52 SeqF1 and 267-RAD52 SeqR1 to determine the presence 
of RAD51 or RAD52 knockout genes respectively (Fig 4.11).  
 
Figure 4.11 Amplification of the RAD51 and RAD2 genes showed no gene knockout using 
a linear DNA fragment 
Colony PCR on a 1% agarose gel was used to confirm integration of RAD51-HIS4 and 
RAD52-HIS4 using primers 264-RAD51 SeqF1 and 265-RAD51 SeqR1 or 266-RAD52 SeqF1 
and 267-RAD52 SeqR1 respectively. Integration of the linear DNA fragments would result 
in a fragment length of approximately 4 Kb, while incomplete gene knockout would result 
in a 1.1 or 1.2 Kb fragment respectively. A) Amplification of the RAD51 gene; B) 
Amplification of the RAD52 gene. 1: 1 Kb Ladder (Fermentas); 2-8: Individual colonies 
from transformation; 9: GS115 
 
Amplification of the RAD51 and RAD52 genes showed no integration of the RAD51-HIS4 or 
RAD52-HIS4 linear fragments (Fig 4.11). Correct integration of the linear DNA fragments would 
amplify a 4 Kb band. However if the linear fragments had not integrated into the RAD51 or 
RAD52 loci the primers would amplify the uninterrupted 1.1 Kb RAD51 or 1.2 Kb RAD52 gene 
respectively. Therefore as integration has not occurred within the RAD51 or RAD52 genes 
integration may occur within the HIS4 gene due to the region of homology present in the DNA 
fragment. The colonies were analysed by colony PCR using the primers 392-HIS4-5’ and 337-
RAD51-5-HIS or 342-RAD52-5-HIS to determine integration at the 5’ end of the HIS4 gene. 
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Primers 395-HIS4-3’ and 340-RAD51-3-HIS or 352-RAD52-3-HIS were used to determine 
integration at the 3’ end of the HIS4 gene. No bands were amplified implying that the RAD51-
HIS4 and RAD52-HIS4 linear DNA fragments had not integrated into the HIS4 locus (data not 
shown). 
As the linear fragment only contained regions of homology to two loci it implies that 
integration is occurring through non-homologous recombination into another locus in the 
genome. Evidence suggests that non-homologous recombination does occur with regular 
frequency in P. pastoris [121, 215]. An alternative possibility is that the vector may be 
integrating in tandem within either the RAD51 or RAD52 gene. If a knockout of RAD51 and 
RAD52 creates a lethal mutation a gene insertion event may occur as opposed to a gene 
replacement. Gene replacement occurs with less frequency than a gene insertion event [65, 
120]. Unfortunately proving the presence of gene insertion as opposed to gene replacement 
was not possible in this instance (data not shown). 
4.5 Genetic Stability was observed with Vectors Integrated into the rDNA Locus 
According to Marx et al. integration of vectors into the rDNA locus results in the production of stable 
multi-copy clones [152]. Nonetheless stability was determined via analysis on whole populations and 
does not account for variations on individual cell basis. Therefore genetic instability was investigated 
on an individual cell basis for vectors integrated into the rDNA locus. 
4.5.1 Vector Creation 
To emulate Marx et al. the vector pGRzαHSA was constructed using the Gibson assembly method 
[152]. The α-MF signal peptide, HSA gene, AOX1 transcription terminator and Zeo(R) resistance gene 
were isolated from the pα-HSA vector. The GAP promoter was extracted from pIB2 and the rDNA 
locus amplified using the primers 370-rDNA-pUC GibF and 371-rDNA-GAP GibR.(Appendix 9.2; Figure 
4.12) [152]. 
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Figure 4.12  pGRzαHSA Plasmid Map 
pGRzαHSA was created through the Gibson Assembly Protocol with the GAP promoter 
from pIB2, the rDNA locus amplified from GS115 genomic DNA and the rest of the vector 
was isolated from pα-HSA. 
 
In addition to replicating the vector from Marx et al. the vector, pARzαHSA, replacing the GAP 
promoter with the AOX1 promoter was created. This allowed comparison to multi-copy clones 
generated by PTVA using the AOX1 promoter (Fig 3.20). We have hypothesised genetic instability 
may be due to the volume of protein being passed through the secretory pathway and 
corresponding secretory stress. The GAP promoter produces less protein than the AOX1 promoter; 
thus stability observed by Marx et al. may be as a consequence of reduced traffic through the 
secretory pathway (Fig 4.13). 
 
Figure 4.13 pARzαHSA Plasmid Map 
The second vector created by cloning, through Gibson Assembly method, the rDNA locus 
into the pα-HSA vector. 
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4.5.2 Initial integration into the rDNA locus  
pGRzαHSA and pARzαHSA were transformed into E. coli JM109 for amplification of the plasmid and 
reisolated using the Qiagen mini-prep kit. The reisolated vectors were sequenced (data not shown) 
before linearisation using SpeI in the rDNA gene. Linearised pGRzαHSA and pARzαHSA were 
transformed into GS115 and plated on YPD plates containing 100 μg mL-1 Zeocin. Colony PCR was 
used to confirm that pGRzαHSA and pARzαHSA had integrated into the rDNA locus using primers 
352-rDNA IntF and 353-rDNA IntR (Fig 4.14; Appendix 9.2).  
 
Figure 4.14 Successful Integration of the pGRzαHSA and pARzαHSA vectors into the 
rDNA locus 
Colony PCR on 1% agarose gels shows integration of the pGRzαHSA and pARzαHSA vectors 
into the rDNA locus. A) Integration at the 5’ end of the vector; B) Integration at the 3’ end 
of the vector. 1: 1 Kb DNA Ladder (Fermentas); 2: pARzαHSA 1; 3: pARzαHSA 2; 4: 
pGRzαHSA 1; 5: pGRzαHSA 2. 
 
Integration of pGRzαHSA and pARzαHSA was confirmed by colony PCR (Fig 4.14). GpGRzαHSA2 
shows a brighter band (particularly for amplification of the 5’ integration site) than the other strains 
analysed. This could suggest the presence of multiple copies of vectors integrated into the rDNA loci. 
HSA gene copy number was determined by qPCR using primers 070-HSAq1 and 071-HSAq2 and 
compared to GpαH1_100, a single copy clone (Fig 4.15). 
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Figure 4.15 Integration into the rDNA Locus results in Multi-Copy Clones 
Copy number was calculated via the ΔΔCt method using qPCR primers (70-HSA-q1 and 71-
HSA-q2) to amplify the HSA gene with comparison to ACT1 as the housekeeping gene. 
Light grey bars indicate colonies containing the pARzαHSA vector and dark grey bars 
represent colonies from containing the GpGRzαHSA vector. 
 
GpGRzαHSA2 was confirmed as a multi-copy clone containing nine copies of the HSA gene, which 
correlates to the brighter band seen through analysis by colony PCR (Fig 4.14 and 4.15). Previously 
the highest copy number observed through integration into the AOX1 locus was five copies. Due to 
the high copy number of GpGRzαHSA2 titre was determined as a comparison to previous multi-copy 
clones. Clones were expressed for 24 hours in either a glycerol or methanol containing medium 
depending on the promoter used. Protein levels were determined by the Albumin Blue Fluorescence 
Assay (Fig 4.16). 
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Figure 4.16 HSA Titre Levels of Clones Integrated into the rDNA Locus containing the 
HSA gene 
HSA titre was determined by the Albumin Blue Fluorescence assay (Active Motif) after 24 
hours growth in methanol medium or glycerol medium depending on the promoter used.  
 
GpGRzαHSA2 produced 13.9 μg mL-1, which is comparable to titre produced by GpαH1_100, a single 
copy clone of HSA integrated into the AOX1 locus (Fig 4.16). GpGRzαHSA uses the GAP promoter for 
expression; therefore may not be comparable to GpαH1_100, which uses the AOX1 promoter. 
Integration into different loci has been known to result in different titre levels, for instance 
integration into the AOX1 promoter produces more protein than integration into the HIS4 locus 
[121, 215]. 
GpGRzαHSA and GpARzαHSA were analysed for HSA transcript levels to determine whether 
integration into the rDNA locus varied from clones with vectors integrated into the AOX1 locus. RNA 
samples were extracted after 24 hours expression in glycerol (GAP promoters) or methanol (AOX1 
promoters), using the RiboPure Yeast RNA Extraction kit (Applied Biosystems). HSA gene expression 
levels were analysed by RT-qPCR using primers 070-HSAq1 and 071-HSAq2 and the ACT1 as the 
house keeping gene  and compared to GpαH1_100, GpαH11_100, GpαH11_2000A (3 copy) and 
GpαH11_2000B (5 copy) (Fig 4.17; Appendix 9.2). 
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Figure 4.17 Clones with Integration into the rDNA Locus show Reduced Transcript Levels 
compared to Clones with Integration in the AOX1 Locus 
HSA gene expression was calculated via the ΔΔCt method using qPCR primers 70-HSA-q1 
and 71-HSA-q2 to amplify the HSA gene with comparison to ACT1 as the housekeeping 
gene as a comparison to GpαH1_100, a known one copy clone. Statistically significant 
values of p<0.05 (compared to GpαH1_100) are indicated by a *. 
 
GpARzαHSA1 and GpGRzαHSA2 produced low levels of transcript compared to the strains integrated 
into the AOX1 locus (Fig 4.17). GpARzαHSA1is a one copy clone therefore HSA transcript should be 
comparable to GpαH1_100 and GpαH11_100. The low HSA titre suggests a reduced flow of traffic 
through the secretory pathway, which can be monitored by analysing the HAC1, KAR2 and PDI gene 
expression levels. Additional stress on the secretory pathway may have a negative effect on protein 
production. Transcript levels were analysed by RT-qPCR using the ACT1 gene as the housekeeping 
gene and as a comparison to GpαH1_100, a known one copy clone (Fig 4.18). 
 
* 
* 
* 
* 
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Figure 4.18 Comparison of UPR signals from clones Integrated into the rDNA Locus 
versus Integration into the AOX1 Locus 
HAC1, KAR2 and PDI gene expression were calculated via the ΔΔCt method using qPCR 
primers 010-KAR2q1, 011-KAR2q2, 012-PDIq1, 013-PDI1q2, 067-HAC1q3 and 068-HAC1q4 
respectively. ACT1 was the housekeeping gene and results were calculated as a 
comparison to GS115. Statistically significant values of p<0.05 (compared to GS115) are 
indicated by a *. 
 
GpARzαHSA1 showed reduced upregulation of UPR compared to the single copy clones integrated 
into the AOX1 (Fig 4.18). This implies that the reduced HSA transcript levels (Fig 4.18) produced by 
GpARzαHSA resulted in less stress on the secretory pathway (Fig 4.21). GpGRzαHSA2 (9 copy) shows 
a 10 fold upregulation of HAC1 gene transcript levels compared to GpαH11_2000A (3 copy). 
Therefore despite low HSA transcript levels there is an upregulation of UPR as a result of increased 
protein production. As GpGRzαHSA2 uses the GAP promoter and not the AOX1 promoter, 24 hours 
may not be sufficient for protein production; therefore, for future experiments strains containing 
the GAP promoter were expressed for 48 hours.  
4.5.3 Creating Multi-Copy Clones of rDNA Integrated Vectors 
PTVA was used to create multi-copy clones to determine whether integration into the rDNA locus 
affects titre compared to multi-copy clones integrated into the AOX1 locus. As using PTVA on plates 
resulted in mixed populations (Fig 3.10) a liquid variant of PTVA was implemented. Colonies were 
inoculated into 24-well microtitre plates with 3 mL YPD containing 100 μg mL-1 Zeocin. After 24 
hours the cultures were centrifuged and resuspended in YPD containing an increased concentration 
of Zeocin and left to grow for a further 24 hours. This was continued until Zeocin concentration 
reached 2000 μg mL-1. As with the initial PTVA experiment concentrations of Zeocin used were 100, 
* * * 
* 
* 
* 
* 
* 
* * 
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200, 300, 500, 1000 and 2000 μg mL-1. After 24 hours growth at the 2000 μg mL-1 Zeocin cultures 
were serially diluted and plated onto YPD containing 2000 μg mL-1 Zeocin and left to incubate at 30°C 
for 3-5 days. 
Post-PTVA individual colonies were expressed in BMGY and BMMY media for 24 hours for strains 
containing the AOX1 promoter and for 48 hours in BMGY for strains containing the GAP promoter. 
Heterologous protein production was visualised on an SDS-PAGE gel using the spent broth from 
expression to ensure that the α-mating factor (MF) secretion signal was active (Fig 4.19). 
 
Figure 4.19 HSA Expression post-PTVA of Vectors Integrated into the rDNA Locus 
HSA expression was determined by expression for 48 hours in BMGY (GAP promoter) or 24 
hours in BMMY (AOX1 promoter) and analysed on a 12% SDS-PAGE gel. 1: GpαH1_2000A; 
2: Pre-stained molecular marker (Fermentas); 3: GpGRzαHSA2_2000C; 4: 
GpARzαHSA1_2000E. 
 
Post-PTVA GpGRzαHSA and GpARzαHSA clones were confirmed to secrete HSA (Fig 4.19). A 
comparison between copy number and titre was analysed to determine the affects of multi-copy 
clones integrated into the rDNA locus. Genomic DNA was extracted using the DNeasy Plant mini-
prep kit (Qiagen) and qPCR was used to analyse copy number using the primers 070-HSAq1 and 071-
HSAq2 compared to GpαH1_100, a known single copy clone (Appendix 9.2). Expression of HSA was 
quantified using the Albumin Blue Fluorescence Assay (Active Motif) after expression for 24 hours in 
BMMY (AOX1 promoter) or 48 hours in BMGY (GAP promoter)(Fig 4.20). 
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Figure 4.20 No correlation between HSA copy number and HSA titre was seen for Clones 
Integrated into the rDNA Locus 
Copy number was calculated via the ΔΔCt method using qPCR primers 070-HSAq1 and 
071-HSAq2 to amplify the HSA gene with comparison to ACT1 as the housekeeping gene. 
HSA titre was determined by the Albumin Blue Fluorescence assay (Active Motif) after 
expression for 24 hours in methanol or 48 hours in glycerol depending on the promoter 
used. pGRzαHSA (GAP promoter) is represented in blue and pARzαHSA (AOX1 promoter) 
in purple. 
 
GpGRzαHSA shows 38 copies of the HSA successfully integrated into the rDNA locus. Previously only 
five copies of the HSA gene had successfully integrated into the AOX1 locus by PTVA. The average 
copy number of clones integrated with pGRzαHSA was 19 copies, whereas with the pARzαHSA vector 
this was 11 copies. Variation in average copy number between clones containing the AOX1 promoter 
and GAP promoter may be due to the limitation in the number of individual clones tested and not 
due to any differences between the two promoters. 
Average expression levels of clones containing the pGRzαHSA and pARzαHSA vectors were 46 and 44 
μg mL-1 respectively, two-tailed t(10) p=0.6511 (Fig 4.20). Multi-copy clones resulted in a three-fold 
increase in titre compared to single copy clones integrated into the AOX1 locus (Fig 4.16 and 4.20).  
There was no correlation between copy number and titre for either of the vectors analysed with r2 
values at 0.0126 and 0.035 (Fig 4.20). As HSA titre did not increase with an increase of HSA genes it 
implies that secretion saturation has been reached.  
HSA transcript levels were analysed by RT-qPCR using primers 070-HSAq1 and 071-HSAq2 to 
determine whether an increase in copy number increased the amount of transcript that was being 
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produced, despite no increase in titre. Of the clones that were generated by PTVA only two were 
selected for further experimentation based on copy number. As with all multi-copy clones selected 
through PTVA clones were named as follows; GpGRzαHSA#_2000 (GH#_2000) or GpARzαHSA#_2000 
(AH#_2000) followed by A-F indicating the relevant colony. The clones containing the highest and 
lowest number of HSA genes were selected; GpARzHSA1_2000A (3 copy), GpARzαHSA1_2000C (25 
copy), GpGRzαHSA2_2000C (38 copy) and GpαGRzHSA2_2000F (3 copy). GpαH1_100, GpαH11_100, 
GpαH11_2000A (3 copy) and GpαH11_2000B (3 copy) were included as a comparison to clones 
integrated into the rDNA locus (Fig 4.22). 
 
Figure 4.21 HSA Transcript is Increased Post-PTVA for Clones with Vectors Integrated 
into the rDNA Locus Compared to Clones with Vectors Integrated into the AOX1 Locus 
HSA gene expression was calculated via the ΔΔCt method using qPCR primers 070-HSAq1 
and 071-HSAq2 to amplify the HSA gene with comparison to ACT1 as the housekeeping 
gene as a comparison to GpαH1_100, a known one copy clone. PTVA strains are indicated 
by 2000 and the relevant colony (A-F) chosen. GpARzαHSA1 (AH1), GpGRzαHSA2 (GH2), 
GpαH1_100 (H1_100), GpαH11_100 (H11_100), GpαH11_2000A (H11_2000A) and 
GpαH11_2000B (H11_2000B). Statistically significant values of p<0.05 (compared to 
GpαH1_100) are indicated by a *. 
 
HSA transcript levels of GpARzαHSA strains show a 13 fold increase compared to GpGRzαHSA clones 
(Fig 4.21). For both GpARzαHSA and GpGRzαHSA clones with the higher copy numbers produced 
increased HSA transcript compared to the corresponding low copy clones. GpGRzαHSA2_2000F (38 
copy) showed a two fold increase in HSA transcript compared to GpGRzαHSA2_2000C (3 copy). 
However, a 1.8 fold increase of HSA  transcript between GpARzαHSA1_2000A (3 copy) and 
GpARzαHSA1_2000C (25 copy) did not correlate to an increase in titre as respectively each secreted 
52 μg mL-1 and 43 μg mL-1 of HSA (Fig 4.24). Furthermore GpGRzαHSA2_2000C (38 copy) secreted 43 
* 
* 
* 
* 
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μg mL-1 while GpGRzαHSA2_2000F (3 copy) secreted 49 μg mL-1 of protein despite transcript levels 
being higher in the 38 copy clone. This implies that blockages within the secretory pathway prevent 
high levels of HSA transcript being converted into protein. Furthermore the decrease in titre of 
GpGRzαHSA2 _2000F (38 copy) and GpARzαHSA1_2000C (25 copy) compared to the low copy clones 
suggests that degradation may be occurring due to secretory stress in the high copy clones. To 
determine if secretory stress is upregulated in the high copy clones HAC1, KAR2 and PDI transcript 
levels were determined by RT-qPCR (Fig 4.22). 
 
Figure 4.22 Gene Expression Levels of UPR Signals Upregulated in Clones Containing 
Vectors integrated into the rDNA Locus Compared to Integration at the AOX1 Locus 
HAC1, KAR2 and PDI gene expression were calculated via the ΔΔCt method using qPCR 
primers 010-KAR2q1, 011-KAR2q2, 012-PDIq1, 013-PDI1q2, 067-HAC1q3 and 068-HAC1qr 
respectively. ACT1 was the housekeeping gene and fold change was calculated as a 
comparison to GS115. PTVA strains are indicated by 2000 and the relevant colony (A-F) 
chosen. GpARzαHSA1 (AH1), GpGRzαHSA2 (GH2). Statistically significant values of p<0.05 
(compared to GS115) are indicated by a *. 
 
 
HAC1 was upregulated in all of the multi-copy clones integrated into the rDNA locus compared to 
vectors integrated into the AOX1 locus (Fig 4.22). PDI and KAR2 transcript levels were similar to 
clones integrated into the AOX1 locus. Only GpGRzαHSA_2000F (3 copy) showed increased 
expression of KAR2 (two tailed t(4) p=0.0016). The significant upregulation of HAC1 in the multi-copy 
clones  integrated into the rDNA locus suggests that UPR is upregulated as a control mechanism to 
manage the flow of proteins through the secretory pathway [160]. HAC1 transcript levels for 
GpGRzαHSA2_2000C (38 copy) and GpARzαHSA1_2000C (25 copy) are increased compared to 
GpGRzαHSA2_2000F (3 copy) and GpARZαHSA1_2000A (3 copy) respectively. Due to the decrease in 
titre of the high copy clones it can be hypothesised that the high HAC1 induction may be an 
indication of the activation of the ERAD, which occurs through prolonged UPR induction. 
* 
* 
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4.5.4 Stability of Multi-Copy Clones 
To determine genetic stability of vectors integrated into the rDNA locus cultures were expressed for 
24 hours in methanol (for clones containing the AOX1 promoter) or 48 hours in glycerol (for clones 
containing the GAP promoter). Post-expression cultures were serially diluted and plated onto YPD 
plates (no selection). Individual colonies were selected post-expression for copy number analysis. 
Genomic DNA was extracted directly from the colonies and analysed by qPCR using the primers 070-
HSAq1 and 071-HSAq2 with comparison to GpαH1_100, a known one copy clone (Fig 4.23). 
         
         
Figure 4.23 Clones with vectors integrated into the rDNA Locus using both the AOX1 and 
GAP promoter show evidence of Genetic Instability 
Copy number was calculated via the ΔΔCt method using qPCR primers 070-HSAq1 and 
071-HSAq2 to amplify the HSA gene with comparison to ACT1 as the housekeeping gene, 
In all graphs the first (and darker) column represents the original copy number before 
expression. A: GpARzαHSA1_2000A (AH1_2000A). B: GpARzαHSA1_2000C (AH1_2000C).C: 
GpGRzαHSA2_2000C (GH2_2000C). D: GpGRzαHSA2_2000F (GH2_2000F). 
 
Post-expression all four strains analysed showed genetic instability with clones both increasing and 
decreasing in HSA copy number (Fig 4.23). GpGRzαHSA2_2000C was initially a 38 copy clone, but 
post expression copy number ranged from two to 28 copies of the HSA gene. Conversely 
GpGRzαHSA2_2000F was initially as a three copy clone but post-expression copy number ranged 
from seven to 46 copies. Copy number of GpARzαHSA1_2000A ranged from a single copy clone up to 
a four copy clone. GpARzαHSA1_2000C showed a decline in copy number to 10 copies of the HSA 
gene with one colony maintaining the initial copy number of 25. 
No clones with vectors integrated into the rDNA locus contained zero copies of the HSA gene as was 
seen in clones with vectors integrated into the AOX1 locus (Fig 3.16 and 3.18). Multi-copy clones 
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integrated into the rDNA locus induce stress in the secretory pathway (Fig 4.22), which could act as a 
counter-selection against stability. However, the stress of a single copy clone on the secretory 
pathway may be insufficient to act as a counter-selection (Fig 4.18). Whilst investigation on whole 
populations suggests integration into the rDNA is stable [152] single colony analysis suggests that 
the repeat sequences of the rDNA locus are recombining post-integration leading to unstable clones. 
4.6 Discussion 
Genetic instability can reduce the efficiency of recombinant expressing strains, which is detrimental 
to pharmaceutical companies producing biopharmaceuticals as clones may not reach their 
expressing potential. Moreover development of multi-copy clones is time consuming and potentially 
costly (especially if PTVA is used with concentrations of Zeocin reaching 2000 μg mL-1). Genetic 
instability in P. pastoris is currently assessed via RT-qPCR or Southern blot on a population level 
culture to determine copy number. However, by isolating individual colonies and assessing copy 
number by qPCR we have ascertained that genetic instability is prevalent (Fig 3.16 and 3.18).  
To investigate whether maintaining a selective pressure had an effect on genetic instability 
GpαH11_2000B, a five copy clone, was expressed maintaining a concentration of 2000 μg mL-1 
Zeocin. Clones isolated post-expression and analysed by qPCR resulted in colonies with lower HSA 
copy number (2 copy) and an increased copy number (9 copy) in non-inducing conditions. In 
inducing conditions copy number ranged from two to six copies (Fig 4.1). This implies that high-copy 
numbers are counter-selected when grown in inducing conditions, as seen by Zhu et al. [210]. No 
clones lost the expression vector completely as seen when expressed in the absence of Zeocin (Fig 
3.16 and 3.18). Therefore maintaining a selective pressure does increase the stability of multi-copy 
clones. However, the cost of Zeocin at approximately £210 g-1 is an unrealistic expense for industrial 
companies.  
To determine stability via maintaining selection through an auxotrophic marker the vector pIBTx3 
was designed, which relies on the complementation of HIS4 and contains three copies of the TRY1 
gene. Transformation of the pIBTx3 vector resulted in clones with only one copy of the AOX1-TRY1 
cassette integrated into the genome (Fig 4.4). As larger vectors are more difficult to transform into P. 
pastoris the 12 Kb vector could reduce transformation efficiency [231]. Additionally as three copies 
of the AOX1 region of homology are included in the vector the likelihood of integration of only part 
of the vector is increased. Recombination between the homologous AOX1 promoter regions would 
result in a smaller linearised DNA inserting into the genome. 
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Despite some strains showing partial integration of pIBTx3 clones that contained three TRY1 genes 
were analysed for stability post-expression. Minimal medium with the absence of histidine was used 
to maintain the selective pressure. Post-expression clones contained either a single copy, two copies 
or three copies of the TRY1 gene implying genetic instability (Fig 4.5). However, the maintained 
stability ensured that no clones lost the vector entirely. This implies that there is counter-selection 
against clones containing multiple copies of the TRY1. As TRY1 is known the induce UPR [87], multi-
copy clones may result in secretory stress leading to the activation of the ERAD. A single copy of 
TRY1 was maintained through the use of the HIS4 auxotrophic marker. Therefore multiple 
auxotrophic complementation may be required for the production of stable multi-copy clones, for 
example the addition a ADE4 knockout, such as strain GS200 [65]. However using strains that require 
multiple auxotrophic complementation require the use of highly defined minimal media, which 
could result in lower titre due reduced cell density and increased protease activity [232]. 
RAD51 and RAD52 mutants were designed to determine whether interrupting the HR or the HR and 
NHEJ pathways had an effect on genetic instability. It was hypothesised that by simultaneously 
inserting a vector into the genome and interrupting the recombination pathways regions of 
homology between the vector and the genome would be prevented from recombining to lose the 
vector. A variety of attempts to create RAD51 and RAD52 knockout strains were unsuccessful. In 
2012 a KU70 knockout strain was successfully developed by Naatsaari et al. designed to interrupt the 
NHEJ recombination pathway [215]. While RAD51 and RAD52 knockout strains were similar in 
concept to the KU70 knockout strain both affected the HR pathway. While S. cerevisiae knockout 
strains of RAD51 are stable there is evidence in other eukaryotic organisms that a RAD51 mutant 
causes severe deleterious effects [225-226]. We can hypothesise that in P. pastoris interrupting the 
HR pathway results in a lethal mutation; thus explaining the absence of RAD51 or RAD52 knockout 
strains. 
The last attempt to create stable multi-copy clones was based on an experiment by Marx et al. with 
integration of multi-copy clones directed into the rDNA locus [152]. Vectors were designed using 
both the GAP promoter and the AOX1 promoter.  Genetic instability was observed for all strains 
analysed post-expression in non-selective media (Fig 4.23). Stability of the rDNA loci in S. cerevisiae 
is dependent upon the relocalisation of the DNA double-stranded breaks from the nucleolus to the 
nucleoplasm, before it associates with the recombination machinery. It is this relocalisation, which 
relies on the Smc5-Smc6 complex and sumoylation of Rad52p that ensures the stability of the rDNA 
loci [233]. Potentially integration of the exogenous DNA may affect the relocalisaton prior to 
exposure to the recombination machinery, resulting in increased instability. 
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Clones containing higher copy numbers of the HSA gene showed increased genetic instability  
compared to lower copy clones, an effect reported by Zhu et al. [210]. GpGRzαHSA2_2000F (3 copy) 
and GpARzαHSA1_2000A (3 copy) showed higher titre levels than the high copy clones 
GpGRzαHSA2_2000C (38 copy) and GpARzαHSA1_2000C (25 copy). Lower copy number clones also 
showed reduced induction of UPR indicating less stress on the secretory pathway. Additionally 
saturation of the secretion pathway when expressing HSA has been reported to occur when five 
copies of the gene are present [152]. Current thoughts are that multi-copy clones are stable when up 
to six copies of the gene of interest are present [152, 210, 215]. Therefore the creation of high copy 
clones may be unnecessary for the production of recombinant proteins when expressing HSA. 
Furthermore as the transformation onto 100 μg mL-1 Zeocin resulted in nine copies of the HSA gene 
high-copy number clones created through the use of PTVA may be unnecessary. While we have been 
unable to generate clones that show no evidence of genetic instability, the inclusion of low multi-
copy clones through integration into the rDNA locus consistently results in the maximum titre of HSA 
without excess stress on the secretory pathway.
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5 The Effects of Using a Codon Optimised Gene for Expression in Pichia 
pastoris 
5.1 Introduction 
5.1.1 Codon Optimised Genes in P. pastoris 
Codon optimisation functions on the premise that different organisms translate particular codons 
more effectively than others [234-235]. Through either point mutations or by buying a genetically 
synthesised gene it is possible to select codons, which can result in increased titre expressed from 
the synthesised gene. Development of codon optimisation varies between companies; often it is 
suggested that replacing rare synonymous codons with favoured codons for the expressing host will 
result in increased titre [236]. However DNA 2.0 suggest that it is not the selection of more 
frequently used codons that result in increased titre but tRNAs that are most highly charged during 
amino acid starvation [237]. 
Codon optimisation has been implemented in P. pastoris; however this method does not 
consistently result in increased titre [65]. The production of codon optimised human 
glucocerebrosidase protein, showed a 10.6 fold increase post-optimisation [238]. Additionally the 
production of equistatin, which was codon optimised to P. pastoris resulted in a four to 10-fold 
increase at protein level [239]. Woo et al. suggest that codon optimisation is essential for the 
production of anti-T cell immunotoxin in P. pastoris [240]. Yet whilst there are examples of increases 
in efficiency through codon optimisation there are counter arguments that suggest that this process 
is not necessary [59]. Sinclair and Choy suggested that altering the codon usage changes the A/T 
ratio of the foreign gene, and it was this ratio that resulted in increased expression. This technique 
appeared to have a similar level of success as that of codon optimisation [238].  
To date no codon optimised HSA gene has been evaluated for titre. As HSA secretion reaches 10 g L-1 
optimisation via media or growth conditions may be sufficient [140]. However, we have observed 
that production of HSA result in induction of UPR (3.6). Therefore using an optimised gene of 
interest could potentially reduce secretion stress, as translational processes will be accelerated by 
readily available tRNAs. A codon optimised HSA gene purchased for GenScript USA Inc. (Piscataway, 
NJ, USA) was used to investigate both titre of an optimised gene compared to the native HSA for 
both single and multi-copy clones.  
5.1.2 Aims  
 To determine the effects of using an optimised HSA gene on titre and UPR 
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 To examine whether the use of an optimised HSA gene affects stability by reducing counter-
selection against multi-copy clones integrated into the rDNA locus. 
5.2 Single Copy Clones of HSAoptimised gene 
The HSA optimised (HSAopt) gene purchased from GenScript was synthesized to be codon optimised 
for P. pastoris. GenScript applies the OptimumGene™ algorithm for developing an optimised gene 
taking into consideration not only preferred codon usage but translation efficiencies and protein 
refolding (Appendix 9.1). As with previous HSA vectors pα-HSAopt was formed of a single copy of the 
HSAopt gene ligated into the pPICzα vector at the EcoRI and NotI sites (Fig 5.1). 
 
Figure 5.1 pα-HSAopt Plasmid Map 
Vector design of HSA optimised gene incorporated into the pPICzα vector using EcoRI and 
NotI. PmeI restriction site linearises the vector for integration into the AOX1 region of the 
genome. 
 
pα-HSAopt was transformed into JM109 E. coli and reisolated using the Qiagen mini-prep kit. The 
vector was digested with PmeI, which cuts within the AOX1 promoter for linearisation. The linearised 
vector was transformed into GS115 and plated onto YPD plates containing 100 μg mL-1 Zeocin. HSA 
titre was determined for single copy clones to determine the effect of using a codon optimised gene. 
Clones were expressed in 24-well microtitre plates for 24 hours in BMGY before being induced with 
methanol in BMMY for a further 24 hours. GpαH1_100 and GpαH11_100 strains were expressed 
simultaneously for reference. The spent media broth was collected through centrifugation and HSA 
titre measured using the Albumin Blue Fluorescence Assay (Active Motif) (Fig 5.2). 
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Figure 5.2 HSA Titre of strains containing the HSAopt Gene showed Increased Secretion 
compared to HSA Gene 
Clones were selected from a transformation onto 100 μg mL
-1
 Zeocin YPD plates and HSA 
titre was measured after 24 hours in BMMY using the Albumin Blue Assay (Active Motif). 
GpαH1_100 and GpαH11_100 were samples collected for the 15 L fermenter to be used as 
a control. 
 
Clones that contained the HSAopt gene showed comparable protein titre compared to GpαH1_100 
and GpαH11_100 (Fig 5.2). GpαHopt7 produced over twice as much HSA than either of the 
GpαH1_100 or GpαH11_100 strains, with past experience suggesting that GpαHopt7 may be a multi-
copy clone. Copy number was analysed by qPCR using primers 188-HSAoptq3 and 189-HSAoptq4 
compared to the housekeeping gene ACT1 (Appendix 9.2; Fig 5.3). 
 
Figure 5.3 Varying Copy Numbers in Transformed Strains of GpαHopt strains 
Copy number was calculated via the ΔΔCt method using qPCR primers 188-HSAoptq3 and 
189-HSAoptq4 to amplify the HSAopt gene with comparison to ACT1 as the housekeeping 
gene. Copy number was calculated as a reference to a known one copy clone.  
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GpαHopt7 was identified as a multi-copy strain, containing two copies of the HSAopt gene, which 
may partially account for the higher expression of HSA detected (Fig 5.2). Additionally GpαHopt2 
was identified as a multi-copy strain, containing two copies of the HSAopt gene; however titre levels 
were comparable to that of the HSAopt single copy clones such as GpαHopt4  and the single copy 
clones GpαH1_100 and GpαH11_100 (Fig 5.2). This variability reinforces the evidence for clonal 
variation, a problem which should be considered in future experimental designs. 
5.3 Generation of Multi-Copy Clones of the HSAopt Gene in the rDNA locus 
5.3.1 Vector Creation 
Experience of using the HSA native gene to create multi-copy clones suggests that to produce clones 
with the highest copies (and with increased stability) vectors should be integrated into the rDNA 
locus (4.5.3). Vectors were designed as described for pGRzαHSA and pARzαHSA (Fig 4.12 and 4.13). 
The pα-HSAopt vector was modified to incorporate regions encoding the rDNA locus for the 
pARzαHSAopt vector. For the pGRzαHSAopt vector the GAP promoter replaced the AOX1 promoter 
(Fig 5.4). 
  
 
Figure 5.4 pGRzαHSAopt and pARzαHSAopt Plasmid Maps 
The vectors pGRzαHSAopt and pARzαHSAopt were created using the Gibson Assembly 
Protocol modifying the original pα-HSAopt vector, containing the HSAopt gene. For the 
pGRzαHSAopt vector the GAP promoter was amplified from pIB2. The rDNA locus was 
amplified from genomic DNA from GS115. 
 
The pARzαHSAopt vector was constructed with the rDNA sequences integrated between the AOX1 
transcription terminator region and the TEF1 promoter region, which differed from the 
pGRzαHSAopt vector, which integrated the rDNA locus between the AOX1 promoter and the pUC 
ori. Subsequently, a revised construct was designed (Fig 5.5) to confirm that the design of the vector 
had no impact on its integration into the genome or on HSA titre. This was possible with vectors 
containing the HSAopt gene due to the removal of the BglII site from within the sequence (Appendix 
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9.1), which was an essential restriction site, lending itself to the same arrangement as was seen in 
the pGRzα vectors (Fig 5.5). 
 
Figure 5.5 pARzαHSAopt BglII Plasmid Map 
Vector with the rDNA locus inserted before the AOX1 promoter as compared to the 
previous pARzαHSAopt vector where it lies between the TEF1 promoter and the AOX1 
transcript terminator. This vector was created for comparison to the pGRzαHSAopt vector. 
 
5.3.2 Initial integration of HSAopt vectors into the rDNA locus  
pGRzαHSAopt, pARzαHSAopt and pARzαHSAopt BglII were transformed into E. coli JM109 for 
amplification of the plasmid and reisolated using the Qiagen mini-prep kit. The reisolated vectors 
were sequenced (data not shown) before linearisation using SpeI in the rDNA gene. Linearised 
pGRzαHSAopt, pARzαHSAopt and pARzαHSAopt BglII were transformed into GS115 and plated on 
YPD plates containing 100 μg mL-1 Zeocin. Colony PCR was used to confirm integration into the rDNA 
locus using primers 352-rDNA IntF and 353-rDNA IntR (Fig 4.14; Appendix 9.2). As seen with the HSA 
constructs, a band of 3 Kb for both forward and reverse reactions would suggest integration into the 
rDNA Locus (Fig 5.6). 
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Figure 5.6 Colony PCR Indicated Correct Integration of pGRzαHSAopt and pARzαHSAopt 
vectors into the rDNA locus 
Colony PCR was carried out to check integration of different transformants into the rDNA 
locus. A) Integration at the 5’ end of the vector; B) Integration at the 3’ end of the vector. 
1: 1 Kb DNA Ladder (Fermentas); 2: pARzαHSAopt 3; 3: pARzHSAopt 4; 4: pARzαHSAopt 
BglII 2; 5: pARzαHSAopt BglII 8; 6: pGRzαHSAopt 3; 7: pGRzαHSAopt 4 
 
Integration of GpGRzαHSAopt, GpARzαHSAopt and GpARαHSAopt BglII into the rDNA locus was 
confirmed by colony PCR (Fig 5.6). As with the integration of the pARzαHSA and pGRzαHSA vectors 
(Fig 4.14) there were bands that appeared brighter than others, suggesting the possible presence of 
multi-copy clones. Copy number was determined by qPCR using primers 188-HSAoptq3 and 189-
HSAoptq4 compared to GpαHopt1_100 (Fig 5.7). 
 
Figure 5.7 Integration into the rDNA Locus results in Multi-Copy Clones 
Copy number was calculated via the ΔΔCt method using qPCR primers (188-HSAoptq3 and 
189-HSAoptq4) to amplifying the HSAopt gene with comparison to ACT1 as the 
housekeeping gene. 
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Single and multi-copy clones were isolated from clones transformed onto 100 μg mL-1 Zeocin (Fig 
5.7). No clones showed integration of nine copies as seen with GpGRzαHSA2 (Fig 4.15). However, 
four copies were present in both GpGRzαHSAopt 3 and (Fig 5.7). GpARzαHSAopt BglII 8 was 
identified as a three copy clone; thus the use of the AOX1 promoter for integration into the rDNA 
locus was comparable to using the GAP promoter for generating multi-copy clones. Clones were 
expressed for 24 hours in either a glycerol or methanol containing medium depending on the 
promoter used. Protein levels were determined by the Albumin Blue Fluorescence assay (Fig 5.8).  
 
Figure 5.8 HSA Titre from Clones Integrated into the rDNA Locus Containing the HSAopt 
Gene 
HSA titre was determined by the Albumin Blue Fluorescence assay (Active Motif) after 24 
hours growth in methanol medium or glycerol medium depending on the promoter used. 
Error bars represent triplicate biological repeats. 
 
Clones produced titre similar to single copy clones of GpARzαHSA and GpGRzαHSA, which were 
observed to be lower than clones with vectors integrated into the AOX1 locus (Fig 5.2 and 5.8). 
Therefore it was of interest to determine HSAopt transcript levels of clones integrated into the rDNA 
locus. HSAopt transcript levels were analysed by RT-qPCR using primers 188-HSAoptq3 and 189-
HSAopt q4 using ACT1 as the housekeeping gene and compared to GpαHopt1_100 (Fig 5.9). 
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Figure 5.9 HSAopt Transcript Levels of Clones Integrated into rDNA locus were lower 
than a Single Copy Clone Integrated into the AOX1 Locus 
HSA gene expression was calculated via the ΔΔCt method using qPCR primers 188-
HSAoptq3 and 189-HSAoptq4 as a comparison to ACT1 as the housekeeping gene. Fold 
change was calculated as a comparison to GpαHopt1_100. Statistically significant values of 
p<0.05 (compared to GpαHopt1_100) are indicated by a *. 
 
HSAopt gene transcript levels were significantly reduced for clones integrated into the rDNA locus 
compared to GpαHopt1_100 (Fig 5.9). This correlates to low HSA titre levels observed (Fig 5.8). To 
observe the impact of low titre on UPR HAC1, KAR2 and PDI gene expression levels were analysed by 
RT-qPCR as a comparison to GpαHopt1_100, a known one copy clone (Fig 5.10). 
 
Figure 5.10 Transcript Levels of Genes involved in UPR of Clones Containing the HSAopt 
Gene Integrated into the rDNA Locus  
HAC1, KAR2 and PDI transcript levels were calculated via the ΔΔCt method using qPCR 
primers 010-KARq1, 011-KAR2q2, 012-PDIq1, 013-PDI1q3, 067-HAC1q3 and 068-HAC1q4 
respectively. ACT1 was the housekeeping gene and resulted were calculated as a 
comparison to GS115. Statistically significant values of p<0.05 (compared to GS115) are 
indicated by a *. 
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GpGRzαHSAopt3 and GpGRzαHSAopt4 showed over four-fold induction of KAR2 compared to 
GpαHopt1_100 (Fig 5.10). PDI also shows significant upregulation in both GpGRzαHSAopt3 (two 
tailed t(4) p=0.0275) and GpGRzαHSAopt4 (two tailed t(4) p=0.0045). Conversely there is no 
significant upregulation of HAC1 in any of the strains with vectors integrated into the rDNA locus 
compared to GpαHopt1_100 (Fig 5.10). Upregulation of UPR signals in GpGRzαHSAopt3 and 
GpGRzαHSAopt4 suggest that the increase in gene dosage correlates to increased flow through the 
secretory pathway. However the low levels of HAC1 suggest that a detrimental level of UPR 
upregulation may not yet be occurring, which is supported by low HSA transcript (Fig 5.9). As 
determined using GpGRzαHSA expression for 24 hours using the GAP promoter may not be sufficient 
for protein production; therefore expression was extended to 48 hours for future experiments. 
5.3.3 Amplification of rDNA vectors by PTVA to generate Multi-Copy Clones 
Multi-copy clones of GpARzαHSA and GpGRzαHSA showed increased titre as well as an indication of 
secretion saturation (Fig 4.20). The use of a codon-optimised gene might a) affect the level that 
secretion saturation occurs and b) affect the secretory stress of the cells (through ease of translation 
due to readily available tRNAs) potentially reducing counter-selection against multi-copy clones.  
PTVA was used to create multi-copy clones as described for GpARzαHSA and GpGRzαHSA. Clones 
were inoculated into YPD containing 100 μg mL-1 Zeocin and after 24 hours growth the medium was 
changed with an increase in concentration of Zeocin. Stepwise concentrations were 100, 200, 300, 
500, 1000 and 2000 μg mL-1 Zeocin. After growth on the maximum concentration of Zeocin cultures 
were serially diluted and plated onto YPD plates containing 2000 μg mL-1 Zeocin and left to incubate 
for 5 days at 30°C.  
Post-PTVA colonies were expressed in BMGY and BMMY media for 24 hours for the GpARzαHSAopt 
strains and for 48 hours in BMGY for GpGRzαHSAopt strains. Heterologous protein production was 
visualised on an SDS-PAGE gel using the spent broth from expression (Fig 5.11). 
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Figure 5.11 HSA Expression post-PTVA of Multi-Copy Clones containing the HSAopt Gene 
Integrated into the rDNA Locus 
HSA expression was determined by expression for 48 hours in BMGY (GAP promoter) or 24 
hours in BMMY (AOX1 promoter) and analysed on a 12% SDS-PAGE gel. 1: GpαH1_100; 2: 
Pre-stained molecular marker (Fermentas); 3: GpGRzαHSAopt3_2000B; 4: 
GpGRzαHSAopt4_2000A; 5: GpARzαHSAopt3_2000F; 6: GpARzαHSAopt BglII 2_2000E; 7: 
GpARzαHSAopt BglII 8_2000D. 
 
Post-PTVA all strains analysed were confirmed to secrete HSA (Fig 5.11). A comparison between 
copy number and titre was used to determine the advantages of a HSAopt gene versus a native HSA 
gene. Genomic DNA was extracted using the DNeasy Plant mini-prep kit (Qiagen) and qPCR was used 
to analyse copy number using the primers 188-HSAoptq3 and 189-HSAoptq4 (Appendix 9.2). 
Expression of HSA was quantified using the Albumin Blue Fluorescence Assay (Active Motif). For 
comparison the results from GpGRzαHSA and GpARzαHSA clones were included for reference (Fig 
5.12).  
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Figure 5.12 Multi-copy clones containing the HSAopt Gene produce lower HSA titre that 
when using the HSA gene  
Copy number was calculated via the ΔΔCt method using qPCR primers 188-HSAoptq3 and 
189-HSAoptq4 to amplifying the HSAopt gene against ACT1 the housekeeping gene. Copy 
number was compared to GpαHopt1_100. HSA titre was determined by the Albumin Blue 
Fluorescence assay (Active motif) after 24 hours expression in methanol (AOX1 promoter) 
or 48 hours in glycerol (GAP promoter). A: Vectors integrated containing the GAP 
promoter. Turquoise – GpGRzαHSA; Purple – GpGRzαHSAopt. B: Vectors containing the 
AOX1 promoter. Green – GpARzαHSA; Pink – GpARzαHSAopt; Blue – GpARzαHSAopt BglII. 
 
For all clones analysed there was no significant correlation between copy number and titre (Fig 
5.12). Furthermore there was no significant difference of expression levels between clones 
integrated with the AOX1 promoter or the GAP promoter (two tailed t(40) p=0.5481). Nevertheless 
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there is a consistent decrease in HSA titre when using the HSAopt gene compared to using the native 
HSA gene (two tailed t(40) p=0.0007). Two clones that were generated by PTVA, containing the 
highest and the lowest copy number, were selected for further experimentation; GpARzαHSAopt 
3_2000E (5 copy), GpARzαHSAopt 3_2000F (21 copy), GpARzαHSAopt BglII 2_2000D (4 copy), 
GpARzαHSAopt BglII 2_2000E (15 copy), GpARzαHSAopt BglII 8_2000D (7 copy), GpARzαHSAopt BglII 
8_2000F (24 copy), GpGRzαHSAopt 3_2000B (14 copy), GpGRzαHSAopt 3_2000F (22 copy), 
GpGRzαHSAopt 4_2000A (6 copy) and GpGRzαHSAopt 4_2000D (38 copy).  
 GpARzαHSAopt and GpGRzαHSAopt clones appear to reach secretion saturation earlier than clones 
integrated with the HSA gene (Fig 5.12). Therefore it was of interest to compare HSA transcript levels 
between the two variants. HSAopt transcript levels were analysed by RT-qPCR using primers 188-
HSAoptq3 and 189-HSAoptq4 as a comparison to GpαHopt1_100. For comparative purposes HSA 
transcript levels were included (Fig 5.13). 
 
Figure 5.13 Quantification of HSA Transcripts of Clones Post-PTVA, Integrated into the 
rDNA Locus using either the HSAopt gene or HSA gene 
HSA gene expression was calculated via ΔΔCt method using qPCR primers 188-HSAoptq3 
and 189-HSAoptq4 to amplify the HSAopt gene or 070-HSAq1 and 071-HSAq2 to amplify 
the HSA gene. ACT1 was used as the house keeping gene with comparison to either 
GpαH1_100 or GpαHopt1_100. Light grey bars indicate clones containing the HSAopt gene 
and dark grey bars indicate clones containing the HSA gene. Statistically significant values 
of p<0.05 (compared to GpαH1_100 or GpαHopt1_100) are indicated by a *. 
 
Transcript levels of clones containing the HSAopt gene show increased levels compared to 
GpαHopt1_100 (Fig 5.13). GpARzαHSAopt BglII 8_2000D, which shows the lowest fold change 
indicates a four-fold increase in HSA transcript compared to a known one copy clone integrated into 
the AOX1 locus. This implies that multi-copy clones successfully result in the increase in HSA 
transcript levels. GpARzαHSA produces more HSA transcript than the GpARzαHSAopt strains, which 
correlates to the increased titre observed in the native HSA containing strains (Fig 5.12). However, 
* 
* 
* 
* 
* * 
* 
* 
* * 
* 
* 
* * 
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GpGRzαHSAopt strains show increased HSA transcript compared to GpGRzαHSA strains, despite 
average expression being lower. This suggests potential blockages within the secretory pathway of 
the GpGRzαHSAopt strains that prevent conversion of transcript to folded protein. Therefore 
secretion stress was examined to evaluate upregulation of UPR. HAC1, KAR2 and PDI transcript levels 
were determined by RT-qPCR as a comparison to GS115 (Fig 5.14). 
 
Figure 5.14 Gene Expression levels of UPR signals upregulated in clones containing the 
HSAopt gene compared to clones containing the HSA gene. 
HAC1, KAR2 and PDI transcript levels were determined by RT-qPCR as a comparison to 
GS115. PTVA strains are indicated by 2000 and the relevant colony (A-F) chosen. 
GpARzαHSAopt3 (AO3), GpαARzαHSAopt BglII2 (B2), GpαARzαHSAopt BglII8 (B8), 
GpGRzαHSAopt3 (GO3), GpGRzαHSAopt4 (GO4), GpARzαHSA1 (AH1), GpGRzαHSA2 (GH2). 
Statistically significant values of p<0.05 (compared to GS115) are indicated by a *. 
 
HAC1 transcript levels were upregulated in both GpARzαHSA and GpGRzαHSA compared to their 
counterpart HSAopt clones (Fig 5.14). Conversely the induction of KAR2 and PDI in clones expressing 
the HSAopt gene using the AOX1 promoter exceeded those with the HSA gene. PDI and KAR2 are 
both ER chaperones available to assist with folding of the protein [153, 241]. Upregulation of both 
PDI and KAR2 implies that despite the lack of HAC1 upregulation these folding chaperones are being 
expressed, potentially to manage excess unfolded protein. Theoretically HAC1 is upregulated in 
GS115 more substantially than both KAR2 and PDI, which would explain the comparatively low levels 
of HAC1 induction for clones expressing the HSAopt gene. 
5.3.4 Stability of Multi-Copy Clones 
Studies using the HSA gene showed that integration into the rDNA locus resulted in reduced levels of 
instability (with no clones losing the vectors entirely) but did not result in stable strains (Fig 4.23). 
* 
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Gene transcript levels for UPR signals of GpGRzαHSAopt were lower than GpGRzαHSA (Fig 5.14). It 
can be hypothesised that reduced stress on the secretory pathway may decrease counter-selection 
against high copy clones; thus increasing stability. Stability was determined by growth for 48 hours in 
glycerol before cultures were serially diluted to single colonies on YPD plates (no selection). Genomic 
DNA was extracted directly from colonies and analysed by qPCR using the primers 188-HSAoptq3 
and 189-HSAoptq4 as a comparison to GpαHopt1_100 (Fig 5.15).  
         
         
Figure 5.15 Instability is Prevalent in Clones with the GAP promoter and HSA optimised 
Gene 
Copy number was calculated via ΔΔCt method using qPCR primers 188-HSAoptq3 and 189-
HSAoptq4 to amplify the HSAopt gene. ACT1 was used as the housekeeping gene with a 
comparison to GpαHopt1_100, a known one copy clone. Dark grey bars represent the 
original copy number of the clone post-PTVA but before expression. Light grey bars 
represent individual colonies post expression. A: GpGRzαHSAopt3_2000B (GO3_2000B). B: 
GpGRzαHSAopt3_2000F (GO3_2000F). C: GpGRzαHSAopt4_2000A (GO4_2000A). D: 
GpGRzαHSAopt4_2000D (GO4_2000D). 
 
Despite reduced UPR stress (Fig 5.14) GpGRzαHSAopt clones show evidence of genetic instability 
post-expression (Fig 5.15). This implies that using the HSAopt gene coupled with the GAP promoter 
does not impact genetic instability. Copy number appears to increase as well as decrease in 
GpGRzαHSAopt 3_2000B, GpGRzαHSAopt 3_2000F and GpGRzαHSAopt 4_2000A, a trend observed 
for GpGRzαHSA and GpARzαHSA clones (Fig 4.23). It was also of interest to determine stability of 
clones containing the AOX1 promoter, as these showed significant upregulation of KAR2 and PDI but 
not of HAC1. HSAopt copy number was calculated by qPCR using primers 188-HSAoptq3 and 189-
HSAoptq4 compared to GpαHopt1_100, a known one copy clone (Fig 5.15). 
A B 
C D 
136 
 
        
        
        
Figure 5.16 Instability is Prevalent in Clones with the AOX1 promoter and HSA optimised 
Gene 
qPCR was performed on clones isolated from YPD plates post 24 hour expression in 
methanol containing media. Two clones from each strain isolated on 100 μg mL
-1
 were 
selected. In all graphs the first (and darker) column represents the original copy number 
before expression. A: GpARzαHSAopt3_2000E (AO3_2000E). B: GpARzαHSAopt3_2000F 
(AO3_2000F). C: GpARzαHSAopt(BglII)2_2000D (B2_2000D). D: 
GpARzαHSAopt(BglII)2_2000E (B2_2000E). E: GpARzαHSAopt(BglII)8_2000D (B8_2000D). 
F: GpARzαHSAopt(BglII)8_2000F (B8_2000F). 
 
Copy number variation was evident in all clones integrated into the rDNA locus expressed using the 
AOX1 promoter (Fig 5.15). As seen with the GpGRzαHSA, GpARzαHSA and GpGRzαHSAopt no clones 
investigated lost the HSAopt gene entirely.  
5.4 Discussion 
The use of an optimised HSA gene for the production of multi-copy clones did not result in increased 
titre compared to expression using a native HSA gene (Fig 5.12). The GenScript OptimumGene™ 
algorithm primarily focuses on codon usage bias; however should the DNA 2.0 GeneTPS technology, 
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which utilises codons that are highly charged during amino acid starvation [237], have been selected 
instead increased titre may have been observed. 
Average secretion levels of GpGRzαHSAopt was 33.0 μg mL-1 compared to GpGRzαHSA which was 
46.2 μg mL-1. The same trend was observed for clones expressing via the AOX1 promoter; 
GpARzαHSAopt average expression was 37.4 μg mL-1 and GpARzαHSA was 44.4 μg mL-1. For 
GpARzαHSAopt clones reduced titre coincided with reduced HSA transcript when compared to 
GpARzαHSA clones (Fig 5.13). Furthermore the upregulation of KAR2 and PDI in GpARzαHSAopt 
strains suggests possible difficulties in protein folding requiring additional chaperones [242]. Codon 
optimisation potentially alters the bottlenecks within the protein production pathway [236]. Love et 
al. have indicated that the main bottleneck identified in protein production with P. pastoris is in the 
secretory pathway [72]. Therefore it is possible to hypothesise that by increasing translational speed 
one is merely increasing the secretory stress of the cell by adding additional throughput. 
Furthermore if one adopts the basic view that prolonged induction of UPR results in upregulation of 
the ER associated degradation pathway (ERAD) then increased secretory stress may explain the 
reduced titre observed.  
Furthermore the use of a codon optimised HSA gene has no impact on the stability of the clones. 
This may be as a result of maintained secretory stress, which increases the likelihood of counter-
selection against high copy clones. It would be of interest to determine the effect of using the 
HSAopt gene on the ERAD to determine if protein degradation is occurring. Furthermore as 
prolonged ER stress has been reported to be linked to an increase in cell death in S. cerevisiae, a cell 
viability assay may determine whether the use of an optimised gene has detrimental effects [243]. In 
this instance the use of an optimised HSA gene has not resulted in increased specific productivity. 
However extensive research suggests that codon optimisation can have an impact on protein titre 
[236, 239, 244-245]. It may be necessary to analyse the advantages of a codon optimised gene on a 
protein dependent basis.
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6 Transcriptomic Analysis of Clonal Variation in Pichia pastoris 
6.1 Introduction 
6.1.1 Evidence of Clonal Variation in Mammalian Cells and Other Organisms 
The phenomenon of clonal variation was first reported for Chinese hamster ovary (CHO) cells in 
1977, where it was noted that clones plated onto an agar plate behave differently from one another, 
with particular reference to colony morphology [246]. This highlighted an underlining heterogeneity 
of CHO cells that had not previously been identified [247-248]. Clonal variation has also been 
observed when using CHO cells as a recombinant protein expression platform, evident through 
differences in titre [249]. In CHO cells much of the variation arises from differences in the integration 
site or the number of copies of the vector of interest [250]. It has also been discovered that the use 
of antibiotics, which sometimes have mutagenic properties, increases the level of clonal variation 
suggesting that differences arise from more than just integration sites and copy number [251]. In 
addition to clonal variation in mammalian cultures there is evidence that this occurs in other 
organisms. Since 1981 variation in plant cells generated through transformation procedures to 
produce transgenic plants has been reported, referred to as somaclonal variation [252]. In plant 
cells, variation is believed to be predominantly influenced by stress factors, including growth in the 
presence of antibiotics [253]. 
6.1.2 Clonal Variation in P. pastoris 
The presence of clonal variation in P. pastoris is widely acknowledged in both academia and industry 
[211, 254-255]. Clonal variation is such an integral part of working with P. pastoris that the Pichia 
Expression Kit manual provided by Invitrogen Corporation discusses methods to select for the 
highest secretor, recommending to screen between 6-10 recombinants per phenotype [120]. In 
industry to select the highest producers typically up to a thousand recombinants are screened [256]. 
However, this is extremely time-consuming and a major drawback for commercial application; 
however, at present there are no procedures in place to reduce the effort to find the best secretors.  
Few investigations have been carried out to examine the origins of clonal variation, with just a single 
paper describing this variation using amplified-fragment length polymorphism (AFLP) [211]. Clare et 
al. suggest that the integration event results in the variation in expression levels and in particular the 
presence of multi-copy clones [254], as seen with mammalian cultures. Yet our experiments have 
shown when comparing titre levels of single copy clones the presence of clonal variation is still 
prominent, which suggests that additional factors are at work. 
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The objective for expression platforms is to produce a strain that expresses the highest titre of 
recombinant protein possible. High secretors selected by extensive screening reduce the need to 
subsequently generate multi-copy clones. Furthermore a good secretor can reduce the need for 
optimisation in regards to media and growth conditions [212]. Hence, due to the highly variable 
productivity of different recombinant clones of P. pastoris extensive screening of clonal variants is an 
intrinsic part of any expression programme.  
6.1.3 Studying Clonal Variation 
For recombinant expression studies clonal variation is primarily reflected in the protein titre 
obtained with individual clones. This has been examined using various techniques including SDS-
PAGE gels, Western blots and ELISAs. However, other underlying factors such as ER stress, indicated 
by the induction of the unfolded protein response (UPR), which affects the production of the protein 
of interest, are also useful markers which can be determined by RT-qPCR. The prevalence of clonal 
variation highlighted in chapters three and four, needs to be investigated in detail and a clearer 
understanding of the phenomenon could enable the development of methods to simplify the 
identification of a “best” secretor.  
6.1.4 Aims for the study of Clonal Variation 
 To establish the extent of clonal variation in P. pastoris 
 To investigate the importance of the integration site of the expression vector in relation to 
clonal variation 
 To evaluate the impact of clonal variation on the unfolded protein response and other stress 
factors 
 To identify key indicators of high or low secretors by microarray analysis 
 
6.2 Clonal Variation in HSA expressing strains 
6.2.1  Clonal Variation in Fed-Batch Fermentation  
From the initial work on multi-copy clones there was evidence for variation in the secretion levels 
between the two one copy clones that were used for expression in batch-fed fermentation (Fig 6.1). 
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Figure 6.1 HSA titre levels of single copy clones GpαH1_100 and GpαH11_100. 
HSA titre levels were calculated using the Albumin Blue Fluorescence assay (Active Motif). 
Samples were taken at 0 hours (pre-induction), 24 hours and 48 hours post-induction. 
Error bars represent technical repeats of the albumin assay. Statistically significant values 
of p<0.05 are indicated by a *. 
 
 
GpαH1_100 secreted more HSA than GpαH11_100 when grown under identical conditions, 
measured at both 24 hours and 48 hours post-induction. After 48 hours GpαH1_100 had secreted 
150% more HSA than GpαH11_100. For any industrial process it is clear that GpαH1_100 would have 
been a better strain for development based on initial secretion level. In order to ascertain whether 
the differences relate to the level of transcription of the HSA gene, HSA transcript levels were 
investigated using RT-qPCR (Fig 6.2). 
 
 
* 
* 
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Figure 6.2 HSA transcript levels for single copy clones GpαH1_100 and GPαH11_100. 
HSA gene expression was calculated via ΔΔCt method using qPCR primers 188-HSAoptq3 
and 189-HSAoptq4 to amplify the HSAopt gene or 070-HSAq1 and 071-HSAq2 to amplify 
the HSA gene. ACT1 was used as the house keeping gene with comparison to GpαH1_100.  
Transcript levels were determined at 0 hours, 24 hours and 48 hours of fed batch culture. 
Statistically significant values of p<0.05 (compared to GS115) are indicated by a *. 
 
Surprisingly, although GpαH11_100 produced less than half as much HSA protein than GpαH1_100 
(Fig 6.1), HSA transcript levels of GpαH11_100 were actually significantly higher at both 24 hours and 
48 hours (two tailed t(4) p<0.0001). This not only suggested that the differences observed were not 
directly due to transcription rates but that there was considerable variation in the rate of 
transcription from supposedly identical constructs. The differences in level of secretion were, 
therefore, post-transcriptional and could be related to secretion stress. The UPR can be taken as an 
indicator of stress within the secretory pathway and prolonged induction will result in the 
upregulation of ERAD, which could account for reduced titre through protein degradation [72, 164]. 
In order to investigate levels of stress within the strains GpαH1_100 and GpαH11_100 were analysed 
for the induction of the UPR, looking for key indicators such as HAC1, KAR2 and PDI (Fig 6.3).  
* 
* 
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Figure 6.3 UPR upregulation in single copy clones GpαH1_100 and GpαH11_100. 
HAC1, KAR2 and PDI transcript levels were determined by RT-qPCR as a comparison to 
GS115. UPR indicators in the single copy clones grown in fed-batch fermenters pre-
induction (0 hours), 24 hours and 48 hours post-induction with methanol of GpαH1_100 
(1_100) and GpαH11_100 (11_100). 
 
Overall GpαH1_100 induced the UPR to a lesser extent than GpαH11_100 (Fig 6.3). Specifically the 
upregulation of PDI in GpαH11_100 after 48 hours showed a two-fold increase compared to GS115. 
Differences in UPR expression levels once again highlight differences caused by clonal variation. 
6.2.2 Range of Variation in a Single Transformation 
To better understand the range of variation in HSA secretion that occurs after transformation pα-
HSA was transformed into GS115 and plated onto 100 μg mL-1 Zeocin plates. Twenty-three colonies 
were selected and copy number was analysed by qPCR (Fig 6.4). 
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Figure 6.4 Copy number analysis of 23 colonies selected from a single transformation of 
pα-HSA determine that all are Single Copy Clones 
Copy number was calculated via the ΔΔCt method using qPCR primers (188-HSAoptq3 and 
189-HSAoptq4) to amplifying the HSAopt gene with comparison to ACT1 as the 
housekeeping gene.  GpαH1_100 was used as the reference strain.  
 
All of the clones selected were confirmed to contain a single copy of the gene of interest (Fig 6.4). 
Expression was carried out in 50 mL centrifuge tubes in BMGY for 24 hours, before being normalised 
to a standard OD600 and induced with methanol containing BMMY to initiate expression of HSA. After 
24 hours expression samples were centrifuged and the spent broth analysed using the Albumin Blue 
Fluorescence Assay (Active Motif; Fig 6.5). 
 
Figure 6.5 HSA expression levels of single copy GpαHSA strains. 
Titre was measured after 24 hours expression in methanol; supernatants were analysed using 
the Albumin Blue Fluorescence Assay (Active Motif). 
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All the clones analysed contained a single copy of the HSA gene (Fig 6.4), yet titre ranged from less 
than 5 mg L-1, GpαHCV14, to 22.5 mg L-1, clone GpαHCV2 (Fig 6.5); a 4-fold difference in expression 
level. 
This demonstrates that clonal variation is not solely attributable to copy number variation [146]. It 
has been reported that non-homologous recombination can arise and this could have a negative 
effect on titre [215]. In order to determine whether the variation in titre observed was a result of 
differences in plasmid integration into the chromosome, DNA sequencing was used to analyse the 
region around the sites of integration. Primers 142-AOX Integr F PmeI and 143-AOX Integr R PmeI 
(Appendix 9.2) were used to sequence upstream and downstream of the integration site (Fig 6.6; 
Appendix 9.5).  
 
Figure 6.6 Sequence alignment of the integration site for clones used in microarray 
analysis. 
Sequence alignment of the region around the PmeI directed integration site of clones 
GpαHCV 2, 5, 7, 8, 14, 15, 16, 18 and 23. PmeI recognises and cuts at the sequence 
GTTTAAAC, located at 467 and highlighted in yellow. Sequences both upstream and 
downstream of the integration site were identical (full sequence shown in Appendix 9.5). 
 
All strains tested showed 100% sequence identity to each other, regardless of the corresponding 
titre levels, suggesting that in these cases variation was not due to changes at the site of insertion of 
the vector (Fig 6.6). 
6.3 Microarray Analysis 
6.3.1 Selecting strains for Microarray Analysis 
As copy number or variable integration did not explain the clonal variation in this dataset, further 
experimentation was done to determine the underlying causes. Microarray analysis was used to 
highlight transcripts that were either up- or downregulated in correlation with titre levels. 
Upregulation in association with improved secretion could provide an opportunity to create a 
 
             460       470       480       490       500       510       520       530       540         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV5   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV7   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV8   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV14  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV15  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV16  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV18  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV23  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
 
             550       560       570       580       590       600       610       620       630         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV5   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV7   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV8   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV14  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV15  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV16  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV18  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV23  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
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reporter system whereby the relevant promoter is linked to expression of e.g. a fluorescence 
protein, or alternatively a negative counter-selection might be employed. 
For microarray analysis clones were grown in 250 mL baffled flasks and nine strains were selected 
for further analysis, chosen based on titre levels measured using the Albumin Blue Fluorescence 
Assay kit (Active Motif). Three high secreting strains were selected; GpαHCV2, GpαHCV18 and 
GpαHCV23, three mid level secreting strains; GpαHCV8, GpαHCV15 and GpαHCV16 and three low 
secreting strains GpαHCV5, GpαHCV7 and GpαHCV14. For simplification the strains are referred to 
as CV# followed by (H) for high, (M) for mid and (L) for low secretors, for example CV2(H) (Fig 6.7). 
 
Figure 6.7 HSA titre levels of the nine Strains selected for microarray analysis, grouped 
into high, medium and low levels. 
Titre levels of single copy GpαHSA strains expressed for 24 hours in methanol containing 
media. Samples were grown in 250 mL baffled flasks in triplicate; error bars displayed 
indicate 95% confidence interval. Green; high secretors, yellow; mid secretors and red; 
low secretors. 
 
Titre levels ranged from 8.87 mg L-1 with strain CV7(L) to 16.6 mg L-1 CV18(H). Using 95% confidence 
intervals indicated that grouping the strains based on titre results in three statistically independent 
sets. 
6.3.2 Genotyping Microarray Strains 
As a preliminary study, the clonal variation (CV) strains were genotyped in order to investigate 
whether there were characteristic differences within the genome. Variation is likely to reflect 
mutations or more major genome rearrangements within the strains. Viader-Salvado and colleagues 
used a simplified version of amplified-fragment length polymorphism (AFLP) to reveal genetic 
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differences between transformants [211]. The theory behind the technique is that by using 
restriction enzymes and adapters it is possible to create and separate out characteristic fragments 
by gel electrophoresis. Variations in the genome will affect fragment size and hence band pattern, 
but this depends on where the restriction enzyme cuts. Due to the nature of AFLP there are 
limitations due to the use of restriction enzymes. Differences may be missed if the restriction 
enzyme does not cut within that particular fragment. Therefore a similar method was developed; 
Random-Amplification-Polymorphic-DNA (RAPD) PCR which has been used to study variation within 
populations [257-259]. Using a random decamer primer (Appendix 9.2) genomic DNA is amplified by 
PCR and according to where the primers anneal within the genome a fragment pattern is produced, 
which can be visualised on a high percentage agarose gel.  
The nine microarray strains and the wild-type GS115 were analysed using RAPD-PCR, and similar 
patterns to those described by Viader-Salvado et al. were seen. This method was used to establish 
whether polymorphisms in the strains selected for microarray analysis were evident (Fig 6.8). 
 
Figure 6.8 RAPD-PCR of strains selected for microarray analysis. 
Nine GpαHSA strains and the wild-type GS115 were analysed by RAPD-PCR to look for 
evidence of gross polymorphisms. 2.5% (w/v) agarose gels were used to get complete 
separation of the small fragments. Ladder; GeneRuler 100 bp Plus DNA Ladder 
(Fermentas). 1: CV2(H); 2: CV18(H); 3: CV23(H); 4: CV8(M); 5: CV15(M); 6: CV16(M); 7: 
CV5(L); 8: CV7(L); 9: CV14(L); 10: GS115. 
 
RAPD-PCR revealed differences both between the selected clonal variants and when compared to 
GS115 (Fig 6.8). The fragment at 750 bp appeared to be of variable abundance and was clearly 
missing in CV15(M), CV14(L) and GS115. Additionally, the abundance of the fragment at approx 910 
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bp appeared quite variable. Although RAPD-PCR did not reveal major changes, the differences 
detected suggest some clonal variation which is neither copy number nor integration site 
dependent.  
6.3.3 Transcript Levels Determined by RT-qPCR 
As the strains for microarray analysis were selected based solely on secreted titre levels, it was of 
interest to look for any systematic variation in transcript levels using RT-qPCR of HSA and UPR 
indicators: HAC1, KAR2 and PDI (Fig 6.9). 
 
Figure 6.9 HSA transcript levels after 24 hour expression. 
Samples were collected after 24 hours induction with methanol in 250 mL baffled flasks.  
HSA transcript was calculated via the ΔΔCt method using qPCR primers 188-HSAoptq3 and 
189-HSAoptq4 as a comparison to ACT1 as the housekeeping gene. Fold change was 
calculated as a comparison to GpαHopt1_100. Green represents high secretors; yellow 
mid-level secretors and red low secretors. 
  
Interestingly HSA transcript levels do not indicate a systematic correlation to titre levels across the 
set of strains analysed. However, CV2(H), CV18(H) and CV23(H) all show a higher transcript level 
than most of the other clones, consistent with their higher levels of  protein production. In contrast, 
CV7(L) showed comparable transcript levels to the high expressing strains, even though it secreted 
half the quantity of protein as CV18(H). As the low HSA titre in CV7(L) does not appear to be 
associated with a reduction in transcription, this suggests that there is a post-transcriptional 
bottleneck possibly in the secretory pathway, which may result in misfolded protein that is 
eventually degraded; hence the low level of secreted protein. Induction of the UPR would indicate a 
stress in the secretory pathway; thus HAC1, KAR2 and PDI were analysed by RT-qPCR to determine 
whether upregulation was occurring (Fig 6.10). 
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Figure 6.10 Induction of the Unfolded Protein Response (UPR) in strains selected from 
microarray analysis. 
HAC1, KAR2 and PDI transcript levels were calculated from samples after 24 hours 
induction with methanol via the ΔΔCt method. qPCR primers 010-KARq1, 011-KAR2q2, 
012-PDIq1, 013-PDI1q3, 067-HAC1q3 and 068-HAC1q4 were used respectively. ACT1 was 
the housekeeping gene and resulted were calculated as a comparison to GS115. 
 
While HSA transcript levels clearly indicated transcriptional or translational blockages, the results 
from analysing gene transcript levels of UPR signals do not reveal such a clear story. CV8(M), which 
showed particularly low levels of HSA transcript, but was a mid-level secretor, also demonstrates 
higher upregulation of all three UPR genes. An initial induction of UPR can be interpreted as positive 
for the production of correctly folded proteins. Both KAR2 and PDI act as folding chaperones; 
therefore an upregulation could increase the flux of correctly folded proteins through the secretory 
pathway [141, 260-261]. UPR may only be considered a negative trait in protein expression when 
prolonged upregulation results in the activation of the ERAD [71, 164]. CV7(L), which showed high 
HSA transcript levels but low levels of protein, did not display upregulated levels of the UPR genes 
HAC1 and PDI (Fig 6.10). However expression of KAR2 was higher than in other low secreting strains 
or in the high secreting strains. 
6.3.4 Microarray Analysis 
Preliminary studies suggest that the groups of high, medium and low secretors do not behave as 
single cohorts and that, while differences are evident, levels of transcription and UPR do not provide 
a complete picture. Therefore, to gain a genome-wide view, microarray analysis was carried out on 
all nine strains, in addition to X33, a wild-type strain. Samples were loaded on five slides of 8x60K, 
with nine probes per gene. As this was the second generation of P. pastoris microarrays carried out 
in our lab, the probes were optimised based on previous experiments (data not shown). Each of the 
149 
 
nine strains and X33, were grown in BMGY for 24 hours, before being induced in methanol 
containing medium BMMY. These were left for a further 24 hours before 1 mL of culture was 
collected and stored in RNALater (Applied Biosystems). The RiboPure Yeast Kit (Applied Biosystems) 
was used to extract the RNA and concentration was checked using the Experion RNA StdSens 
analysis kit (Bio-Rad). In addition to quantifying the amount of RNA a numerical RNA quality 
indicator (RQI) is derived based on the levels of 18S and 28S RNA. For this experiment a minimum of 
330 ng μL-1 was used with a range up to 1955 ng μL-1, while the minimum RQI used was 8.7, with 10 
being the best score. The samples were sent to the Bacterial Microarray Group at St. George’s 
Hospital for analysis. The samples were run on an Agilent High Resolution Microarray scanner having 
previously been labelled using the One-Colour Quick Amp Labelling Kit (Agilent Technologies UK Ltd). 
Data sets were formed as comparisons to the wild-type X33, which with the exception of having an  
intact histidine pathway made functional through re-complementation, should be identical to GS115 
[262]. Three biological replicates (i.e. independent expression) of each of the nine clones were 
analysed with the mean values being used for comparisons, with a false discovery rate (fdr) 
threshold set at 0.05 or less. From this data, different behaviours of the clones both individually 
compared to the wild-type and comparisons between the groups were revealed.   
Initially volcano plots were used to portray the levels of significant variation between each of the 
clonal variation strains in contrast to the wild-type strain (Appendix 9.6). From these plots it was 
apparent that there were aspects that showed significant variation in all of the different strains in 
comparison to wild-type with an fdr ≤ 0.05. 
6.3.4.1 Manual Annotation of the microarray data to reveal differentially expressed 
genes  
Using the Bioconductor package in R, gene transcripts were quantified for each sample and 
compared to those for X33. Differences in expression with an fdr ≤0.05 were used to identify 
differentially expressed genes. Those genes that showed significant variation compared to the wild-
type were assigned a category based on their function. The categories used were degradation, 
stress, secretion, folding, ribosome, mitochondria, DNA replication/repair, peroxisome, biosynthesis, 
transcription, translation, spliceosome, recycling of material within the cell, cell wall, 
chromosome/cell cycle, nuclear import/export or nuclear pore, sporulation and cytoskeleton/actin.   
For each strain the percentage of genes that were up- or downregulated in each category, compared 
to the wild-type, were calculated with reference to the total number of genes assigned to each 
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category. An example using CV2(H) can be seen in figure 6.11, with all other comparisons in 
Appendix 9.7. 
 
Figure 6.11 Percentage of Genes Up- or Downregulated in CV2(H) through manual 
annotation 
Percentage of genes that are up (A) or down (B) regulated in CV2(H) compared to wild-
type X33.  
 
Several trends can be observed through these manual annotations especially when comparing the 
different groups together (Fig 6.11, Appendix 9.7). All three of the high secreting strains showed a 
higher percentage of peroxisome-related genes upregulated (approximately 70%), compared to the 
mid and low level secreting strains, which showed an upregulation of approximately 50%. When P. 
pastoris grows in the presence of methanol, the abundance of peroxisomes within the cell increases 
in order to process the methanol [77, 263-264]. If the number of genes expressed relating to 
peroxisome biogenesis is increased then it suggests that these strains may be metabolising more 
methanol than the wild-type strain, consistent with the metabolic demand of producing a 
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heterologous protein in high yields. As the mid and low secretors are producing less peroxisomes 
this could make them energy limited; thus impacting the protein production capabilities. (Appendix 
9.7). 
Further trends indicate that the high secreting strains showed more genes upregulated in the 
chromosome or cell cycle pathways compared to the mid and low secretors. This could potentially 
be related to the growth rate of the strains; therefore growth curves were observed in order to 
determine whether they were significantly different amongst the clonal variant strains (Fig 6.12). 
 
Figure 6.12 Growth Curves of Clonal Variation Strains Grown in Glycerol or Methanol 
Containing Rich Media 
Growth curves were carried out in baffled flask with samples taken every hour. All nine 
clonal variation strains were grown, with the addition of X33 as a control. A: Growth curve 
in glycerol containing media for 24 hours. B: Growth curve from cultures originally grown 
in glycerol containing media and induced with methanol after 24 hours. 
 
B 
A 
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According to the growth curves in both glycerol and methanol containing media there is minimal 
variation between the strains. In glycerol CV2(H) appears to grow faster than the other strains 
reaching an OD600 of 18.7 at 10 hours, while the other strains showed a maximum of OD600 13.8 after 
the same time. All CV strains reached a similar maximum growth yield, with a plateauing of growth 
occurring at approximately 11 hours in glycerol. Growth in methanol will be limited due to 
competition with protein production for resources. One would expect a strain producing fewer 
proteins to grow more significantly in methanol. However, variations between the high, mid and low 
secretors did not appear significant upon induction with methanol. 
According to the data from the growth curves there are not enough significant differences that allow 
differentiation between the three clonal variation groups when grown on methanol. As growth 
curves do not indicate the size or viability of cultures, fluorescent activated cell sorting (FACS) 
analysis was used to analyse these aspects. Invitrogen’s FungaLight® Yeast Viability kit compares the 
number of live cells versus dead cells. Cells were grown for 24 hours in the glycerol containing 
medium (BMGY), before being induced with methanol containing medium BMMY for 24 hours. 
Samples of 1 mL were collected from both media types at 24 hours and washed in TBS. Cells were 
analysed by flow cytometry with 1 μL of SYTO9® and 1 μL of propidium iodide (PI) added for staining 
according to the manufacturer’s instructions. SYTO9® is a green-fluorescent protein that will bind to 
nucleic acids, while PI will only penetrate yeast cells with damaged membranes reducing the green 
fluorescence and indicating damaged or dead cells [265]. Cell size was determined by looking at the 
forward light scattered reflected in histograms for both cells grown in the presence of glycerol (Fig 
6.13) and grown in the presence of methanol (Fig 6.14) [266-268]. 
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Figure 6.13 Histogram to Show Forward Scatter of Clonal Variation Strains Grown in 
Glycerol containing Media to Determine Average Cell Size 
The forward scatter of light determined by flow cytometry on the nine clonal variation 
strains and X33 (wild-type) when grown in BMGY. The mean of scatter gives an indication 
of average cell size.  
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Figure 6.14 Histogram to Show Forward Scatter of Clonal Variation Strains Grown in 
Methanol containing Media to Determine Average Cell Size 
The forward scatter of light determined by flow cytometry on the nine clonal variation 
strains and X33 (wild-type) when grown in BMMY. The mean of scatter gives an indication 
of average cell size. 
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In glycerol cultures the mean forward scatter, with the exception of CV2(H), was similar amongst all 
of the strains indicating that there is no size variation amongst the strains. As CV2(H) grows faster on 
glycerol than the other strains it suggests that this strain has a high division rate. Furthermore X33 
also indicates a small cell size, which suggests that the remaining CV strains have slower division 
rates. However post-methanol induction CV5(L), CV7(L) and CV14(L) represented the three highest 
means in terms of cell size. As the growth rates were comparable to the mid and high secreting 
strains this implies that an increase in size is accountable for the density of the culture and not an 
increase in cell numbers (Fig 6.12). This coincides with the high proportion (approximately 40%) of 
chromosome genes, downregulated in CV7(L) and CV14(L) compared to X33 (Appendix 9.7.7-9.7.8). 
Growth curves measured by spectrophotmetry may be distorted due to the accumulation of dead 
cells. Therefore viability staining using FACS would determine the proportion of cells that were alive. 
Growth in both a glycerol containing medium (BMGY) and a methanol containing medium (BMMY) 
was carried out for 24 hours to determine viability after each growth phase (Fig 6.15 and 6.16). 
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Figure 6.15 FACS analysis of Clonal Variation Strains and X33 Grown in Glycerol 
Containing Media 
FACS analysis of clonal variation strains grown for 24 hours in glycerol containing media. 
FL1_H: SYTO9®, FL2-A: propidium iodide. BG: Background noise. Quadrant displays 
proportion of live/dead cells and background noise.  
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Figure 6.16 FACS analysis of Clonal Variation Strains and X33 Grown in Methanol 
Containing Media 
FACS analysis of clonal variation strains grown for 24 hours in glycerol containing media. 
FL1-H: SYTO9®, FL2-A: propidium iodide. BG: Background noise. . Quadrant displays 
proportion of live/dead cells and background noise. 
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All clonal variants of P. pastoris exhibit varying degrees of cell death when grown in glycerol as 
demonstrated by the double staining of SYTO9® and PI, but none exceeded 14% of the population as 
observed in CV2(H). The least amount of cell death was observed in CV7(L) with 3.4%, while X33 the 
wild-type strain showed a cell death percentage of  10.7%. However, the proportion of dead cells 
dramatically increased post-induction with methanol. Although X33 shows a comparable percentage 
of cell death to that seen when cultured in BMGY, for all of the clonal variation strains the ratio of 
live to dead cells is considerably reduced with CV23(H) exhibiting an almost 1:1 ratio. A common 
trend is that the three high secretors indicate a higher level of cell death than the mid or low 
secretors. CV18(H) shows the least amount of cell death between the three at 31.5%. The only other 
strain that shows cell death at a comparative level is CV7(L), which has been highlighted as a 
potentially anomalous strain, with 32.9% exhibiting cell death. Excluding CV7(L) the other strains 
show a maximum cell death level of 25.5% (CV16(H)), and a low of 18.1% (CV14(L)). This suggests 
that through the production of recombinant protein increased stress may be detrimental to cell 
viability. It would have been of interest to observe titre levels in relation to viability over time, as 
increased cell death should reduce productivity.  
Further trends observed through analysing the microarray data suggests that with the exception of 
CV7(L), which according to the transcript and expression data may be anomalous, the high secretors 
showed the highest percentage of genes related to stress and secretion upregulated (Fig 6.11, 
Appendix 9.7). A higher number of upregulated secretion genes might have been expected as better 
secretion or an amplified secretion apparatus would result in more protein being released into the 
supernatant. The number of genes involved in secretion which were upregulated in low sectors was 
half of that seen in the other strains. With regards to transcription and spliceosome related genes, 
there were twice the number of genes downregulated in these three strains compared to all of the 
other strains. It would appear for low secretors that through the induction of UPR, or some other 
feedback control loop, transcription is being reduced in order to preserve resources instead of using 
these for a function (that of producing proteins) which will only be degraded due to an inability to 
deal with the strain on the secretory machinery.  
Reduced titre can be explained if proteins are being degraded, possibly through ERAD, as there will 
be fewer proteins to secrete. CV16(M) is a mid-level secretor that shows higher levels of stress on 
the secretory pathway than that of the other mid-level secreting strains, CV8(M) and CV15(M). This 
highlights the fact that the differences seen through clonal variation are multi-variate, and that the 
high, mid and low secretion groupings probably do not correlate with common underlying traits.  
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Clones CV7(L), CV14(L) and CV16(M) appear to follow similar trends to one another with regards to 
degradation; almost twice the number of genes were upregulated in degradation compared to the 
high secreting strains. This suggests that pathways such ERAD or autophagy are upregulated. By 
looking at examples of degradation genes that are upregulated in these strains it is possible to 
highlight the pathways that seem to be more active. These include UBX7 which is an ubiquitin-
dependent protein which binds to Cdc48p, which is known to be involved in the ERAD associated 
pathways [269-270]. CKS1 which is involved in recruiting proteins to the proteasome for degradation 
[271-272] is involved in both the cell cycle and cell death. JDI1 is also a gene upregulated which is 
involved in ER-associated degradation of misfolded proteins [273-274]. This implies that many 
different aspects of degradation are upregulated including the ERAD, proteasome and cell death 
pathways.  
The secretion of high levels of a heterologous protein does not necessarily result in an increase in 
stress on the system; however, an increase in the number of stress genes expressed in high secretors 
does suggest upregulation of control systems such as UPR [261]. Considering that many of these 
stress genes are in fact involved in repair or recovery from cellular stress, oxidative stress or osmotic 
stress, deliberately increased expression of some of these genes could produce a strain that is 
predisposed to deal with the imposed stress [275-276]. 
6.3.4.2 Pathway Analysis  
Initial analysis has indicated the there is considerable variation in gene expression in the different 
clonal variants. More specific detail of individual pathways was generated by analysing the 
microarray data using the program KOBAS, which maps different genes to KEGG pathways [201-203]. 
KOBAS creates a comprehensive list with significant p-values based on the number of genes which 
vary within the pathway, as well as a corrected p-value which takes into consideration the total 
number of genes in the analysed dataset. 
Having generated the lists it was possible to determine which pathways were significantly up or 
downregulated within the three comparison groups; for instance whether there were common 
pathways that were always upregulated in high secretors. When using a corrected p-value of 0.2 or 
less no common pathways were observed within the individual high, mid and low secretory groups. 
Therefore, although a less stringent comparison, it was decided to compare pathways using a p-
value of less than or equal to 0.1 to increase the number of pathways analysed. In KOBAS the p-value 
differs from the corrected p-value as it does not take into consideration the total number of genes 
that are up- or downregulated within a gene set. When comparing differentially expressed pathways 
in the high secreting strains it becomes immediately apparent that using this approach increases the 
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number of pathways significantly up- or downregulated. To visualise significantly varied pathways 
the online tool Venny was used to create Venn diagrams, and only pathways that had a p-value of 
0.1 or less were included (Fig 6.17-6.19) [277]. 
 
Figure 6.17 A comparison of Pathways Up- and Downregulated in High Secreting Strains 
at p≤0.1 
Venn diagrams to represent the pathways that are significantly upregulated or 
downregulated for each of the high secreting strains in comparison to X33. A p-value of 
≤0.1 was used. A) Pathways that were significantly upregulated. B) Pathways that were 
significantly downregulated. 
 
Immediately it is apparent that two pathways were upregulated in all of the high secreting strains: 
oxidative phosphorylation and ribosome biogenesis in eukaryotes pathways. These correspond with 
the ability to release energy and the production of protein. CV18(H) and CV23(H) have upregulation 
in three other pathways in common which are peroxisomes, RNA degradation and the spliceosome. 
There were no pathways that were commonly downregulated in all of the high secreting strains, but 
there were three pathways that were downregulated in both CV18(H) and CV23(H); steroid 
biosynthesis, protein processing in the ER and riboflavin metabolism. Additionally there were five 
pathways downregulated in CV2(H) and CV18(H); lysine biosynthesis, MAPK signalling pathway, 
alanine, aspartate and glutamate metabolism, phenylalanine , tyrosine and tryptophan biosynthesis 
and finally starch and sugar metabolism. The downregulation of biosynthesis pathways indicates 
that the strains have reduced capacity to synthesise these amino acids de novo, which would 
normally be required for growth and production of protein. Given that the strains are producing high 
levels of protein this probably reflects a slowdown in growth rate and degradation of endogenous 
protein and redirection of resource. This could also explain why the RNA degradation and 
spliceosome pathways are upregulated in order to manage a transient excess of mRNA that is not 
being used to make cellular protein. This is also consistent with the downregulation of protein 
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processing pathways, which may be expected after 24 hours growth, and evidence of increased cell 
death as seen in figure 6.16.  
 
Figure 6.18 A comparison of Pathways Upregulated and Downregulated in Mid-Level 
Secreting Strains at p≤0.1 
Venn diagrams to represent the pathways that are significantly upregulated or 
downregulated for each of the mid-level secreting strains in comparison to X33. A p-value 
of ≤0.1 was used. A) Pathways that were significantly upregulated. B) Pathways that were 
significantly downregulated. 
 
In the mid-level secreting strains two pathways were upregulated in all three strains; ribosome 
biogenesis (as with high secreting strains) and porphyrin metabolism. While porphyrin metabolism 
may not be an obvious pathway to be upregulated in P. pastoris, this pathway is linked to steroid 
biosynthesis and glycine, serine and threonine metabolism. The pathways that were commonly 
upregulated in CV8(M) and CV15(M) were biosynthesis of secondary metabolites, peroxisome and 
arginine and proline metabolism. The common pathway between CV8(M) and CV16(M) was purine 
metabolism, and the common pathways between CV15(M) and CV16(M) were ribosome, oxidative 
phosphorylation and RNA transport. It appears that the majority of the pathways upregulated relate 
to metabolism or biosynthesis of metabolites, which would be required for growth or production of 
proteins. 
The single pathway downregulated for all of the mid-level secreting strains was the ubiquitin 
mediated proteolysis pathway, which encompasses the majority of the ERAD pathway. Only CV8(M) 
and CV16(M) had other pathways downregulated in  common which were MAPK signalling pathway 
and mismatch repair. 
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Figure 6.19 A comparison of Pathways Upregulated and Downregulated in Low 
Secreting Strains at p≤0.1 
Venn diagrams to represent the pathways that are significantly upregulated or 
downregulated for each of the low secreting strains. A p-value of ≤0.1 was used. A) 
Pathways that were significantly upregulated. B) Pathways that were significantly 
downregulated. 
 
Finally for the low secreting strains there was one pathway that was upregulated in all three strains 
which was the peroxisome pathway, which is to be expected due to the growth on methanol. Three 
pathways were upregulated in both CV5(L) and CV14(L); purine metabolism, RNA polymerase and 
ribosome biogenesis. The common pathways upregulated between CV7(L) and CV14(L) were 
ribosome, biosynthesis of secondary metabolites, cysteine and methionine metabolism and 
ubiquinone and other terpenoid-quinone biosynthesis pathways. Once again it is apparent that most 
of the pathways upregulated relate to metabolism or biosynthesis. Nonetheless differing 
metabolism pathways are upregulated amongst the different groups indicating different 
requirements of each strain. 
For pathways downregulated in all three low secreting strains there was only one common to all 
which, as with the mid secreting strains, was the ubiquitin mediated proteolysis. Other pathways 
downregulated in both CV5(L) and CV14(L) were protein processing in the ER as well as glutathionine 
metabolism, the former being particularly important  as this implies that protein production is lower 
than observed in the wild-type strain. This highlights potential blockages within the pathways that 
could explain the low titre. CV7(L) and CV14(L) had the largest number (8)  of common pathways 
downregulated; cell cycle, MAPK signalling pathway, regulation of autophagy, nucleotide excision 
repair, mismatch repair, endocytosis, natural killer cell mediated cytotoxicity and SNARE interactions 
in vesicular transport. P. pastoris undergoes a form of autophagy known as pexophagy whereby 
peroxisomes are degraded in order to release resources for protein production or growth [80, 278-
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279]. As autophagy is downregulated in both CV7(L) and CV14(L) compared to X33 it implies that the 
regulation of resources may not be as efficient in these strains. This may in part be due to a lower 
growth rate on methanol, as the demand for cellular reorganisation will be reduced if less 
peroxisomes are generated. Furthermore downregulation of the cell cycle, nucleotide excision repair 
and mismatch repair suggests a slow in growth rate, potentially due to a lack of resources. 
While it would have been interesting to do a comparison of pathways that were up or 
downregulated in the different groups of high, mid and low secretors it is apparent that within the 
groups there is no uniformity of pathways that are significantly changed. From these results it is 
apparent that while different and clear cut titre levels can be determined (Fig 6.7), the causes of 
clonal variation are variable and as a result it becomes necessary to look at the strain individually 
instead of grouping them together. 
6.3.4.3 KEGG Pathway Mapper for the Visualisation of Significantly Changed Pathways 
Once the KOBAS program had determined pathways that were significantly up or downregulated for 
each clonal variant compared to wild-type it was possible to use the KEGG Mapper Search & Colour 
pathway tool to create a visual display [202, 204-205]. An fdr threshold of p≤ 0.05 was established 
for gene expression that was significantly different from X33. Genes for which expression was 
upregulated in a clonal variant were assigned the colour blue and for gene expression that was 
downregulated, the colour red (Fig 6.20; Appendix 9.8). 
 
Figure 6.20 Protein Processing in the Endoplasmic Reticulum Pathway of CV2(H) 
Pathway of protein processing in the endoplasmic reticulum of strain CV2(H) compared to 
wild-type. Genes in blue are upregulated, while genes in red are downregulated in the 
clonal variant strain compared to X33. Green boxes indicate organism-specific pathways. 
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Once relevant pathways had been mapped for each of the clonal variants it was possible to compare 
individual genes of pathways which may be significant. PDI, which is an indicator of UPR stress, was 
downregulated in the three high secretors and the three low secretors compared to the wild-type 
strain. Conversely it was upregulated in the three mid-level secretors. This could suggest that in the 
high level strains the level of PDI is lower as the feedback loop that is the UPR has recovered to a 
homeostatic equilibrium. It is also possible to hypothesise that in the low secreting strains no 
induction of UPR has occurred; thus explaining the low PDI upregulation. The number of disulfide 
bonds within a protein may affect the requirements for PDI upregulation. HSA has 17 disulfide bonds 
and it would be interesting to observe the expression levels of PDI for a protein that either had more 
or less disulfide bonds  [187, 280].  
The UPR in mammalian cells functions through three separate pathways; IRE1, PERK and ATF6; 
however in S. cerevisiae only the IRE1 pathway is present [70-71, 153, 155, 241]. According to the 
results from the KEGG pathway mapper, all strains with the exception of CV23(H) show 
downregulation in a PERK – like transcript (Fig 6.23 and Appendix 9.8). The downregulation of this 
particular gene suggests that there may be a homolog in P. pastoris of the PERK-like transmembrane 
protein. While S. cerevisiae does not contain a PERK homolog, Caenorhabditis elegans contain both 
an IRE1 pathway and a PERK pathway [281]. Thus, P. pastoris may resemble C. elegans in this regard, 
differing from S. cerevisiae in terms of the UPR, a theory which is supported by the difference in the 
size of the intron of the HAC1 mRNA [162]. Bioinformatic analysis (blastp) revealed that the 
sequence similarity between P. pastoris and S. cerevisiae PERK-transmembrane protein is 42%. The 
downregulated PERK-like gene shows 41% sequence identity to the S. cerevisiae gene GCN2, which is 
also a protein kinase that phosphorylates the alpha-translation initiation factor eIF2 in response to 
starvation [282]. As none of the strains show significant growth after 24 hours on methanol (growth 
appears to stop after 8 hours; Fig 6.12), starvation could be occurring due to resources being utilised 
for protein production. In mammalian cells both GCN2 and PERK contribute to eIF2α 
phosphorylation which occurs after the activation of the UPR [283].  
It is also of interest to note that IRE1 transcript levels were downregulated in the majority of the 
strains with only CV15(M), CV16(M) and CV23(H) showing no significant variation from wild-type 
levels (Fig 6.23 and Appendix 9.8). Furthermore none of the strains showed an upregulation of IRE1. 
Unfortunately HAC1 does not appear on the KEGG pathways, but it was possible to monitor the 
behaviour when looking at the raw data. CV16(M) strain showed a downregulation of HAC1 
compared to wild-type, CV14(L), CV2(H) and CV18(H) showed no difference, while HAC1 in CV5(L), 
CV7(L), CV8(M), CV15(M) and CV23(H) was upregulated compared to wild-type. A downregulation of 
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HAC1 nonetheless, does not suggest that there is no UPR being upregulated as X33 will show a 
baseline level of UPR; furthermore a downregulation could suggest that the strain has returned to 
homeostasis. PDI expression, which should increase in the presence of misfolded protein to aid 
folding, shows an upregulation in strains CV5(L), CV7(L), CV8(M), CV15(M) and CV23(H), the same 
strains that show an increase in HAC1 transcript.  All other strains were not significantly different 
from wild-type. However, no strains showed an increase in KAR2 expression compared to wild-type, 
with CV7(L), CV8(M) and CV16(M) showing no difference and all the other strains exhibiting a 
decrease in KAR2 expression. Release of unfolded protein from KAR2 is often the trigger for 
activation of ERAD [284-285]. Potentially the downregulation of KAR2 is as a result of the length of 
time that the cultures were expressed for. 
 Other pathways that were analysed in detail included ERAD, taking into consideration genes such as 
HRD1, which is the link between ERAD and the unfolded protein response [164]. Two strains showed 
upregulation of HRD1, CV5(L) and CV23(H), whereas CV7(L) & CV14(L) had reduced expression of 
HRD1. It is of interest that CV5(L) contrasts with the other low expressing strains, another clear 
indicator that  grouping the strains together based on expression levels probably has no mechanistic 
correlation. In order to investigate this further the ubiquitin mediated proteolysis pathway was 
investigated to reveal whether the ERAD was upregulated. 
In line with the downregulation of HRD1, a downregulation of approximately half of the genes 
involved in the proteolysis pathway was observed in CV7(L) (Fig 6.21).  
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Figure 6.21 Ubiquitin Mediated Proteolysis Pathway in CV7(L) 
Pathway of ubiquitin mediated proteolysis in CV7(L) compared to wild-type. Genes in blue 
are upregulated, while genes in red are downregulated in the clonal variant strain 
compared to wild-type. Green boxes indicate organism-specific pathways. 
 
CV14(L), which also exhibited downregulation of HRD1, showed downregulation of a large 
proportion of the pathway, with the exception of 2 genes within the E2 complex (Fig 6.22). 
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Figure 6.22 Ubiquitin Mediated Proteolysis Pathway in CV14(L)   
Pathway of ubiquitin mediated proteolysis in CV14(L) compared to wild-type. Genes in 
blue are upregulated, while genes in red are downregulated in the clonal variant strain 
compared to wild-type. Green boxes indicate organism-specific pathways. 
 
While CV5(L) showed upregulation of HRD1 the majority of the ERAD pathway was not upregulated, 
with a higher proportion  of expressed genes than with CV7(L) and CV14(L), showing no variation 
compared to wild-type (Fig 6.23). 
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Figure 6.23 Ubiquitin Mediated Proteolysis Pathway in CV5(L) 
Pathway of ubiquitin mediated proteolysis in CV5(L) compared to wild-type. Genes in blue 
are upregulated, while genes in red are downregulated in the clonal variant strain 
compared to wild-type. Green boxes indicate organism-specific pathways. 
 
CV23(H), which like CV5(L) was upregulated in  HRD1 expression, shows upregulation in more steps 
in the pathway. This was supported by the KOBAS pathway analysis which indicates this pathway 
was significantly upregulated (Fig 6.24). 
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Figure 6.24 Ubiquitin Mediated Proteolysis Pathway in CV23(H) 
Pathway of ubiquitin mediated proteolysis in CV23(H) compared to wild-type. Genes in 
blue are upregulated, while genes in red are downregulated in the clonal variant strain 
compared to wild-type. Green boxes indicate organism-specific pathways. 
 
When considering the different groups of secretors, the low secretors were all downregulated in a 
large part of the ERAD pathway, while the high secretors showed upregulation. While CV18(H) was 
significantly downregulated in the ubiquitin mediated proteolysis pathway (according to the KOBAS 
analysis) approximately half of the in E1 and E3 subunit genes were upregulated (Appendix 9.9). As 
ERAD works as a control mechanism to prevent excess stress in the cells, thus reducing the 
likelihood of cell death, then upregulation of ERAD could potentially be a good indicator of a high 
expressing strain [261, 286-287]. Skp1, an adaptor protein involved in the multi subunit type E3 
complex, is upregulated in all of the high expressing strains, but not in any of the other strains, and 
as a result may be a useful tool in the identification of a good secretor. 
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To look for other signals that may be used to identify high secretors the transcript results were 
analysed to identify genes that were solely up or downregulated in the high secreting strains (Table 
6.1 and 6.2). 
Table 6.1 Genes Upregulated in High Secretion Strains Only 
 
Gene Name Functionality Relevant Pathways Reference 
ALG13 
Catalytic component of UDP-GlcNAc 
transferase, required for the second 
step of dolichyl-linked oligosaccharide 
synthesis; anchored to the ER 
membrane via interaction with Alg14p 
N-Glycan biosynthesis 
Metabolic Pathways 
[288] 
VAN1 
Component of the mannan 
polymerase I 
N-Glycan biosynthesis [289] 
 
CAB4 
Pantotheine-phosphate 
adenylyltransferase (PPAT), which 
catalyzes the fourth step in the 
biosynthesis of coenzyme A from 
pantothenate 
Pantothenate and CoA 
biosynthesis 
Metabolic pathways 
[290] 
TAF11 
Transcription initial factor TFIID 
subunit 11 
Basal transcription factors [291] 
RAD3 
5’ to 3’ DNA helicase involved in 
nucleotide excision and repair 
transcription 
Basal transcription factors 
Nucleotide excision repair 
[292] 
SAR1 
GTPase; GTP-binding protein of the 
ARF family, component of COPII coat 
of vesicles   
Protein processing in the 
endoplasmic reticulum 
[293] 
REC8 
Meiosis-specific component of sister 
chromatid cohesion complex 
Meiosis [294] 
NFS1 
Cysteine desulfurase involved in iron-
sulfur cluster (Fe/S) biogenesis; 
required for the post-transcriptional 
thio-modification of mitochondrial and 
cytoplasmic tRNAs 
Thiamine metabolism 
Sulphur relay system 
[295] 
NSP1 
Essential component of the nuclear 
pore complex, which mediates nuclear 
import and export RNA transport 
RNA transport [296] 
SKP1 
Evolutionarily conserved kinetochore 
protein that is part of multiple protein 
complexes, including the SCF ubiquitin 
ligase complex, the CBF3 complex that 
binds centromeric DNA, and the RAVE 
complex that regulates assembly of 
the V-ATPase 
Cell cycle 
Ubiquitin mediated proteolysis 
Protein processing in the 
endoplasmic reticulum 
[297] 
RPN6 
Essential, non-ATPase regulatory 
subunit of the 26S proteasome lid 
required for the assembly and activity 
of the 26S proteasome 
Proteasome [298] 
CMD1 
Calmodulin; Ca++ binding protein that 
regulates Ca++ independent processes 
and Ca++ dependent processes 
(stress-activated pathways) 
Phosphatidylinositol signalling 
system 
 
[299] 
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Table 6.2 Genes Downregulated in High Secretion Strains Only 
 
Gene Name Functionality Relevant Pathways Reference 
SPE1 
Ornithine decarboxylase; catalyzes the 
first step in polyamine biosynthesis; 
degraded in a proteasome-dependent 
manner in the presence of excess 
polyamines 
Arginine and proline 
metabolism 
Glutathione metabolism 
Metabolic pathways 
Biosynthesis of secondary 
metabolites 
[300] 
TKL1 
Transketolase; similar to Tkl2p Pentose phosphate pathway 
Methane assimilation 
Metabolic pathways 
Biosynthesis of secondary 
metabolites 
[301] 
ORC6 
Subunit of the origin recognition 
complex, which directs DNA 
replication by binding to replication 
origins and is also involved in 
transcriptional silencing; 
phosphorylated by Cdc28p 
Cell Cycle 
Meiosis 
[302] 
ORC5 
Subunit of the origin recognition 
complex 5 
Cell Cycle 
Meiosis 
[302] 
MTR2 
mRNA transport regulator, essential 
nuclear protein 
Ribosome biogenesis 
RNA transport 
mRNA surveillance pathway 
[303] 
PFK27 
6-phosphofructo-2-kinase, catalyzes 
synthesis of fructose-2,6-bisphosphate 
Fructose and mannose 
metabolism 
[304] 
RPL7A 
Protein component of the large (60S) 
ribosomal subunit 
Ribosome [305] 
 
Considering that over 5000 genes were analysed to determine differences there were few that 
appear to be solely up- or downregulated in the high copy strains compared to wild-type strain that 
was not exhibited in the other strains. No clear patterns of pathways upregulated can be discerned, 
although there is an indication that a number of biosynthetic pathways are upregulated. There are 
two cell cycle genes that are downregulated in the high copy strains, which correlate with the 
increase in cell death during growth on methanol observed by FACS analysis (Fig 6.16). Tkl1p, like 
Tkl2p, is required for the biosynthesis of aromatic amino acids [301, 306] as the CV2(H) and CV18(H) 
show a downregulation of phenylalanine , tyrosine and tryptophan biosynthesis this suggest the 
downregulation of TKL1 may coincide with the reduced production of aromatic amino acids. As 
aromatic amino acids in HSAp only constitute 9.2% perhaps this low percentage corresponds to the 
reduced biosynthesis.  
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Interestingly there are no genes which are commonly up- or downregulated exclusively in low 
secreting strains compared to X33 that are not evident in all high or mid-level secretors. This 
suggests that the causes of low secretors may be more multidimensional and that the evidence we 
have seen highlighting good secretors may just be as a result of increased titre. 
UBLE1A, which is involved in the E1 subunit of the ERAD, is only upregulated in high secreting strains 
with the exception of CV5(L). While CV5(L) is a low secreting strain and shows no obvious differences 
from the other low expressing genes in terms of titre (Fig 6.9) there are signs that indicate it often 
behaves as a high secreting strain. This suggests that CV5(L) may be a low secretor due to an 
overactive ERAD. Contrarily exocytosis of cellular transport vesicles occurs through the SNARE-
interaction in vesicular transport pathway.  VAM4, which is involved in this pathway was 
upregulated in CV5(L) (Fig 6.25). 
 
Figure 6.25 SNARE-Interactions in Vesicular Transport Pathway in CV5(L) 
Pathway of SNARE-Interactions in Vesicular Transport in CV5(L) compared to wild-type. 
Genes in blue are upregulated, while genes in red are downregulated in the clonal variant 
strain compared to wild-type. Green boxes indicate organism-specific pathways. 
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This suggests that CV5(L) has signals similar to the high secretors but that there are blockages 
elsewhere within the system that result the low titre observed. This highlights the potential 
problems of creating an indirect screening method by which to select high secretors. Additional 
screening of titre levels would clearly be required after establishing a reporter system to determine 
a good secretor. 
6.3.5 The anomalous CV7(L) 
The titre levels exhibited by CV(L) was 9 mg L-1, which is in the same range as the other low 
secretors, yet the HSA transcript levels was 40-fold that of the other low secretors, comparable to 
the high secreting strains (Fig 6.7 and 6.9). Clearly, this suggests that this strain has a post-
transcriptional  blockage in the secretory pathway. What is apparent when looking at CV7(L) is the 
large number of genes that were significantly up- or downregulated compared to all of the other 
strains. 3934 genes were differentially regulated compared to wild-type, whereas in CV5(L) only 
2124 genes and CV14(L) 3535 genes were regulated significantly differently from X33. The number 
of pathways up- and downregulated in CV7(L) are higher than in any other strain (Table 6.3). 
Table 6.3 Pathways Significantly (p<0.1) Up- and Downregulated in CV7(L) 
 
Pathways Upregulated in CV7(L) Pathways Downregulated in CV7(L) 
Ribosome Ubiquitin mediated proteolysis 
Biosynthesis of secondary metabolites Cell cycle - yeast 
Oxidative phosphorylation MAPK signalling pathway - yeast 
Metabolic pathways Regulation of autophagy 
Cysteine and methionine metabolism Nucleotide excision repair 
Lysine biosynthesis Mismatch repair 
Valine, leucine and isoleucine biosynthesis Meiosis - yeast 
Phenylalanine, tyrosine and tryptophan biosynthesis Proteasome 
Alanine, aspartate and glutamate metabolism DNA replication 
Ubiquinone and other terpenoid-quinone biosynthesis Endocytosis 
Terpenoid backbone biosynthesis Natural killer cell mediated cytotoxicity 
Peroxisome SNARE interactions in vesicular transport 
Sulfur metabolism Folate biosynthesis 
Aminoacyl-tRNA biosynthesis  
mRNA surveillance pathway  
Tyrosine metabolism  
Phenylalanine metabolism  
 
When looking at the regulation of the autophagy pathway all other strains showed consistent 
upregulation of ATG7, but in CV7(L) this gene was downregulated. The protein ATG7 is involved in 
cytoplasm to vacuole transport and also plays a role in autophagy. It is predicted to be an E1-like 
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activating enzyme and essential for the upregulation of autophagy [79, 307].The majority of genes 
involved in the CV7(L) autophagy pathway were significantly downregulated. As the ubiquitin 
mediated pathway was also downregulated (Fig 6.24) this implies that, despite the transcript level, 
protein production was not excessive, suggesting that either translation was reduced in CV7(L) or 
perhaps protein was not being correctly targeted to the ER (Fig 6.26). 
 
Figure 6.26 Regulation of Autophagy pathway in CV7(L) 
Genes downregulated in CV7(L) compared to wild-type X33 in the regulation of autophagy 
pathway as mapped by KEGG Mapper. Green boxes indicate organism-specific pathways. 
 
According to a paper that discusses autophagy post-methanol induction in what is described as the 
“lag phase autophagy” (LPA), starvation of amino acids could elicit the induction of autophagy [308]. 
Autophagy is required to recycle amino acids for either the production of proteins or for the cellular 
reorganisation of the cell in order to deal with a methanol feed (predominantly the increase in 
peroxisomes) [80, 309]. Perhaps the fact that CV7(L) does not upregulate autophagy (more than 
wild-type) suggests that this basal ability to recycle amino acids is missing. Thus the cell may be 
starving, consistent with the FACS data which indicates that after 24 hours on methanol 32.9% of the 
cells are non-viable (Fig  6.16). 
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If the transcript is not being translated efficiently to protein, then perhaps RNA degradation may be 
occurring. In CV7(L) RNA degradation is upregulated in some aspects, though this appears to be 
consistent with pathways in all three groups (Fig 6.27). 
 
Figure 6.27 RNA Degradation Pathway in CV7(L) 
Genes up or down regulated in CV7(L) compared to wild-type X33 in the RNA degradation 
pathway as mapped by KEGG Mapper. Red genes indicate downregulation compared to 
wild-type and blue genes indicate upregulation. Green boxes indicate organism-specific 
pathways. 
 
In support of the suggestion that there is limited translation CV7(L) gene expression in the SNARE 
interactions in vesicular transport pathway is generally lower than any other strain; a comparison 
with CV18(H) (vs. X33) highlights the differences that can be seen in the genes  that are up or 
downregulated (Fig 6.28). 
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Figure 6.28 A Comparison of the SNARE Interactions in Vesicular Transport pathway 
between CV7 and CV18 
Genes up or downregulated in A: CV7(L) to B: CV18(H) compared to wild-type X33 in the 
SNARE Interactions in Vesicular Transport pathway as mapped by KEGG Mapper. Red 
indicates genes downregulated, and blue genes upregulated in comparisons to X33. Green 
boxes indicate organism-specific pathways. 
 
The downregulation of large portions of the SNARE interactions in vesicular transport pathway 
confirms that there is a reduction in secretion of protein, even compared to the non-recombinant 
wild-type. This was confirmed by assessing the number of genes up or downregulated for protein 
export (Fig 6.29).  
 
A B 
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Figure 6.29 Protein Export in CV7(L) 
Genes up or down regulated in CV7(L) compared to wild-type X33 in the protein export 
pathway as mapped by KEGG Mapper. Red genes indicate downregulation compared to 
wild-type and blue genes indicate upregulation. Green boxes indicate organism-specific 
pathways. 
 
There were more protein export genes significantly downregulated in CV7(L) than in all of the other 
strains. This supports the theory that there is a bottleneck between transcription and translation in 
this particular strain. 
Investigation of the pathways upregulated in CV7(L) shows that a large number are related to amino 
acid biosynthesis. These include the alanine, aspartate and glutamate pathway, the lysine 
biosynthesis pathway and the cysteine and methionine pathway. This is consistent with this strain 
being starved for amino acids because of limited autophagy-related turnover which limits 
translational activity. This hypothesis is supported by manual annotation of the data which indicated 
that CV7(L) showed 50% of biosynthesis genes upregulated, whereas the other low copy strains 
showed an average of 22.7% (Appendix 9.7).  
UPR and ERAD were not upregulated as protein synthesis was restricted. Thus there was no build up 
of unfolded protein, which would typically trigger these responses. This also helps explain why 
SNARE interactions are minimal; there is little recombinant protein around to migrate through the 
relevant pathways.  It would be an interesting experiment to supplement CV7(L) growth medium 
with excess amino acids, as although these strains were grown in rich media the requirements may 
not have been met using the standard media. It is also important to note that this strain had been 
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growing for 24 hours, a typical time for producing protein and one equivalent to industry standards. 
A time course would have to be analysed in order to determine whether amino acid starvation 
occurred pre-induction or early post-induction with methanol. 
6.4 Discussion 
Clonal variation does not seem to arise from a single attribute such as differences in the secretory 
pathway. It is suggested that clones vary in protein production for multiple different reasons. From 
the RT-qPCR results alone the increased transcription of some strains can explain the increase in 
secretion (Fig 6.7), although this does not explain the reasons for higher transcriptional levels in 
these strains. However, other strains which show high levels of transcript are not able to successfully 
translate this into a high level of protein. 
The decision to split the clones into three cohorts based on high, medium and low secretion rates 
proved not to have any basis in terms of common mechanisms and it became apparent that it was 
more accurate to evaluate each clone on an individual basis. When looking at the specific pathways 
assigned by the program KOBAS that were up or downregulated there was very little uniformity 
amongst the groups, even at the lower stringency eventually applied. The corrected p-value takes 
into consideration the total number of genes that were analysed, which in this case was over 5000. 
This large number can make it insensitive. For instance, in the proteasome pathway CV2(H) has 17 
out of 34 genes that are statistically upregulated in comparison to X33, but using the corrected p-
value of ≤0.2 failed to recognise this pathway as upregulated.  
Interestingly in both the mid and low secreting strains the ubiquitin mediated proteolysis pathway 
was downregulated, but this was not the case for the high secreting strains. CV2(H), CV18(H) and 
CV23(H) all showed upregulation of the gene SKP1 which is involved in the ubiquitin mediated 
proteolysis pathway, but no other strains show an upregulation of this gene. This immediately 
highlights a potential difference between the strains that may be of diagnostic use in the future. It, 
therefore, seems that upregulation of ERAD is a common feature of the high secreting strains, which 
also show an increased level of cell death after induction with methanol as shown by FACS analysis 
(Fig 6.16). Induction of the ERAD is clearly a sign of stress which directly or indirectly affects cell 
viability; an apoptosis like phenomena has been reported in P. pastoris [310-311]. 
This increased cell death leads to an interesting question regarding the appropriate length of 
expression. It had been determined that 24 hours resulted in sufficient protein to differentiate 
between a good secretor and a poor secretor, but perhaps leaving cells for this long explains some of 
the results that were observed. For instance, UPR was not obviously upregulated for many of the 
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strains; HAC1 for instance was only upregulated in CV5(L), CV7(L), CV8(M), CV15(M) and CV23(M), 
but if a sample had been taken earlier perhaps upregulation of this key UPR signal might have been 
observed in all of the strains. A paper by Whyteside et al. indicates that while upregulation of the 
UPR can be maintained up to 48 hours post-induction with methanol some signals decrease after 24 
hours, as can be seen with the levels of HAC1 transcript in the wild-type strain [173]. 
Furthermore as UPR is a feedback control loop it is possible that these strains have effectively 
controlled the amount of unfolded protein being passed through the system thus returning to a 
baseline comparable to that of X33 [153]. Continuous upregulation of UPR leads to ERAD activation 
[164] explaining why ERAD is upregulated in the high secretory strains. It would have been beneficial 
to analyse these strains over a time course to distinguish whether different signals are prevalent 
early or late in the expression profile. 
The fact that (with the exception of CV7(L)) the high secreting strains exhibited much higher levels of 
cell death than the low and mid secreting strains when grown in methanol as indicated by the 
LIVE/DEAD flow cytometry analysis (Fig 6.16) may be a factor that could be developed for creating a 
more efficient secreting strains. If it was possible to reduce cell death in these strains, productivity 
should increase, leading to higher titres. This has been investigated by Weis et al. who attempted to 
limit cell death through a strict feeding strategy [310]. It was determined that cell death increased 
with starvation due to poor mixing of cultures, which may occur in shake flasks as well as micro-titre 
plates. Therefore a controlled feed would limit starvation in the attempts to limit cell death. Growing 
cultures of these CVs in a bioreactor may have given more detailed explanations of how the cultures 
behave on a production scale. 
As indicated CV7(L) appeared to be nutritionally starved resulting in a level of cell death comparable 
to that of the high copy strains (Fig 6.16). If the cells were nutritionally starved it is logical that cell 
death may occur due to excessive stress on the cells [310]. However, it is not possible to determine 
precisely what makes it nutritionally starved, except that UPR, ERAD and autophagy are not induced. 
Upregulation of the biosynthetic pathways should clearly compensate for nutritional starvation.  
Clonal variant strains were analysed using microarray analysis in order to comprehensively 
determine differences related to gene expression profiles. The development of three “P. pastoris” 
sequences was essential for the annotation of the microarray analysis [91-93]. Genome sequencing, 
whilst extremely comprehensive, results in difficulties when establishing the effects of variation on 
functionality [312]. Nonetheless, once varying functionalities have been ascertained as key aspects 
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to be investigated (as carried out through this report) genome sequencing could be used to pinpoint 
precise mutations within genes to identify areas for strain engineering [312]. 
All three pathways involved in the UPR appear on the KEGG map irrespective of the fact that only 
IRE1 is known to exist in P. pastoris [71]. However, a PERK homolog appeared to be consistently 
downregulated in the CV strains, irrespective that no PERK homology being confirmed in P. pastoris. 
This raises questions regarding UPR activation in P. pastoris. Details regarding this particular gene 
indicate that it is a protein kinase involved in the interaction with eIF2, which ultimately works as a 
translation initiation factor [92]. Bioinformatic analysis reveals that this gene shows 42% sequence 
identity to PERK and 41% to S. cerevisiae GCN2. A knockout of the PERK gene would determine the 
loss of function phenotype. Interestingly both PERK and GCN2 are important for the attenuation of 
the cell cycle progression upon the activation of UPR [281, 283, 313]. 
In addition to using KOBAS and KEGG pathway mapper it would have been interesting to perform 
gene ontology (GO) analysis on the data sets in order to provide another dimension. Unfortunately 
this was not possible as no P. pastoris database for GO analysis is available. A paper from 2011 
extensively used GO analysis to investigate methanol utilization, protein chaperone, RNA 
polymerase and protein secretion or transportation [314]. However, due to the restriction of 
databases on GO this analysis was done using S. cerevisiae related genes. A similar analysis was not 
performed in this instance as, while many of the genes between the two species are related, there is 
an inherent bias towards well studied pathways in S. cerevisiae which may differ in P. pastoris. 
Clonal variation in P. pastoris is often attributed to differences in copy number and the integration 
site of the vector. Studies described in this chapter show that variation occurs due to factors other 
than vector integration. This raises a question as to where the variation arises from, whether it is 
from intrinsic differences within the host strain population or whether the transformation or 
selection method could give rise to the variation seen. Further work will be required to fully 
understand the extent to which clonal variation occurs; attempts to prevent it occurring would be an 
interesting area of future research.
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7 General Discussion and Future Work 
7.1 Understanding Genetic Instability 
From initial experiments of expression multi-copy clones showed evidence of genetic instability.  
Therefore, it was not possible to determine if clones reached secretion saturation or if counter-
selection against high copy numbers of the HSA gene was occurring to reduce copy number.  The 
upregulation of UPR indicates that multi-copy clones experience secretory stress. However, evidence 
of genetic instability in non-inducing conditions (Fig 3.17 and 3.18) indicates that instability is not 
solely due to secretory stress. Therefore the recombinogenic nature  of P. pastoris could result in a 
baseline level of instability in regions of high homology [82]. 
Through maintaining selection (either through maintaining Zeocin or through using a minimal media 
in HIS4 complemented strains) a level of stability was achieved. No clones showed evidence of losing 
the integrated vector entirely with a minimum copy number retained at two, compared to the initial 
five-copy starting strain whilst maintaining Zeocin (Fig 4.1 and 4.5). Maintaining Zeocin for 
expression in a 3 mL culture for 2 days at 2000 μg mL-1 equates to approximately £2.8 per sample 
making this uneconomical. Based on 15L fed-batch fermentations run for 96 hours, the total cost of 
maintaining 100 μg mL-1 Zeocin a single clone would cost £1050 and for 2000 μg mL-1 Zeocin £21000. 
Therefore the use of auxotrophic selection markers was examined. Complementation of HIS4 with 
the integration of pIBTx3 resulted in stability of a single copy of the vector and multi-copy clones 
were still unstable (Fig 4.5). Generating stable multi-copy clones multiple auxotrophic markers may 
be more financially viable. Nonetheless the use of auxotrophic markers relies on using minimal 
media which results in a significant lower titre [232]. Additionally integration into the HIS4 locus 
results in a greater proportion of false positive colonies; hence an increased screening process in 
order to ascertain true transformants [215].  
RAD51 and RAD52 knockout strains were designed to interrupt the homologous recombination (HR) 
and the HR and non-homologous end joining (NHEJ) recombination pathways respectively. No viable 
knockout strains of RAD51 or RAD52 were isolated. Naatsaari et al. created a KU70 knockout strain 
in P. pastoris to interrupt the NHEJ pathway, producing viable clones that showed evidence of 
stability with seven copies of the GFP, although based on analysis of the whole culture. [215]. 
Therefore we can hypothesise that it is the HR pathway in P. pastoris that is essential for viability. 
This differs from S. cerevisiae, which is able to recover from a RAD51 mutation due to other 
recombination mechanisms [221, 223]. Bioinformatic analysis (blastp) revealed that protein 
homology of RAD51 between P. pastoris and S. cerevisiae was 74%. To date no detailed investigation 
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into recombination pathways in P. pastoris have been published; potentially S. cerevisiae may be 
able to recover from RAD51 due to an additional pathway that is not present in P. pastoris. 
According to Marx et al. integrating vectors into the rDNA locus results in stable strains as 
determined on a population level by RT-qPCR [152]. Our analysis of the replicated HSA vector 
containing the GAP promoter resulted in unstable strains on an individual cell basis. The use of 
promoter had no implications on the levels of stability when integrating vectors into the rDNA locus. 
Unlike integration into the AOX1 locus, no clones in the rDNA locus lost the vector completely (Fig 
3.16 and 3.18). Stability under non-inducing conditions was not analysed for clones integrated into 
the rDNA locus, and it would have been interesting to draw a comparison compared to strains with 
vectors integrated into the AOX1 locus. Furthermore a vector which directed cytoplasmic expression 
of HSA would help identify whether stress on the secretory pathway did have an effect on stability.  
7.2 Examining the possibility of a fully stable clone 
The use of in-vitro multimerisation to generate multi-copy clones did not result in full vector 
stability; however integration of a single copy of the TRY1 gene remained faithful. Multiple regions 
of homology will increase the likelihood of trans recombination. Thus it can be hypothesised that 
relying on only one sequence of homology to the genome and increasing copy number without the 
addition of further regions of homology may lead to a more stable clone. The use of an internal 
ribosome entry site (IRES) could be the solution to integrating genes in tandem without repeated 
regions of homology [315]. However; a recent paper using the IRES system for the production of a 
light chain and heavy chain antibody reported that production of both proteins was reduced in 
comparison to using two separate promoters [316]. 
The generation of a KU70- strain suggests that, through interruption of the NHEJ pathway, multi-
copy clones show increased stability [215]. As copy number was analysed by RT-qPCR on a 
populational level it would be of interest to determine the level of stability of this KU70- knockout 
strain on an individual cell basis. Furthermore it may be of benefit to combine the KU70- knockout 
strain with vectors that integrate into the rDNA locus. This could potentially target vectors more 
specifically to different loci, which may increase stability. 
Integration into the rDNA locus may result in more stable clones based on which rDNA locus the 
vectors are integrated. We have hypothesised that it is the repeat regions of homology that result in 
the loss of the vector. GS115 contains 16 copies of the rDNA locus in tandem; therefore theoretically 
up to 16 copies of the vector may integrate into the genome with only two regions of homology 
within the same locus [92]. No investigation into precise integration site of the rDNA locus has been 
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undertaken. If multiple vectors integrate into a single rDNA locus instability may be increased 
compared to single vectors integrating into multiple rDNA loci. In order to determine point of 
integration the technique of genome walking can be utilised [317]. Additionally it has been reported 
that rDNA stability in S. cerevisiae is controlled epigenetically and that Sir2p may increase stability by 
suppressing replication-dependent rDNA recombination [318]. Theoretically overexpressing Sir2p 
(which naturally occurs in P. pastoris) will increase vector stability. 
It is my personal belief that the advent of a fully stable P. pastoris clone will not be possible. As 
researchers we rely on the recombinogenic nature of P. pastoris to successfully integrate 
recombinant proteins into the genome. However, we seem unwilling to accept that recombination 
of vectors out of the genome will occur just as easily. Ultimately if individual cells reach secretion 
saturation and maximum titre is produced then the development of a stable P. pastoris clone may 
not be necessary. 
7.3 Improving screens for genetic instability 
All current investigations into genetic instability measure copy number on a population level and not 
on an individual cell basis [152, 210, 215]. As volumetric productivity when expressing in P. pastoris 
is high, but specific productivity is low, analysis of genetic instability on an individual cell basis should 
be examined to ensure the entire culture is secreting protein to the maximum capacity. The method 
for determining copy number on individual colonies is a time consuming and expensive method. 
Genomic DNA is extracted from individual colonies before copy number is determined by RT-qPCR. 
In our investigations it has been impossible to determine the significance of the variation of copy 
number observed due to limitations in the number of colonies that were analysed due to time 
constraints. A streamlined process needs to be developed if analysing copy number on individual 
colonies is to be adopted by the scientific community. Possibilities include using novel equipment 
such as Bio-Rad’s QX100 droplet system, which calculates on a per molecule scale the concentration 
of a gene of interest. This method does not rely on quantification using either a housekeeping gene 
or comparison to a known one copy clone as is required by ΔΔCt [197]. Unfortunately this method 
still requires the extraction of genomic DNA in order to assess copy number, which is often the most 
time consuming aspect. 
An alternative option would be to create a fluorescence based system for use with FACS, or some 
other tagged protein which will be visible depending on the number of genes that are present. 
Mattanovich and Borth reviewed the use of cell sorting to determine concentrations of protein 
through various organisms, including P. pastoris where Vijayasankaran et al.  fused GFP to the 
promoters of three polyhydroxyalkanoates to determine protein expression levels [319-320]. A 
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method would need to be determined so that protein production was not the aspect being 
investigated; potentially adding a fluorescence tag to the antibiotic marker (if multiple copies of the 
expression cassette are amplified such as in PTVA). 
7.4 Choosing the best protein 
Many of the aspects that have been investigated in this thesis are dependent on the model protein. 
Secretion saturation and UPR induction is dependent on folding capabilities of the protein.  As the 
production of HSA results in one of the largest titre recorded for production by P. pastoris at 10 g L-1 
it is possible to hypothesise that secretion saturation is reached with fewer gene copy numbers due 
to overloading the secretory pathway [140]. If we consider that stress on the secretory pathway may 
be linked to genetic stability, different proteins may have an impact on the stability observed. 
Furthermore it would be of interest to determine whether indicators of high secretors identified 
through transcriptomic analysis were consistently up- or downregulated through the production of a 
different protein. 
An alternative model protein which could be chosen is glucose oxidase from A. niger. The stability of 
glucose oxidase is high in S. cerevisiae and titre has reached 3 g L-1  [321]. We have discussed the 
advantages of codon bias towards yeast systems and as this protein has yeast origins it may be more 
suitable for expression. Furthermore it is possible to create a biosensor using glucose oxidase that 
better monitors secretion levels through an activity assay [322]. 
Additionally we hypothesised that an optimised HSA gene speeds up the translation efficiency due to 
ease of translation through readily available tRNAs; thus resulting in increased titre [236]. However, 
integration of multi-copies of the HSAopt gene into the rDNA locus did not result in increased in titre 
compared to the use of the native HSA gene, although secretion saturation appears to have been 
reached. It would appear that using an optimised gene merely shifts the blockage to the secretory 
pathway; thus increasing stress on the cells through aspects such as UPR. GpARzαHSAopt strains 
showed on average over a five-fold increase of KAR2 upregulation and a four-fold increase of PDI 
upregulation compared to GpARzαHSA strains (Fig 4.22 and 5.14). Therefore due to reduced average 
titre of multi-copy clones containing the HSAopt gene compared to clones containing the HSA gene, 
codon optimisation in this instance does not increase the specific productivity of P. pastoris.  
The method of codon optimisation used can have an effect on protein expression. As suggested by 
Sinclair and Choy when expressing human glucocerebrosidase increasing the A/T ratio is sufficient to 
increase titre [238]. Optimisation was based on the OptimumGene™ algorithm that takes into 
consideration not only idea codon usage for P. pastoris but also transcriptional and translational 
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efficiencies [191]. DNA2.0 utilises GeneGPS technology, which is designed on the premise that 
increased titre is highly affected by the frequency of highly charged tRNAs  codons, especially during 
amino acid starvation [237]. It would be of interest to compare optimised HSA genes synthesised 
using different algorithms and techniques to ascertain whether the use of a HSAopt gene can have 
an effect on titre levels. Additionally comparing the success of alternative proteins may help identify 
under what conditions protein optimisation is beneficial. 
7.5 Understanding Clonal Variation 
The second aspect of this thesis was to investigate clonal variation through the use of transcriptomic 
analysis. Selecting high secreting single-copy clones could reduce the requirements for the 
generation of high copy clones if secretion saturation is reached with a limited number of copies of 
the gene of interest. Clonal variation was observed with the original GpαH1_100 and GpαH11_100 
clones (Fig 6.1), in addition to the variation observed from single colonies isolated from a single 
transformation (Fig 6.5). To determine the effects of clonal variation DNA microarrays were used to 
compare gene expression levels of nine single copy HSA strains.  
The three published genomes of P. pastoris allow for ease of interpretation of microarray data [91-
93]. Gene expression analysis allows for a genome wide view of differences without biasing data 
towards targeted aspects [323]. Up- or downregulated pathways were established without 
previously determining functionality related to expression. For instance, all of the mid-level 
secretion strains showed a significant upregulation of the porphyrin and chlorophyll metabolism 
pathway when analysed at p ≤ 0.1 despite the apparent insignificance of this pathway for protein 
production. To supplement microarray data next generation sequencing may determine the cause of 
variation observed [324]. Potentially strains showing upregulation of particular genes may be due to 
mutations within the promoter regions. CV7(L) has been identified to be nutritionally starved; 
however the cause for this is unknown. Genome sequencing would be able to determine whether it 
is a mutation within a coding region of a gene required for breaking down amino acids for nutrients 
(such as a ubiquitin gene) or another cause. If the clonal variation strains were sequenced and 
compared to current genome sequences differences between clones could be identified. 
Furthermore genome sequencing removes experimental bias as cross-hybridisation to user-defined 
sequences is not required as in gene expression experiments [43, 325].  
However, genome sequencing has limitations, for instance it does not take into consideration any 
epigenetic variations between strains. Current techniques to analyse epigenetic variations between 
strains are being continuously developed. In 2011 Nucelosome Occupancy and Methylome 
Sequencing (NoME-Seq) was published, which uses high-resolution single molecule analysis to 
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determine nucleosome positions and DNA methylation [326]. By investigating epigenetic variations 
between P. pastoris strains it may be possible to achieve a more thorough understanding of the 
differences between strains.   
One of the advantages of microarray analysis compared to whole genome sequencing is that gene 
expression levels under different conditions can be analysed. Clonal variant strains were analysed for 
24 hours in 250 mL flasks; however this does not give an indication of variation over time or with a 
tightly controlled feeding regime. Theoretically strains may show a different gene expression profile 
to low secreting strains at an earlier time course; for instance UPR may be significantly upregulated 
within the first few hours before reaching homeostasis [162]. As the high secreting strains show 
upregulation of ERAD we can hypothesise that UPR may be more significantly upregulated in these 
strains, or potentially upregulation may occur earlier. If this is the case identifying strains that show 
upregulation of UPR quickly after induction may indicate a good secretor. 
In P. pastoris clones that secrete well in small scale do not necessarily correlate to clones that 
secrete well in large scale expression systems [310]. This has been reported to largely be as a result 
of poor feeding regimes, something that has been tackled by the company Biosilta (Oulu, Finland) 
who have produced a tablet called Enpresso Y Defined tablets that with the addition of an enzyme, 
slowly release the carbon source for utilisation by the culture [327-328]. As controlled feeding 
strategies have been identified as detrimental towards controlling cell death the use of a slow 
release feeding system may limit the amount of cell death observed (Fig 6.16). Furthermore, as 
bioreactors use feeding strategies based on the growth profiles of cultures 250 mL flasks with the 
inclusion of slow releasing media may be more comparable for industrial processes. 
Through comparisons between high secreting strains and low secreting strains we have been able to 
identify signals that could be developed as reporter signals to be used in an easy screening method, 
such as Skp1 (Table 6.1). If a fluorescent protein was fused to SKP1 then it would be possible to 
determine when this gene was significantly upregulated via electron microscopy for FACS. Therefore, 
clones that show an increased fluorescence may be indicators of high secreting strains. Furthermore 
the microarray analysis has highlighted areas that can be improved to create a more functional 
strain, such as reducing the cell-death phenomenon in high secreting strains. Upregulation of cell 
death in the high secreting strains may be as a result of activation of the ERAD. If cell death can be 
limited (potentially through a more controlled feeding strategy [310]) titre levels in the high 
secreting strains may be increased. Furthermore it may be possible to encourage strains to 
upregulate UPR to prevent activation of ERAD, while this  may suggest that less protein would be  
produced, as this system works on a control loop it may prevent cell death from occurring [329]. 
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7.6 Identifying the underlying cause of clonal variation 
To understand clonal variation it is essential to determine where differences arise from. There are 
two possible causes; inherent variability in the host strain or integration of the vector into the 
genome. By screening the wild-type strain pre-transformation with a heterologous protein it may be 
possible to determine if variation can be observed. A screen could be developed using a native 
protein that can be monitored without the insertion of any foreign material. P. pastoris only secretes 
a limited number of native proteins [330]. Therefore it may be possible to monitor membrane 
proteins, which are advantageous as they are directed through the secretory pathway, to look for 
differences in the host strain [72]. Custom designed antibodies for immunofluorescence can be 
raised against membrane specific proteins for P. pastoris. It would then be possible to analyse 
variations by FACS or microscopy to determine whether wild-type cultures are homogeneous [331].  
If wild-type cells consistently indicate homogeneous cultures then variation may be as a result of 
integration of recombinant genes into the genome. In this situation a screen should be applied post-
integration of heterologous proteins to determine whether heterogeneity exists within cultures. 
Screens post-integration can identify indicators of high secretors (such as described for SKP1). 
However if heterogeneous cultures are identified pre-integration of a recombinant gene then wild-
type strains need to be monitored more stringently. It may be possible to identify clones with 
proficiencies for high secretion rates. If these strains are able to be selected then potentially 
integration of the recombinant gene may lead to higher titres.  
7.7 Conclusions 
P. pastoris has been used for over 20 years as a tool for expressing proteins by the 
biopharmaceutical industry; however a detailed understanding regarding the molecular biology has 
often been overlooked. At the 2012 Pichia 2012 conference, Alpbach, Austria, it was evident that 
more groups are delving into the “black box” of P. pastoris molecular biology, often funded by 
pharmaceutical companies. This PhD was a multifaceted approach that started as an investigation 
into understanding the limitations of P. pastoris in terms of secretion saturation and its relationship 
to the UPR, but became more about understanding the full impact of clonal variation and uncovering 
the depth that genetic instability occurs. The impact of both clonal variation and genetic instability 
can have severe detrimental effects on recombinant protein expression. By rigorously screening for 
clonal variation and ensuring the most stable clones are selected generating clones that produce the 
highest titre possible may become easier. Furthermore current investigations into expanding the 
secretory capacity [72] may lead to higher titre making P. pastoris the preferential protein 
expression tool of the future. 
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9 Appendix 
9.1 HSA Codon Optimised DNA Sequence 
 
ATGAAATGGGTCACTTTTATCAGTTTGTTGTTTTTGTTTAGTTCCGCCTACTCAAGAGGTGTTTTTAGAAGAGAT 
GCACATAAGTCTGAAGTCGCCCATAGATTCAAGGATTTGGGTGAAGAGAACTTCAAGGCACTTGTTTTGATTGCC 
TTTGCACAATACTTGCAACAGTGTCCATTCGAAGATCATGTTAAATTGGTCAACGAAGTTACTGAGTTTGCTAAG 
ACATGTGTTGCTGATGAATCTGCCGAGAATTGCGACAAATCCCTTCACACTTTGTTCGGTGACAAGTTGTGTACT 
GTTGCTACACTTAGAGAAACATATGGAGAGATGGCAGATTGTTGCGCTAAACAAGAACCAGAGAGAAACGAATGT 
TTCTTGCAGCACAAGGATGACAACCCAAATCTTCCTAGATTGGTTAGACCTGAGGTTGATGTCATGTGCACCGCT 
TTTCATGACAATGAAGAGACTTTCTTGAAGAAATACCTTTACGAAATCGCTAGAAGACACCCATACTTCTATGCT 
CCTGAGTTGTTGTTTTTCGCCAAAAGATACAAGGCTGCCTTTACTGAATGTTGCCAAGCAGCTGATAAAGCCGCA 
TGTTTGCTTCCAAAGCTTGATGAATTGAGAGACGAGGGTAAAGTTTCTTCCGCAAAACAAAGATTGAAGTGTGCT 
TCCCTTCAGAAATTTGGAGAAAGAGCTTTCAAGGCTTGGGCCGTTGCAAGATTGTCCCAAAGATTTCCTAAGGCA 
GAATTTGCTGAGGTCTCAAAATTGGTTACCGATCTTACTAAGGTTCATACTGAATGTTGCCACGGAGATTTGCTT 
GAGTGTGCTGATGACAGAGCCGACTTGGCAAAGTACATCTGCGAAAACCAGGATTCAATCTCTAGTAAGTTGAAG 
GAATGTTGCGAGAAACCTTTGCTTGAAAAGTCTCATTGTATTGCAGAAGTTGAGAACGATGAGATGCCAGCTGAC 
CTTCCTTCATTGGCTGCCGATTTTGTCGAAAGTAAAGACGTTTGTAAGAATTACGCTGAGGCCAAGGACGTTTTC 
TTGGGAATGTTCCTTTACGAATATGCTAGAAGACATCCAGATTACTCTGTTGTCTTGCTTTTGAGATTGGCCAAA 
ACATATGAAACTACATTGGAGAAGTGTTGCGCAGCTGCCGACCCTCACGAATGTTATGCTAAAGTCTTTGATGAG 
TTCAAGCCATTGGTTGAAGAGCCTCAAAACTTGATCAAACAGAACTGTGAATTGTTCGAGCAACTTGGAGAATAC 
AAGTTTCAGAACGCTCTTTTGGTTAGATATACTAAGAAAGTCCCACAAGTTTCTACCCCTACTTTGGTTGAAGTC 
TCCAGAAATTTGGGTAAAGTTGGATCAAAATGTTGCAAGCATCCAGAAGCCAAGAGAATGCCTTGTGCAGAGGAC 
TACTTGAGTGTTGTCCTTAATCAGTTGTGCGTCCTTCACGAAAAGACTCCAGTCTCCGATAGAGTTACAAAGTGT 
TGCACCGAGAGTTTGGTTAACAGAAGACCATGTTTCTCTGCTTTGGAAGTCGACGAGACTTATGTTCCTAAAGAG 
TTTAACGCCGAGACTTTTACTTTCCATGCAGATATCTGTACATTGTCTGAAAAGGAGAGACAAATCAAGAAACAG 
ACCGCTTTGGTCGAACTTGTTAAGCACAAACCTAAGGCTACTAAAGAGCAATTGAAGGCCGTCATGGATGACTTT 
GCAGCTTTCGTTGAAAAATGTTGCAAGGCTGATGACAAGGAGACTTGTTTTGCTGAAGAAGGAAAGAAATTGGTT 
GCTGCATCCCAGGCTGCCCTTGGTTTG  
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9.2 Oligonuclotides Used throughout this Study 
Table 9.1 Oligonucleotides 
Primer Name 5’ – 3’ Sequence Target 
001-AOX1F GACTGGTTCCAATTGACAAGC 
AOX1 promoter from pPICzA and 
pPICzαA 
002-AOX1R GCAAATGGCATTCTGACATCC 
AOX1 promoter from pPICzA and 
pPICzαA 
004-pPIC F TTT CTA CGG GGT CTG ACG CTC 
Amplification of the AOX1 cassette from 
pPICzA and pPICzαA 
005-pPIC R TTT GAA GCT ATG GTG TGT GGG G 
Amplification of the AOX1 from pPICzA 
and pPICzαA 
010-KAR2q1 TCA AAG ACG CTG GTG TCA AG 
qPCR primer for KAR2 (BiP) 150 bp 
amplicon 
011-KAR2q2 TAT GCG ACA GCT TCA TCT GG 
qPCR primer for KAR2 (BiP) 150 bp 
amplicon  
012-PDIq1 GCC GTT AAA TTC GGT AAG CA qPCR primer for PDI 144bp amplicon  
013-PDIq2 TCA GCT CGG TCA CAT CTT TG qPCR primer for PDI 144bp amplicon  
020-ACT1q1 GCT TTG TTC CAC CCA TCT GT 
qPCR primer for ACT1 163 bp amplicon. 
Housekeeping gene 
021-ACT1q2 TGC ATA CGC TCA GCA ATA CC 
qPCR primer for ACT1 163 bp amplicon. 
Housekeeping gene 
022-Zeoq1 CAA GTT GAC CAG TGC CGT TC 
qPCR primer for Sh ble (Zeocin 
resistance gene) 108 bp amplicon 
023-Zeoq2 GAA GTC GTC CTC CAC GAA GT 
qPCR primer for Sh ble (Zeocin 
resistance gene) 108 bp amplicon 
047-HSA2 
AAA GCG GCC GCT TAT AAG CCT 
AAG GCA GCT TGA C 
HSA gene from GS115/HSA into pPICz 
A/pPICzα A with 3’ NotI restriction site 
050-HSA3 
CCC GAA TTC  AAAA ATG AAG TGG 
GTA ACC TTT ATT TCC C 
HSA gene from GS115/HSA into pPICz A 
with 5’ EcoRI restriction site 
053-HSA4-SP 
AAA GAA TTC AGG GGT GTG TTT 
CGT CGA GAT GC 
HSA gene from GS115/HSA into pPICzα A 
removing native signal peptide with 5’ 
EcoRI restriction site 
067-HAC1q3 
CGA CTA CAT TAC TAC AGC TCC 
ATC A 
qPCR primers for HAC1 124 bp amplicon 
068-HAC1q4 
TGC TGT AAT GTG TAA AGA TGA 
ATC C 
qPCR primers for HAC1 124 bp amplicon 
070-HSAq1 GGT GTT GAT TGC CTT TGC TCA G qPCR primers for HSA 138 bp amplicon 
071-HSAq2 GCA TTC ATT TCT CTC AGG TTC TTG qPCR primers for HSA 138 bp amplicon 
120-optHSA-SP 
CCC GAA TTC AGA GGT GTT TTT 
AGA AGA GAT GC 
HSAopt gene without signal peptide with 
5’ EcoRI restriction site for cloning into 
pPICzαA  
121-optHSArev 
AAA GCG GCC GCT TAC AAA CCA 
AGG GCA GCC 
HSAopt gene without signal peptide with 
5’ EcoRI restriction site for cloning into 
pPICzαA 
142-AOX integr F PmeI GAA CAT CAC TCC AGA TGA GGG 
Sequencing primers across the AOX1 
integration site 50 bp 5’ PmeI 
143-AOX inter R PmeI CTG GCC GTT AGC ATT TCA ACG 
Sequencing primers across the AOX1 
integration site 50 bp 3’ PmeI 
146 – RAPD3 AGT CAG CCA C Random decamer primer for RAPD-PCR 
188-HSAoptq3 TGA CTT TGC AGC TTT CGT TG qPCR primer for HSAopt 91 bp amplicon 
189-HSAoptq4 GGA TGC AGC AAC CAA TTT CT qPCR primer for HSAopt 91 bp amplicon 
242-pIB2 inv1 
CGG TAC CCG GGG ATC CAC TAG 
TCT CG 
Inverse PCR from pIB2 to remove the 
GAP promoter 
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243-pIB2 inv2 
AAA AGA TCT GTC AGA GGT TTT 
CAC CGT CAT CAC C 
Inverse PCR from pIB2 to remove the 
GAP promoter 
264- RAD51 SeqF1 CTTCCAATGATGGCGTTTCT 
Sequencing primer for αTx3R51 250 bp 
5’ RAD51 
265- RAD51 SeqR1 ATATGGCTCCGGAGTTTTGA 
Sequencing primer for αTx3R51 250 bp 
3’ RAD51 
266- RAD52 SeqF1 AGGCTAAAGGGCAGAGCAAT 
Sequencing primer for αTx3R52 250 bp 
5’ RAD52 
267- RAD52 SeqR1 CAC TGT AGG TTG GGG GCT AA 
Sequencing primer for αTx3R52 250 bp 
3’ RAD52 
280-Zeo SeqF2 
GGT AGG GGT TTG GGA AAA TCA 
TTC G 
Sequencing primer for TEF1, EM7, Sh 
ble, CYC1 TT  
281-Zeo SeqR2 GCG GCC TTT TTA CGG TTC CTG G 
Sequencing primer for TEF1, EM7, Sh 
ble, CYC1 TT 
293 -GibR51-pIB2 
TAT CAC GAG GCC CTT TCG TCA 
ATT GCA GTG CTG ATC ACT AAT 
CAA GTT 
Gibson Primer pIBTx3R51: Forward 
attaching RAD51 3' to pIB2-HIS4 
294-GibR51-3-5-EcoRV 
ATG ACT TCA TGG TTC GAC ATG 
ATA TCT TAG TCA TCA TCC TCT CTA 
GGG TCC 
Gibson Primer pIBTx351: Reverse 
attaching RAD51 3' to RAD51 5' with an 
EcoRV site 
295-GibR51-5-EcoRV 
AAA GAT ATC ATG TCG AAC CAT 
GAA GTC ATA GAG G    
Gibson Primer pIBTx3R51: Forward 
RAD51 5' plus EcoRV site (5') 
296-GibR52-pIB2 
TAT CAC GAG GCC CTT TCG TCGAA 
CGT GGA AGA AAA GTT CAA CCC  
Gibson Primer pIBTx3R52: Forward 
attaching RAD52 3' to pIB2-HIS4 
297-GibR52-3-5-EcoRV 
ATG CGT TTG AGC TCA GCG TCG 
ATA TCG GAG AGT TTT CTT TTC 
CTG GGG C 
Gibson Primer pIBTx3R52: Reverse 
attaching RAD52 3' to RAD52 5' with an 
EcoRV site 
298-GibR52-5-EcoRV 
AAA GAT ATC GAC GCT GAG CTC 
AAA CGC ATA T     
Gibson Primer pIBTx3R52: Forward 
RAD52 5' plus EcoRV site (5') 
331-RAD51-5 
ATG TCG AAC CAT GAA GTC ATA 
GAG G 
Gibson Primer 51-HIS: Forward RAD51 5' 
337-RAD51-5-HIS 
TGC GTA TGC AGG TAG CAA GGG 
AAA TGT CAT TAA CAG TAA GCA 
GAG CTC TTT TAG GAG T 
Gibson Primer 51-HIS: Reverse RAD51 5' 
(250 bp) with HIS4 homology 
338-HIS4-RAD51-5 
ATA CTC CTA AAA GAG CTC TGC 
TTA CTG TTA ATG ACA TTT CCC TTG 
CTA CCT GC 
Gibson Primer 51-HIS: Forward HIS4 
with homology to RAD51 5' (250 bp) 
339-HIS4-RAD51-3 
ACA ACT TGA TTA GTG ATC AGC 
ACT GCA ATT TTA AAT AAG TCC 
CAG TTT CTC CAT ACG AAC C 
Gibson Primer 51-HIS: Reverse HIS4 with 
homology to RAD51 3' (250 bp) 
340-RAD51-3-HIS 
GTT CGT ATG GAG AAA CTG GGA 
CTT ATT TAA AAT TGC AGT GCT 
GAT CAC TAA TCA AG 
Gibson Primer 51-HIS: Forward RAD51 3' 
(250bp) with HIS4 Homology 
341-RAD52-5 ATG TCT TTC GAT GAC GCT GAG C Gibson Primer 52-HIS: Forward RAD52 5' 
342-RAD52-5-HIS 
TGC GTA TGC AGG TAG CAA GGG 
AAA TGT CAT GAA TAA CAG ACG 
AAA GTC CCA TTG A 
Gibson Primer 52-HIS: Reverse RAD52 5' 
with HIS4 homology 
343-HIS4-RAD52-5 
AAA TTT CAA TGG GAC TTT CGT 
CTG TTA TTC ATG ACA TTT CCC TTG 
CTA CCT GC 
Gibson Primer 52-HIS: Forward HIS4 
with homology to RAD52 5' 
344-HIS4-RAD52-3 
TTC GTA GGA TCT ACA GTT CTT CTT 
AAA GAA TTA AAT AAG TCC CAG 
TTT CTC CAT ACG AAC C 
Gibson Primer 52-HIS: Reverse HIS4 with 
homology to RAD52 3' 
345-RAD52-3-HIS 
GTT CGT ATG GAG AAA CTG GGA 
CTT ATT TAA TTC TTT AAG AAG 
AAC TGT AGA TCC TAC GAA 
Gibson Primer 52-HIS: Forward RAD52 3' 
with homology to HIS4 
346-RAD52-3 TTA ATT CGA AGC TGG AGA GTT Gibson Primer 52-HIS: Reverse RAD52 3' 
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TTC TT 
353-rDNA IntF TTC CCC GTT ACC CGT AGA AAC C 
Forward primer to check integration into 
rDNA locus 
354-rDNA IntR TGT TCA CCC ACT AAT AGG GAA CG 
Reverse Primer to check integration into 
rDNA locus 
366-GAP-rDNA GibF 
TAA CCT GTC TCA CGA CGG TCT 
AAA CCC AGC AGA TCC TTT TTT 
GTA GAA ATG TCT TGG  
Gibson Primer pGRz: Forward GAP + 
rDNA homology 
367-GAP-aMF GibR 
AGT AAA AAT TGA AGG AAA TCT 
CAT CGT TTC ATA GTT GTT CAA TTG 
ATT GAA ATA GGG 
Gibson Primer pGRz: Reverse GAP + 
alpha MF homology 
368-amF-GAP GibF 
TGT CCC TAT TTC AAT CAA TTG AAC 
AAC TAT GAA ACG ATG AGA TTT 
CCT TCA AT 
Gibson Primer pGRz: Forward alpha MF 
+ GAP homology 
369-pUC-rDNA GibR 
TTT CTG CCC TAT CAA CTT TCG ATG 
GTA GGA GAT CTC ATG ACC AAA 
ATC CCT TAA C 
Gibson Primer pGRz: Reverse pUC + 
rDNA homology 
370-rDNA-pUC GibF 
CTC ACG TTA AGG GAT TTT GGT 
CAT GAG ATC TCC TAC CAT CGA 
AAG TTG ATA GGG CAG 
Gibson Primer pGRzα: Forward rDNA + 
pUC homology 
371-rDNA-GAP 
ACA CCA AGA CAT TTC TAC AAA 
AAA GGA TCT GCT GGG TTT AGA 
CCG TCG TGA 
Gibson Primer pGRzα: Reverse rDNA + 
GAP homology 
372-rDNA-AOX1TT GibF 
AG AAG ATT AAG TGA GAC CTT 
CGT TTG TGCG TCC TAC CAT CGA 
AAG TTG ATA GGG C 
Gibson Primer pARzα: Forward rDNA + 
homology to AOX1 TT 
373-rDNA-TEF1 GibR 
ACA TTT TGA AGC TAT GGT GTG 
TGG GGG ATC GCT GGG TTT AGA 
CCG TCG TGA G 
Gibson Primer pARzα: Reverse rDNA + 
homology to TEF1 promoter 
374-rDNA-pUC GibF 
TCA CGT TAA GGG ATT TTG GTC 
ATG AGA TCA TCC TAC CAT CGA 
AAG TTG ATA GGG C 
Gibson Primer pARzαHSAopt BglII: 
Forward rDNA + Homology to pUC 
375-rDNA-AOX1P GibR 
ATT CAA CCT TTC GTC TTT GGA TGT 
TAG ATC GCT GGG TTT AGA CCG 
TCG TGA G 
Gibson Primer pARzαHSAopt BglII: 
Reverse rDNA + Homology to AOX1 
promoter 
383-TRY1q7 TCC CTC ATC AAC GAA CAG TG qPCR primers for TRY1 133 bp amplicon 
384-TRY1q8 GGA TGA TCT TGG CTG CAT TG qPCR primers for TRY1 133 bp amplicon 
 
Oligonucleotides were purchased from Invitrogen, Paisley, UK. 
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9.3 Zeocin Gene and Promoter Region Sequencing 
 
9.1 Alignment of DNA sequences within the TEF1 promoter region from strains selected on 100 μg mL-
1 Zeocin or 2000 μg mL-1 shows variation within the promoter regions 
DNA sequencing of TEF1 and EM7 promoter, Sh ble gene and CYC1 transcription termination region of 
clones that showed increased resistance to Zeocin but did not show an increase in copy number. Both 
parental and progeny (post-PTVA) clones are present to show where the variation occurs. 1_100, 
11_100 and their progeny are included as positive controls as the progeny clones show an increase in 
copy number. 
 
  
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pPICzαA  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
1_100    GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
1_2000A  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTT-CTTTT-CTTGAAAATTTTTTTTTTT-GATTTTT  
11_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
11_2000B GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTT--GATTTT  
6_100    GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTTTGATTTTT  
6_2000   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCT-GAAAATTTTTTTTTTT-GATTTTT  
14_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
14_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
17_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAAATTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTG--ATTTTT  
17_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
22_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTG--ATTTTT  
22_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
25_100   GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTT-CTTGAAAATTTTTTTTTTT-GATTTTT  
25_2000  GACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTT-GATTTTT  
 
                100       110       120       130       140       150       160       170       180         
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pPICzaA  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
1_100    TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
1_2000A  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
11_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
11_2000B TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
6_100    TTCTCTTTCGATGACCTCCCCATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
6_2000   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
14_100   TTCTCTTTCGATGACCTCC--ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
14_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
17_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
17_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
22_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
22_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
25_100   TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
25_2000  TTCTCTTTCGATGACCTCCC-ATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTAC  
 
                  190       200       210       220       230           
          ....|....|....|....|....|....|....|....|....|....|....|... 
pPICzaA  AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
1_100    AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
1_2000A  AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
11_100   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
11_2000B AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
6_100    AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
6_2000   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
14_100   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
14_2000  AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
17_100   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
17_2000  AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
22_100   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
22_2000  AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
25_100   AACTTTTTTT-ACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
25_2000  AACTTTTTTTTACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGGGCG  
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9.4 GpαH11_2000B Fermentation Trace 
 
9.2 Fermentation Traces GpαH11_2000B 
Example fermentation trace from 15 L fermentation. The example show is from pαH11_2000B, the five 
copy strain. A) Fermentation trace of temperature, stirrer speed, pO2 percentage, pH and airflow. B) 
Carbon dioxide evolution rate (CER) and Oxygen uptake rate (OUR).  1: Initiation of fed-batch. 2: 
Glycerol-feed turned off and methanol shot given. 3: Methanol feed turned on. 
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9.5 DNA Sequencing of Clonal Variants for Integration Site into the P. pastoris 
genome 
 
 
              10        20        30        40        50        60        70        80        90                  
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TGGTATTGT-GAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV5   TGGTATTGT-GAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV7   TGGTATTGTTGAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV8   -----TTGT-AAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV14  ----TTTGT-GGAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV15  ---TATTGT-GGAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV16  ---TATTGT-GGAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV18  TGGTATTGTGGAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
CV23  TGGTATTGT-GAAATAGACGCAGATCGGGAACACTGAAAAATAACAGTTATTATTCGAGATCTAACATCCAAAGACGAAAGGTTGAATGA  
 
             100       110       120       130       140       150       160       170       180         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV5   AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV7   AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV8   AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV14  AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV15  AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV16  AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV18  AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
CV23  AACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACACATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGC  
 
             190       200       210       220       230       240       250       260       270         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV5   AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV7   AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV8   AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV14  AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV15  AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV16  AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV18  AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
CV23  AAACGCAGGACCTCCACTCCTCTTCTCCTCAACACCCACTTTTGCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTC  
 
             280       290       300       310       320       330       340       350       360         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV5   ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV7   ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV8   ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV14  ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV15  ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV16  ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV18  ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
CV23  ATTCCAATTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTTGTTTATTT  
 
             370       380       390       400       410       420       430       440       450         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV5   CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV7   CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV8   CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV14  CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV15  CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV16  CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV18  CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
CV23  CCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGGGTCAAATAGTTTCATGTTCCCCAAA  
 
             460       470       480       490       500       510       520       530       540         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV5   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV7   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV8   TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV14  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV15  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV16  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV18  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
CV23  TGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAAAAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTG  
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9.9.3 Sequence alignment of the integration site for clones used in microarray analysis. 
Sequence alignment of the region around the PmeI directed integration site of clones GpαHCV 2, 5, 7, 8, 
14, 15, 16, 18 and 23. PmeI recognises and cuts at the sequence GTTTAAAC, located at 467 and 
highlighted in yellow. Sequences both upstream and downstream of the integration site were identical. 
 
             550       560       570       580       590       600       610       620       630         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV5   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV7   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV8   AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV14  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV15  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV16  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV18  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
CV23  AAATGCTAACGGCCAGTTGGTCAAAAAGAAACTTCCAAAAGTCGGCATACCGTTTGTCTTGTTTGGTATTGATTGACGAATGCTCAAAAA  
 
             640       650       660       670       680       690       700       710       720         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TAATCTCATTAATGCT-AGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV5   TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV7   TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV8   TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV14  TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV15  TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV16  TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV18  TAATCTCATTAATGCTTAGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
CV23  TAATCTCATTAATGCT-AGCGCAGTCTCTCTATCGCTTCTGAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTTT  
 
             730       740       750       760       770       780       790       800       810         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV5   TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV7   TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV8   TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV14  TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV15  TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV16  TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV18  TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
CV23  TGGATGATTATGCATTGTCTCCACATTGTATGCTTCCAAGATTCTGGTGGGAATACTGCTGATAGCCTAACGTTCATGATCAAAATTTAA  
 
             820       830       840       850       860       870       880       890       900         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV5   CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV7   CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV8   CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV14  CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV15  CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV16  CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV18  CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
CV23  CTGTTCTAACCCCTACTTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACT  
 
             910       920       930       940       950       960       970       980       990         
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV5   TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV7   TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV8   TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV14  TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV15  TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV16  TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV18  TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
CV23  TTCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATT  
 
             1000      1010      1020      1030      1040      1050      1060      1070      1080        
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CV2   CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV5   CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV7   CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV8   CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV14  CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV15  CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV16  CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV18  CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
CV23  CGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGA  
 
             1090      1100      1110      1120      1130             
      ....|....|....|....|....|....|....|....|....|....|....|.. 
CV2   TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV5   TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV7   TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV8   TGAAACGGCACAAATTCCGGCTGA-GCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV14  TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAACGGGA  
CV15  TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV16  TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV18  TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
CV23  TGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGA  
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9.6 Volcano plots of Microarray Expression Data for Clonal Variant strains 
compared to X33 
9.6.1 High Secreting Strains 
CV2(H) 
 
CV18(H) 
 
CV23(H) 
 
9.4 Volcano plots for High Secreting Strains CV2(H), CV18(H) and CV23(H) at fdr ≤ 0.05 
compared to X33 
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9.6.2 Mid-Level Secreting Strains 
CV8(M) 
 
 
CV15(M) 
 
 
CV16(M 
 
9.5 Volcano plots for Mid-Level Secreting Strains CV8(H), CV15(H) and CV16(H) at fdr ≤ 
0.05 compared to X33 
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9.6.3 Low Secreting Strains 
CV5(L) 
  
 
CV7(L) 
 
 
CV14(L) 
 
 
9.6 Volcano plots for Low Secreting Strains CV5(H), CV7(H) and CV14(H) at fdr ≤ 0.05 
compared to X33
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9.7 Manual annotation of Microarray analysis 
9.7.1 CV18(H) 
 
Figure 9.7 Percentage of Genes Up- or Downregulated in CV18(H) through manual 
annotation compared to wild-type X33. 
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9.7.2 CV23(H) 
 
9.8 Percentage of Genes Up- or Downregulated in CV23(H) through manual annotation 
compared to wild-type X33. 
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9.7.3 CV8(M) 
 
9.9 Percentage of Genes Up- or Downregulated in CV8(M) through manual annotation 
compared to wild-type X33. 
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9.7.4 CV15(M) 
 
9.10 Percentage of Genes Up- or Downregulated in CV15(M) through manual annotation 
compared to wild-type X33. 
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9.7.5 CV16(M) 
 
9.11 Percentage of Genes Up- or Downregulated in CV16(M) through manual annotation 
compared to wild-type X33. 
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9.7.6 CV5(L) 
 
9.12 Percentage of Genes Up- or Downregulated in CV5(L) through manual annotation 
compared to wild-type X33. 
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9.7.7 CV7(L) 
 
9.13 Percentage of Genes Up- or Downregulated in CV7(L) through manual annotation 
compared to wild-type X33. 
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9.7.8 CV14(L) 
 
9.14 Percentage of Genes Up- or Downregulated in CV14(L) through manual annotation 
compared to wild-type X33. 
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9.8 Protein Processing in the Endoplasmic Reticulum Pathways  
9.8.1 High Copy Strains  
 
9.15 Protein Processing in the Endoplasmic Reticulum Pathways in High Secreting Strains 
Genes in blue are upregulated, while genes in red are downregulated in the clonal variant 
strain compared to X33. A) CV18(H); B) CV23(H). Green boxes indicate organism-specific 
pathways. 
 
A 
B 
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9.8.2 Mid-Level Secreting Strains 
 
9.16 Protein Processing in the Endoplasmic Reticulum Pathways in Mid-Level Secreting Strains 
Genes in blue are upregulated, while genes in red are downregulated in the clonal variant 
strain compared to X33. A) CV8(M); B) CV15(M); C) CV16(M). Green boxes indicate 
organism-specific pathways. 
A 
B 
C 
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9.8.3 Low-Level Secreting Strains 
 
9.17 Protein Processing in the Endoplasmic Reticulum Pathways in Low Secreting Strain 
Genes in blue are upregulated, while genes in red are downregulated in the clonal variant 
strain compared to X33. A) CV5(L); B) CV7(L); C) CV14(L). Green boxes indicate organism-
specific pathways. 
A 
B 
C 
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9.9 Ubiquitin Mediated Proteolysis Pathway in High Secreting Strains 
 
 
9.18 Ubiquitin Mediated Proteolysis Pathway in High Secreting Strains 
Genes in blue are upregulated, while genes in red are downregulated in the clonal variant 
strain compared to wild-type.  A) CV2(H); B) CV18(H). Green boxes indicate organism-
specific pathways. 
A 
B 
